TW201406750A - Substituted pyrazolone compounds and method of use - Google Patents

Abstract

The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Description

Substituted pyrazolone compounds and methods of use thereof

This invention relates to novel substituted pyrazolone compounds and salts thereof for use in the treatment of highly proliferative diseases, such as cancers associated with mammals. In particular, the present invention relates to a compound which inhibits the activity of a protein tyrosine kinase by inhibiting the activity of a protein tyrosine kinase by using the compound of the present invention, thereby inhibiting an intercellular or intracellular signal response. The invention is also directed to a method of treating a mammal, especially a human hyperproliferative disorder, using a compound of the invention or a composition comprising a compound of the invention.

Protein kinases represent a large class of proteins that play an important role in the maintenance of cellular function and the regulation of various cytopathic effects. By regulating the signaling pathway, protein kinases control cell metabolism, cell division cycle progression, cell proliferation and apoptosis, differentiation and survival. There are currently 500 human kinase groups, of which up to 150 are associated with various human diseases, such as inflammatory diseases, cardiovascular diseases, metabolic diseases, neurodegenerative diseases and cancer.

The list of kinases includes abl, AATK, ALK, Akt, axl, bmx, bcr-abl, Blk, Brk, Btk, csk, c-kit, c-Met, c-src, c-fins, CDK1, CDK2 , CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSF1R, CSK, DDR1, DDR2, EPHA, EPHB, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FER, FGFR1, FGFR2 , FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, GSG2, GSK, Hck, ILK, INSRR, IRAK4, ITK, IGF-1R, INS-R, Jak, KSR1, KDR, LMTK2, LMTK3 , LTK, Lck, Lyn, MATK, MERTK, MLTK, MST1R, MUSK, NPR1, NTRK, MEK, PLK4, PTK, P38, PDGFR, PIK, PKC, PYK2, RET, ROR1, ROR2, RYK, ros, Ron, SGK493, SRC, SRMS, STYK1, SYK, TEC, TEK, TEX14, TNK1, TNK2, TNNI3K, TXK, TYK2, TYRO3, Tie, tie2, TRK, Yes, and Zap70.

Protein tyrosine kinases are subfamilies of protein kinases and can also be classified as growth factor receptors (eg, Axl, VEGFR, c-Met (HGFR), Ron, EGFR, PDGFR, and FGFR) or non-receptors (eg, C-src and bcr-abl) kinases. The receptor tyrosine kinase is a transmembrane protein that enables the growth factor to maintain the extracellular binding region across the cell membrane. The transmembrane region and the intracellular portion function as kinases, phosphorylating a specific protein tyrosine residue, thereby Affects cell proliferation. Abnormal expression or protein kinase activity is directly involved in the pathogenesis of many human cancers.

Angiogenesis is the process of forming new capillaries from pre-existing blood vessels, which plays a key role in the development of embryonic organs in the reproductive circulatory system of female/female animals, and also plays an important role in the healing of inflammatory diseases and wounds. The role. It is well known that certain diseases are associated with uncontrolled angiogenesis, such as ocular neovascularization, retinopathy (including diabetic retinopathy), age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory Diseases such as rheumatoid or rheumatic inflammatory diseases, especially arthritis (rheumatoid arthritis), or other chronic inflammations such as chronic asthma, arterial or post-transplant atherosclerosis, endometriosis and hyperplasia Sexual diseases such as solid tumors and liquid tumors (such as leukemia) as generally described. Solid tumors rely in particular on angiogenesis to supply nutrients, nutrients, and waste treatment. In addition, angiogenesis also promotes the growth of tumors in cells or other locations.

New angiogenesis is a highly complex and highly coordinated process that requires large amounts of growth factor stimulation, but vascular endothelial growth factor (VEGFR) signaling responses typically represent a critical rate-limiting phase in physiological and pathological angiogenesis. . VEGF binds to and activates receptor tyrosine kinases. There are three VEGFR subtypes that have been confirmed by humans: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). VEGFR-2 mediates the major cellular responses of VEGF, particularly mitosis and angiogenesis. VEGFR-1 regulates VEGFR-2 signaling or isolates VEGF and VEGFR-2 as a virtual/trapping receptor. The expression of VEGFR-1 is positively regulated by hypoxia, and its mechanism is similar to that of VEGF regulated by HIF-1; its function varies depending on the type and stage of development of the cell. (Stuttfeld E, Ballmer-Hofer K (September 2009), "Structure and function of VEGF receptors". IUBMB Life 61(9): 915-22.)

VEGFR-2 is primarily responsible for mitosis and survival of vascular endothelial cells (EC) while maintaining angiogenesis and microvascular permeability. Thus, direct inhibition of the activity of the kinase VEGFR-2 will reduce angiogenesis and tumor growth, and inhibit VEGFR-2 targeting to the activity of genetically more stable host epithelial cells, rather than inhibiting variable tumor tissue, Will reduce the chances of drug resistance development.

Some drugs are targeted for VEGFR signaling, either alone or in combination with other chemotherapeutic drugs, and are effective in patients with advanced malignancies ("VEGF-targeted therapy: mechanisms of anti-tumor activity," Nature Reviews Cancer , 2008, 8, 579 ; "Molecular basis for sunitinib efficacy and future clinical development," Nature Reviews Drug Discovery , 2007 , 6 , 734; and "Angiogenesis: an organizing principle for drug discovery?" Nature Reviews Drug Discovery , 2007 , 6 , 273).

c-Met, the hepatocyte growth factor receptor (HGFR), whose main site of action is in endothelial cells, has been shown to be expressed in endothelial cells, myogenic cells, hematopoietic cells and motor neurons. The natural ligand for c-Met is hepatocyte growth factor (HGF), which is a multifunctional growth factor, the dispersion factor (SF). In fetuses and adults, initiation of c-Met promotes the formation of certain forms. For example, invasive growth leads to rapid cell growth, intercellular division, and migration of cells to its surroundings ("From Tpr-Met to Met , tumorigenesis and tubes, "Oncogene, 2007 , 26 , 1276; and "Met Receptor Tyrosine Kinase as a Therapeutic Anticancer Target," Cancer Letter, 2009 , 280 , 1-14).

Extensive human malignancies have persistent c-Met stimulation, overexpression or mutation, including breast cancer, liver cancer, lung cancer, ovarian cancer, kidney cancer, thyroid cancer, colon cancer, glioblastoma, prostate cancer and the like. c-Met is also involved in atherosclerosis and pulmonary fibrosis. Through the interaction of tumor stroma, including the HGF/c-Met pathway, the aggressive growth rate of these cancer cells is completely increased. Therefore, a large body of evidence indicates that c-Met signaling response is associated with the development of some cancer diseases and enhances its role in the development of cancer drugs with c-Met as its main target ("Molecular cancer therapy: can our expectation Be MET,"Euro.J. Cancer, 2008, 44, 641-651; and "Targeting the c-Met Signaling Pathway in Cancer," Clin. Cancer Res., 2006 , 12 , 3657). Agents targeting c-Met signaling pathway are Now under clinical investigation. ("Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer," Clinical Cancer Research, 2009, 15, 2207), and "Drug development of MET inhibitors: targeting oncogene addiction and expedience," Nature Review Drug Discovery, 2008 , 7 , 504).

Axl belongs to the subfamily of tyrosine kinase receptors (RTKs), including Tyro3 and Mer (TAM). The TAM receptor is characterized by combining two immunoglobulin analog regions and a binary fibronectin type III in the extracellular region and the cytoplasmic kinase region. The ligand for the TAM receptor is Gas6 (growth arrest-specific 6) and protein S. The two vitamin K-dependent proteins have a 43% amino acid sequence and have a similar regional structure ("The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases, "Cell, 1995 , 80 , 661-670; and "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6 ," Nature, 1995 , 373 , 623-626).

There is ample evidence that the Gas6/Axl system plays an important role in advancing the growth and survival of normal cells and cancer cells ("TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer," Adv Cancer Res, 2008 , 100, 35-83). Axl overexpression and signaling are involved in several human malignancies such as colon cancer, breast cancer, glioma, thyroid cancer, gastric cancer, melanoma, lung cancer, and renal cell carcinoma (RCC). The more specific role of Axl in biology has been confirmed in studies of gliomas, that is, reducing the signal response of Axl will reduce the growth of gliomas and breast tumors, where Axl will promote cell migration, pipeline formation, and regeneration. Angiogenesis and tumor growth. Axl has been shown to play multiple roles in tumorigenesis, and antibody therapy to inhibit Axl not only blocks Axl function in malignant cells, but also blocks its function in mesenchymal tumor cells. The inhibitory effect of Axl and the additional effect of anti-VEGF suggest that blocking the function of Axl will be an effective way to improve anti-angiogenesis therapy ("Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis." Oncogene, 2009, 28, 3442-3455; and "TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer," Adv Cancer Res, 2008, 100, 35-83).

RON ( MST1R , recepteur d'origine nantais ) is another member of the MET family and is a receptor tyrosine for ligand macrophage stimulating protein (MSP, also known as MSTI or hepatocyte growth factor (HGFL)). Acid kinase, which is involved in cell differentiation, migration, and stromal invasion in vitro and in vivo - all of these processes are surrogate markers of invasive growth tumor phenotypes with metastatic potential. RON primarily regulates tumor phenotypes in lung, thyroid, pancreas, prostate cancer, colon and breast cancer cells and predicts poor prognosis in human breast cancer. Co-expression of RON and MET and RON expression induced by HGF-MET signaling have been described in the study of hepatocellular carcinoma. In addition, co-expression of RON and MET in ovarian, breast and bladder cancers predicts a worse prognosis. Considering the verbose length of RON and MET, the most likely way is to suppress the signal response of MET, and mainly by RON signal response ("RON( MST1R )is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma."Cancer Biol Ther .2011 July 1;12(1):9-46.).

The role of the MSP-RON signal axis in the pathogenesis of cancer has been extensively studied in various disease model systems. Both in vivo and in vitro studies have shown that MSP-RON signaling responses are important in the aggressive growth of different types of cancer. Abnormal RON priming, as evidenced by the overexpression of proteins and the production of oncogenic subtypes and the sustained initiation of multicellular signaling, is present in a variety of different types of cancer. The RON signal response is also necessary for the growth and survival of cancer cells. These properties make RON a drug target for cancer therapy ("MSP-RON signalling in cancer: pathogenesis and therapeutic potential." Nature Reviews Cancer, 2013, 13, 466-481).

It is well known that cancer cells often use a variety of mechanisms to avoid tight cell regulation processes such as cell proliferation, apoptosis and aging. Therefore, many tumors will escape from the inhibition of a single kinase. A broad systematic analysis of tumors indicates that tyrosine kinase receptor (RTK) co-activation works chemically through cancer cells and serves as an important biological mechanism. One approach is to overcome RTK co-activation, which may involve both therapeutic targeting of multiple RTKs to block carcinogenic RTK signaling responses and overcome compensatory mechanisms. ("Receptor Tyrosine Kinase Coactivation Networks in Cancer," Cancer Research, 2010, 70, 3857). Anti-tumor methods that target VEGFR, c-Met, Ron and/or Axl signaling can prevent tumor cells from overcoming the independent inhibition of VEGFR, c-Met (HGFR), Ron and/or Axl, thereby improving cancer treatment effect.

The present invention relates to novel substituted pyrazolone compounds and methods of treating cell proliferative disorders. The compounds of the invention have an inhibitory effect on protein tyrosine kinase activity. Even more satisfyingly, the compounds of the invention have multiple inhibitory functions that inhibit signal responses like VEGFR, c-Met (HGFR), Ron and/or Axl. Accordingly, the present invention also provides novel inhibitors of protein tyrosine kinase receptor signaling responses, such as VEGF receptor signaling, HGF receptor signaling, Ron receptor signaling, and/or Axl receptor signaling. .

In particular, the compounds of the present invention, and pharmaceutically acceptable compositions thereof, are effective as tyrosine kinase receptor inhibitors, such as inhibitors of VEGFR, c-Met, Ron and/or Axl.

In one aspect, the invention relates to a compound of formula (I): Or a stereoisomer, geometric isomer, tautomer, oxynitride, hydrate, solvate, metabolite, pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q in formula (I) The definitions of R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , W, X, Y and Z are as follows.

In some embodiments, in Formula (I): Q is H, NR ^a R ^b , OR ^a , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a W is CR ⁷ or N; each X, Y and Z are independently H, D, C _1-6 alkyl, C _3-8 cycloalkyl, C _3-8 cycloalkyl-C _1-4 alkylene , C _3-7 heterocyclyl, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl, heteroaryl consisting of 5-10 atoms, C _6-10 aryl -C _1-4 alkylene or (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group, wherein the C _1-6 alkyl group, C _3-8 cycloalkyl group, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclic, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl, 5-10 A heteroaryl group of an atom, a C _6-10 aryl-C _1-4 alkylene group and a (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group may optionally be 1,2 , 3, 4 or 5 independently selected from D, F, Cl, Br, CN, C _2-6 alkenyl, C _2-6 alkynyl, OR ^a , NR ^a R ^b , R ^a OC _1-4 alkylene Substituted by a substituent of R ^a R ^b NC _1-4 alkylene; each R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ^{7 are} independently H, D, F, Cl ,Br,CN,N ₃ ,OR ^a ,C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl or C _{2 -6} alkynyl Each of R ^a , R ^b and R ^{c is} independently H, C _1-6 aliphatic, C _1-6 haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _1-4 Alkyl, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-4 alkylene, C _6-10 aryl, heteroaryl group 5-10 atoms, C _6-10 aryl a group -C _1-4 alkylene or (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group, when R ^a and R ^{b are} bonded to the same nitrogen atom, R ^a , R ^b And, together with the nitrogen atom to which they are attached, may optionally form a substituted or unsubstituted heterocyclic ring of 3-8 atoms, wherein the C _1-6 aliphatic, C _1-6 haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _1-4 alkylene, C _3-6 heterocyclic, C _3-6 heterocyclyl-C _1-4 alkylene, C _{6- 10} aryl, heteroaryl group of 5-10 atoms, C _6-10 aryl-C _1-4 alkylene group, (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group And a heterocyclic ring consisting of 3-8 atoms may optionally be 1, 2, 3 or 4 independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _C1-6 alkoxy or substituted C _1-6 alkylamino group substituted; and R ^d is H, C _1-6 alkyl, C _3-8 cycloalkyl, -C _1-4 alkylene , C _3-7 heterocyclyl, C _3-7 heterocyclyl -C _1-4 alkylene or C _6-10 aryl group, when ^{R 1, R 2, R 3} , R 5 ( or R ^4), When R ⁶ and R ^{7 are} both H and R ⁴ (or R ⁵ ) is F, R ^{d is} not a C _3-7 heterocyclic group, wherein the C _1-6 alkyl group, C _3-8 cycloalkyl group -C _1-4 alkylene, C _3-7 heterocyclyl, C _3-7 heterocyclyl-C _1-4 alkylene and C _6-10 aryl may optionally be 1, 2, 3 or 4 independently selected from D, F, Cl, Br, CN, OR ^a , NR ^a R ^b , C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, R ^a OC _1-4 Substituted by an alkylene group or ^a substituent of R ^a R ^b NC _1-4 alkylene group.

In still other embodiments, Q in formula (I) is NR ^a R ^b , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a .

In still other embodiments, each of X, Y and Z in formula (I) is independently H, D, C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _{1- 2} alkylene, C _3-6 heterocyclic, C _3-6 heterocyclyl-C _1-2 alkylene, phenyl, heteroaryl consisting of 5-10 atoms, phenyl-C _1-2 An alkylene group or a heteroaryl group of 5-10 atoms, a C _1-2 alkylene group, wherein the C _1-4 alkyl group, a C _3-6 cycloalkyl group, a C _3-6 cycloalkane -C _1-2 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-2 alkylene, phenyl-C _1-2 alkylene, (5-10 Heteroaryl group of the atomic composition) -C _1-2 alkylene group, phenyl group and heteroaryl group of 5-10 atoms may optionally be 1, 2, 3 or 4 independently selected from D, F, Cl ,Br,CN,C _2-4 alkenyl, C _2-4 alkynyl, OR ^a , NR ^a R ^b ,R ^a OC _1-2 alkylene or R ^a R ^b NC _1-2 alkylene group substitution Substituted by the base.

In other embodiments, each of R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ^{7 in} formula (I) is independently H, D, F or Cl.

In still other embodiments, each of R ^a , R ^b and R ^c in formula (I) is independently H, C _1-4 alkyl, C _1-4 haloalkyl, C _3-6 cycloalkyl, C _{3- 6} cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl or C _3-6 heterocyclyl-C _1-2 alkylene, when R ^a and R ^{b are} bonded to the same nitrogen atom And R ^a , R ^b , together with the nitrogen atom to which they are attached, may optionally form a substituted or unsubstituted heterocyclic ring of 3-8 atoms, wherein said C _1-4 alkyl group, C _{1 -4} haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-2 The alkyl group and the heterocyclic ring of 3-8 atoms may be optionally 1, 2, 3 or 4 independently selected from the group consisting of D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-3 haloalkyl Substituted with a C _1-3 alkoxy group or a C _1-3 alkylamino group.

In still other embodiments, R ^d in formula (I) is H, D, C _1-4 alkyl, C _3-6 cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl or C _3-6 Heterocyclyl-C _1-2 alkylene group, when R ¹ , R ² , R ³ , R ⁵ (or R ⁴ ), R ⁶ and R ^{7 are} simultaneously H, and R ⁴ (or R ⁵ ) is When F is, R ^{d is} not a C _3-6 heterocyclic group, wherein the C _1-4 alkyl group, C _3-6 cycloalkyl-C _1-2 alkylene group, C _3-6 heterocyclic group or C _3-6 Heterocyclyl-C _1-2 alkylene may be optionally 1, 2, 3 or 4 independently selected from D, F, CN, OR ^a , NR ^a R ^b , C _1-3 alkane Substituent, C _2-4 alkenyl, C _2-4 alkynyl, R ^a OC _1-2 alkylene or R ^a R ^b NC _1-2 alkylene substituent.

In still other embodiments, Q in formula (I) is NH ₂ or -N(R ^c )C(=O)R ^d .

In still other embodiments, each of X, Y and Z in formula (I) is independently H, D, CH ₃ , CH ₂ CH ₃ , phenyl or is 1, _{2, 3} , 4 or 5 independently selected from D a phenyl group substituted with a substituent of F or Cl.

In still other embodiments, Q in formula (I) is:

In still other embodiments, the compounds of the invention have the structure of formula (II): Among them, the definitions of Q, X, Y and Z in the formula (II) are as follows.

In some embodiments, in Formula (II): Q is NR ^a R ^b , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a ; each X,Y And Z are independently H, D, C _1-6 alkyl, C _3-8 cycloalkyl, C _3-7 heterocyclyl, C _6-10 aryl, heteroaryl consisting of 5-10 atoms, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 alkylene, or (5 -10 atomic heteroaryl)-C _1-4 alkylene, wherein said C _1-6 alkyl, C _3-8 cycloalkyl, C _3-7 heterocyclic, C _6-10 Aryl, heteroaryl consisting of 5-10 atoms, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 The aryl-C _1-4 alkylene group and the (5-10 atom heteroaryl group)-C _1-4 alkylene group may be optionally 1, 2, 3, 4 or 5 independently selected from D , F, Cl, Br, CN, C _2-6 alkenyl, C _2-6 alkynyl, OR ^a , NR ^a R ^b , R ^a OC _1-4 alkylene or R ^a R ^b NC _1-4 Substituted by a substituent of an alkyl group; each of R ^a , R ^b and R ^{c is} independently H, C _1-6 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclic, C _6-10 aryl group, composed of 5-10 atoms heteroaryl, C _3-6 cycloalkyl, -C _1-4 alkylene, C _3-6 heterocyclyl -C _1-4 Alkyl, C _6-10 aryl or -C _1-4 alkylene (5-10 atoms heteroaryl) -C _1-4 alkylene, wherein said C _1-6 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclyl, C _6-10 aryl, heteroaryl group of 5-10 atoms, C _3-6 cycloalkyl-C _1-4 alkylene, C _3-6 heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 alkylene and (heteroaryl group of 5-10 atoms)-C _1-4 alkylene The group may be optionally 1, 2, 3 or 4 independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _1-6 alkoxy or C ₁ Substituted by a substituent of a _-6 alkylamino group; and R ^d is a C _1-6 alkyl group, wherein the C _1-6 alkyl group may be optionally 1, 2, 3 or 4 independently selected from D, Substituted by a substituent of F, Cl, OH, NH ₂ , C _1-6 alkoxy or C _1-6 alkylamino.

In still other embodiments, Q in formula (II) is NR ^a R ^b or -N(R ^c )C(=O)R ^d .

In still other embodiments, each of X, Y and Z in formula (II) is independently H, D, C _1-4 alkyl or phenyl, wherein said C _1-4 alkyl and phenyl are optional The ground is replaced by 1, 2, 3, 4 or 5 substituents independently selected from D, F or Cl.

In still other embodiments, each R ^a , R ^b and R ^c in formula (II) is independently H, C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclyl, C _{3 -6} cycloalkyl-C _1-2 alkylene or C _3-6 heterocyclyl-C _1-2 alkylene, wherein said C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 Heterocyclyl, C _3-6 cycloalkyl-C _1-2 alkylene and C _3-6 heterocyclyl-C _1-2 alkylene may be optionally 1, 2, 3 or 4 Substituents independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _1-6 alkoxy or C _1-6 alkylamino are substituted.

In other embodiments, of formula (II), R ^d is Me, Et, n -Pr, i -Pr, n -Bu, i -Bu , or t -Bu.

In still other embodiments, Q in formula (II) is NH ₂ or -N(R ^c )C(=O)R ^d .

In still other embodiments, each of X, Y and Z in formula (II) is independently H, D, Me, CH ₂ D, CHD ₂ , CD ₃ , ethyl, propyl, isopropyl, phenyl or 1, 2, 3, 4 or 5 phenyl groups independently substituted with substituents selected from D, F or Cl.

In still other embodiments, Q in formula (II) is:

In another aspect, the present invention relates to a pharmaceutical composition comprising (1) a compound of the invention and (2) A pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or a combination thereof.

In some embodiments, the pharmaceutical composition of the present invention further comprises an additional therapeutic agent selected from the group consisting of a chemotherapeutic drug, an anti-proliferative agent, a drug for treating atherosclerosis, and a lung for treating Fibrotic drugs, or a combination thereof.

In still other embodiments, the pharmaceutical composition of the present invention, wherein the additional therapeutic agent involved is Adriamycin, Rapamycin, Temsirolimus, Everolimus, Ixabepilone, Gemcitabin, cyclophosphamide, dexamethasone, etoposide, fluorouracil, afatinib, alisertib, amuvatinib, axitinib ), bosutinib (brsutinib), brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, danusertib, dovitinib, erlotidine Erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib , motesanib, neratinib, niraparib, nilotinib, oprozomib, olaparib, pazopanib, pictilis Ib,ponatinib,quizartinib,regorafenib,rigosertib,rucaparib,ruxolitinib,sacatinib,saridegib,sorafenib,sunitinib,tasocitinib,telatinib,tivantinib,tivozanib,tofacitinib, Trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, an interferon, carboplatin, topotecan, taxol, vinblastine, Vincent (vincristine), temozolomide, tositumomab, trabedectin, belimumab, bevacizumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, ranibizumab, rituximab, tositumomab , trastuzumab or a combination thereof.

In another aspect, the use of a compound or pharmaceutical composition of the invention to prepare a medicament for protecting, treating, treating or ameliorating a proliferative disorder in a patient can be used.

In some embodiments, the proliferative disorder of the invention is metastatic cancer, colon cancer, gastric gland Cancer, bladder cancer, breast cancer, kidney cancer, liver cancer, lung cancer, skin cancer, thyroid cancer, brain tumor, neck cancer, prostate cancer, pancreatic cancer, CNS (central nervous system) cancer, malignant glioma, myeloproliferative disease, Atherosclerosis or pulmonary fibrosis.

In another aspect, the invention relates to the use of a compound or pharmaceutical composition of the invention for the preparation of a medicament for inhibiting or modulating protein kinase activity in a biological specimen, the use comprising the use of a compound or pharmaceutical composition of the invention and said biological specimen contact.

In some of these embodiments, the protein kinase of the invention is a receptor tyrosine kinase.

In other embodiments, the receptor tyrosine kinase of the invention is VEGFR, c-Met, Ron, Axl or a combination thereof.

In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention as a tyrosine kinase receptor inhibitor, or a stereoisomer, geometric isomer, tautomer, solvate, metabolite thereof Or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or a combination thereof. In some embodiments, the pharmaceutical compositions provided herein comprise a compound that is responsive to VEGF receptor signaling, HGF receptor signaling, Ron receptor signaling, and Axl receptor signaling inhibitor, or a stereoisomer thereof , geometric isomers, tautomers, solvates, metabolites, or pharmaceutically acceptable salts thereof, or pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles, or their combination. In other embodiments, the pharmaceutical compositions of the present invention further comprise an additional therapeutic agent.

In another aspect, the invention relates to a method of inhibiting protein tyrosine kinase activity comprising contacting a compound of the invention or a pharmaceutical composition thereof with said kinase. In some of these embodiments, the invention relates to a method of inhibiting VEGF receptor signaling, HGF receptor signaling, Ron receptor signaling, and Axl receptor signaling, comprising a compound of the invention or a pharmaceutical composition thereof Receptor contact. Inhibition of receptor protein kinase activity, particularly VEGF, HGF, Ron and Axl receptor signaling, can be performed in single or multicellular organisms. If present in a multicellular organism, the methods described herein comprise administering an organism using a compound or composition of the invention. In some embodiments, the organism is a mammal, and in other embodiments, the organism is a human. In other embodiments, the method further comprises contacting the protein kinase with an additional therapeutic agent.

In another aspect, the invention relates to a method of inhibiting cell proliferation activity comprising a dose of a compound of the invention or a pharmaceutical composition thereof effective to inhibit cell proliferation in contact with a cell. In some embodiments, the methods of the invention further comprise contacting the additional therapeutic agent with the cells.

In another aspect, the invention relates to a method of treating a cell proliferative disorder in a patient, the method comprising administering to a patient a dose effective to treat a compound of the invention or a composition thereof. In some embodiments, the methods of the invention further comprise administering an additional therapeutic agent.

In another aspect, the invention features a method of inhibiting tumor growth in a patient, the method comprising administering to a patient a dose effective to treat a compound of the invention or a composition thereof. In some embodiments, the methods of the invention further comprise the administration of an additional therapeutic agent.

In another aspect, the invention relates to a process for the preparation, isolation and purification of a compound encompassed by formula (I) or formula (II).

The foregoing description merely summarizes certain aspects of the invention, but is not limited thereto. These and other aspects will be described in more detail below.

Definitions and general terms

The present invention will list the documents corresponding to the specific content of the determination, and the examples are accompanied by the diagrams of the structural formula and the chemical formula. The present invention is intended to cover all alternatives, modifications, and equivalents, which may be included in the field of the present invention as defined by the scope of the claims. Those skilled in the art will recognize many methods and materials that are similar or equivalent to those described herein, which can be used in the practice of the present invention. The invention is in no way limited to the description of methods and materials. There are many documents and similar materials that differ or contradict the application of the present invention, including but not limited to the definition of terms, the use of terms, the techniques described, or the scope as controlled by the present application.

The invention will apply the following definitions unless otherwise indicated. For the purposes of the present invention, chemical elements are defined in accordance with the Periodic Table of the Elements, CAS version and Handbook of Chemicals , 75, ^th Ed, 1994 . In addition, the general principles of organic chemistry can be found in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999 , and "March's Advanced Organic Chemistry," by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007 , therefore all The content is a fusion of references.

As described herein, the compounds of the present invention may be optionally substituted with one or more substituents, such as the compounds of the above formula, or specific examples, subclasses, and inclusions of the present invention. A class of compounds. It should be understood that the term "optionally substituted" and the term "substituted or unsubstituted" are used interchangeably. In general, the term "optionally" whether or not preceded by the term "substituted" means that one or more hydrogen atoms in the given structure are replaced by a particular substituent. Unless otherwise indicated, an optional substituent group can be substituted at each substitutable position of the group. It should be noted that in the present invention, when R ^a and R ^{b are} bonded to the same nitrogen atom, R ^a , R ^b together with the nitrogen atom to which they are attached may optionally form a substituted or unsubstituted 3-8 atom. The heterocyclic rings, i.e., R ^a , R ^b , together with the nitrogen atom to which they are attached, may form a heterocyclic ring of 3 to 8 atoms or may not form a heterocyclic ring, and other structures well known to those skilled in the art, such as NR. ^a -R ^b or R ^a -NR ^b and the like. When more than one position in the given formula can be substituted by one or more substituents selected from a particular group, the substituents may be substituted at the various positions, either identically or differently. The substituents described therein may be, but are not limited to, D, F, Cl, Br, N ₃ , NO ₂ , CN, OH, NH ₂ , OR ^a , CH ₂ D, CHD ₂ , CD ₃ , R ^a OC _1-4 alkylene, SR ^a , NR ^a R ^b , R ^a R ^b NC _1-4 alkylene, -C(=O)NR ^a R ^b , -N(R ^c )C(=O) NR ^a R ^b , -N(R ^c )C(=O)R ^d , -N(R ^c )S(=O)NR ^a R ^b , -N(R ^c )S(=O)R ^a ,- N(R ^c )S(=O) ₂ NR ^a R ^b ,-N(R ^c )S(=O) ₂ R ^a ,methyl,ethyl, n-propyl, isopropyl, methoxy, benzene Base, phenyl-C _1-2 alkylene, C _1-6 alkyl, C _1-6 aliphatic, C _1-6 haloalkyl, C _1-6 alkoxy, C _1-6 alkylamino, C _2-6 alkenyl, C _2-6 alkynyl, C _3-8 cycloalkyl, C _3-7 heterocyclyl, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 Heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 alkylene, (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group, C _{6 a -10} aryl group, or a heteroaryl group of 5-10 atoms, wherein R ^a , R ^b and R ^c have the definitions as defined in the present invention.

The term "aliphatic" or "aliphatic group" as used herein, denotes a straight-chain (ie unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturations. . Unless otherwise specified, an aliphatic group contains from 1 to 20 carbon atoms, some of which are, wherein the aliphatic group contains from 1 to 10 carbon atoms, and in other embodiments, the aliphatic group contains from 1 to 8 A carbon atom, in other embodiments, the aliphatic group contains 1-6 carbon atoms, and in other embodiments, the aliphatic group contains 1-3 carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl or alkynyl groups, such as _C1-6 aliphatic groups, including straight chains or branches. A chain, a substituted or unsubstituted C _1-6 alkyl group, a C _2-6 alkenyl group, or a C _2-6 alkynyl group. Such examples include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, ethylene, propylene, butene, 2-butene, acetylene, propyne , butyne, 2-butyne, and the like, and the aliphatic group may be independently unsubstituted or substituted with one or more substituents described herein.

The term "alkyl" or "alkyl group" as used herein, denotes a saturated straight or branched monovalent hydrocarbon radical containing from 1 to 20 carbon atoms. Unless otherwise specified, an alkyl group contains from 1 to 20 carbon atoms, some of which are, wherein the alkyl group contains from 1 to 10 carbon atoms, and in other embodiments, the alkyl group contains from 1 to 8 A carbon atom, in other embodiments, the alkyl group contains 1-6 carbon atoms, in other embodiments, the alkyl group contains 1-4 carbon atoms, and in other embodiments, the alkyl group contains 1-3 carbon atoms.

Examples of alkyl groups include, but are not limited to, methyl (Me, -CH ₃ ), ethyl (Et, -CH ₂ CH ₃ ), n-propyl ( n -Pr, -CH ₂ CH ₂ CH ₃ ), isopropyl ( i- Pr, -CH(CH ₃ ) ₂ ), n-butyl ( n -Bu, -CH ₂ CH ₂ CH ₂ CH ₃ ), isobutyl ( i -Bu, -CH ₂ CH (CH ₃ ) ₂ ), sec-butyl ( s -Bu, -CH(CH ₃ )CH ₂ CH ₃ ), tert-butyl ( t -Bu, -C(CH ₃ ) ₃ ), n-pentyl (-CH) ₂ CH ₂ CH ₂ CH ₂ CH ₃ ), 2-pentyl (-CH(CH ₃ )CH ₂ CH ₂ CH ₃ ), 3-pentyl (-CH(CH ₂ CH ₃ ) ₂ ), 2-methyl -2-butyl (-C(CH ₃ ) ₂ CH ₂ CH ₃ ), 3-methyl-2-butyl (-CH(CH ₃ )CH(CH ₃ ) ₂ ), 3-methyl-1- Butyl (-CH ₂ CH ₂ CH(CH ₃ ) ₂ ), 2-methyl-1-butyl (-CH ₂ CH(CH ₃ )CH ₂ CH ₃ ), n-hexyl (-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₃ ), 2-hexyl (-CH(CH ₃ )CH ₂ CH ₂ CH ₂ CH ₃ ), 3-hexyl (-CH(CH ₂ CH ₃ )(CH ₂ CH ₂ CH ₃ )), 2-methyl-2-pentyl (-C(CH ₃ ) ₂ CH ₂ CH ₂ CH ₃ ), 3-methyl-2-pentyl (-CH(CH ₃ )CH(CH ₃ )CH ₂ CH ₃ ), 4-methyl-2-pentyl (-CH(CH ₃ )CH ₂ CH(CH ₃ ) ₂ ), 3-methyl-3-pentyl (-C(CH ₃ )(CH ₂ CH ₃ ) _2), 2-methyl-3-pentyl _{(-CH (CH 2 CH 3)} CH (CH 3) 2) 2,3-dimethyl-2-butyl _{(-C (CH 3) 2 CH} (CH 3) 2), 3,3- dimethyl-2-butyl _{(-CH (CH 3) C (} CH ₃ ) ₃ ), n-heptyl, n-octyl, and the like, wherein the alkyl group may be independently unsubstituted or substituted with one or more substituents described herein.

As used herein, the term "alkyl" and its first "alkane", both contain straight-chain and branched saturated carbon chains.

The term "alkylene" means a saturated divalent hydrocarbon group derived by removing two hydrogen atoms from a linear or branched saturated hydrocarbon group. Unless otherwise specified, an alkylene group contains from 1 to 10 carbon atoms, and in other embodiments, an alkylene group contains from 1 to 6 carbon atoms. In still other embodiments, an alkylene group contains 1 - 4 carbon atoms, in other embodiments, the alkylene group contains 1-2 carbon atoms. Such examples include methylene (-CH ₂ -), ethylene (-CH ₂ CH ₂ -), isopropylidene (-CH(CH ₃ )CH ₂ -), and the like, wherein the alkylene group The group may be independently unsubstituted or substituted by one or more substituents described herein.

The term "alkenyl" denotes a straight or branched chain monovalent hydrocarbon radical of 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, or 2 to 4 carbon atoms, at least One position is an unsaturated state, that is, one CC is a sp ² double bond, wherein the alkenyl group may be independently unsubstituted or substituted by one or more substituents described herein, including a group having " The positioning of ""正" or "E""Z", including but not limited to, vinyl (-CH=CH ₂ ), allyl (-CH ₂ CH=CH ₂ ), etc. .

The term "alkynyl" means a straight or branched chain monovalent hydrocarbon radical of 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, or 2 to 4 carbon atoms, at least one of which The position is an unsaturated state, that is, one CC is a sp triple bond, wherein the alkynyl group may be independently unsubstituted or substituted by one or more substituents described in the present invention, and specific examples include, but are not limited to, , ethynyl (-C≡CH), propargyl (-CH ₂ C≡CH), 1-propynyl (-C≡C-CH ₃ ) and the like.

The term "alkoxy" denotes an alkyl group attached to the remainder of the molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains from 1 to 20 carbon atoms, some of which are, the alkoxy group contains from 1 to 10 carbon atoms, and in other embodiments, the alkoxy group Containing from 1 to 8 carbon atoms, in other embodiments, the alkoxy group contains from 1 to 6 carbon atoms, and in other embodiments, the alkoxy group contains from 1 to 4 carbon atoms, and other embodiments Yes, the alkoxy group contains 1-3 carbon atoms.

Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH ₃ ), ethoxy (EtO, -OCH ₂ CH ₃ ), 1-propoxy ( n- PrO, n- Propyloxy, -OCH ₂ CH ₂ CH ₃ ), 2-propoxy ( i- PrO, i -propoxy, -OCH(CH ₃ ) ₂ ), 1-butoxy (n-BuO, n- Butoxy, -OCH ₂ CH ₂ CH ₂ CH ₃ ), 2-methyl-1-propoxy ( i- BuO, i -butoxy, -OCH ₂ CH(CH ₃ ) ₂ ), 2-butyl Oxygen (s-BuO, s-butoxy, -OCH(CH ₃ )CH ₂ CH ₃ ), 2-methyl-2-propoxy ( t- BuO, t -butoxy, -OC(CH) ₃ ) ₃ ), 1-pentyloxy (n-pentyloxy, -OCH ₂ CH ₂ CH ₂ CH ₂ CH ₃ ), 2-pentyloxy (-OCH(CH ₃ )CH ₂ CH ₂ CH ₃ ), 3-pentyloxy (-OCH(CH ₂ CH ₃ ) ₂ ), 2-methyl-2-butoxy (-OC(CH ₃ ) ₂ CH ₂ CH ₃ ), 3-methyl-2-butoxy (-OCH(CH ₃ )CH(CH ₃ ) ₂ ), 3-methyl-1-butoxy (-OCH ₂ CH ₂ CH(CH ₃ ) ₂ ), 2-methyl-1-butoxy (-OCH ₂ CH(CH ₃ )CH ₂ CH ₃ ), and the like, wherein the alkoxy group may be independently unsubstituted or substituted with one or more substituents described herein.

The term "haloalkyl", "haloalkenyl" or "haloalkoxy" denotes an alkyl, alkenyl or alkoxy group substituted by one or more halogen atoms, examples of which include, but are not limited to, Trifluoromethyl, trifluoromethoxy, and the like.

The term "carbocyclic", "carbocyclyl" or "cyclic aliphatic" means having one or more attachment points attached to the remainder of the molecule, non-aromatic, saturated or partially unsaturated, including 3-12 Monocyclic, bicyclic and tricyclic systems having one carbon atom, or 3 to 10 carbon atoms, or 3 to 8 carbon atoms, or 3 to 6 carbon atoms. Suitable cyclic aliphatic groups include, but are not limited to, cycloalkyl, cycloalkenyl and cycloalkynyl. Examples of the cyclic aliphatic group further include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-enyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-1-enyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexadienyl, Cycloheptyl, cyclooctyl, cyclodecyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.

The term "cycloalkyl" refers to a monocyclic, bicyclic or tricyclic ring system having one or more attachment points attached to the remainder of the molecule, saturated, having from 3 to 12 carbon atoms. Its bicyclic system comprises a spiro bicyclic ring and a fused bicyclic ring. Some of these examples are ring systems containing from 3 to 10 carbon atoms, others are ring systems containing from 3 to 8 carbon atoms, and other embodiments are ring systems containing from 3 to 6 carbon atoms, others Examples are ring systems containing from 5 to 6 carbon atoms, and the cycloalkyl groups can be independently unsubstituted or substituted with one or more substituents described herein.

The term "cycloalkylalkylene" means that the alkyl group may be substituted by one or more cycloalkyl groups, wherein the alkyl and cycloalkyl groups have the meanings as described herein. In some of these embodiments, a cycloalkylalkylene group refers to a "lower cycloalkylalkylene" group, i.e., a cycloalkyl group attached to a _C1-6 alkyl group. In other embodiments, a cycloalkyl group is attached to a _C1-4 alkyl group. In other embodiments, a cycloalkyl group is attached to the _C1-3 alkyl group. In other embodiments, a cycloalkyl group is attached to the C _1-2 alkyl group. Such examples include, but are not limited to, cyclopropylethyl, cyclopentylmethyl, cyclohexylmethyl, and the like. The cycloalkylalkylene group may be independently unsubstituted or substituted with one or more substituents described herein. Such examples include, but are not limited to, cyclopropylethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

The terms "heterocycle", "heterocyclyl" or "heterocycle" are used interchangeably herein to refer to a monocyclic, bicyclic, or tricyclic ring system wherein one or more atoms on the ring are optionally independently Substituted by a heteroatom, the ring may be fully saturated or contain one or more degrees of unsaturation, but by no means an aromatic type, only one point of attachment is attached to the remainder of the molecule. Its bicyclic system comprises a spiro bicyclic ring and a fused bicyclic ring, and one of the rings may be a monocarbocyclic ring or a monoheterocyclic ring. Hydrogen atoms on one or more of the rings are independently, optionally, substituted by one or more substituents described herein. In some embodiments, a "heterocyclic""heterocyclyl" or "heterocyclic" group is a monocyclic ring of 3-7 atoms (2-6 carbon atoms and selected from N, O, P, S) 1-3 heteroatoms, where S or P is optionally substituted with one or more oxygen atoms to give a group like SO, SO ₂ , PO, PO ₂ ), and in other embodiments, 3-6 a single ring composed of atoms (2-5 carbon atoms and 1-3 heteroatoms selected from N, O, P, S, where S or P is optionally substituted by one or more oxygen atoms to give an image a group of S=O, SO ₂ , PO, PO ₂ , when the ring is a three-membered ring, wherein there is only one hetero atom), or a double ring of 7-10 atoms (4-9 carbon atoms and One to three heteroatoms selected from N, O, P, S, wherein S or P is optionally substituted with one or more oxygen atoms to give a group like SO, SO ₂ , PO, PO ₂ ).

The heterocyclic group may be a carbon group or a hetero atom group. "Heterocyclyl" also includes groups formed by the condensation of a heterocyclic group with a saturated or partially unsaturated ring or heterocyclic ring. Examples of heterocyclic rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, acridinyl, Morpholinyl, thiomorpholinyl, thiazolidine, pyridazinyl, oxazinyl, azetidinyl, oxetanyl, thioheterobutyl, homoacridinyl, propylene Base, azepanyl, oxetanyl, thietyl, oxazepine, diazepine, sulfur Rhodamine, 2-pyrroline, 3-pyrolinyl, indanyl, 2H-pyranyl, 4H-pyranyl, dioxolyl, 1,3-dioxopentyl, pyridyl Oxazolinyl, dithiaalkyl, dithiamethane, dihydrothienyl, pyrazolidinyl imidazolyl, imidazolidinyl, 1,2,3,4-tetrahydroisoquinolinyl. Examples of the heterocyclic group further include a 1,1-dioxothiomorpholinyl group, and wherein two carbon atoms in the ring are substituted with an oxygen atom such as a pyrimidinedione group.

The term "heterocyclylalkylene" means that the alkyl group may be substituted by one or more heterocyclyl groups, wherein the alkyl and heterocyclyl groups have the meanings as described herein. In some of these embodiments, a heterocyclylalkylene group refers to a "lower heterocyclylalkylene" group, i.e., a heterocyclyl group attached to a _C1-6 alkyl group. In other embodiments, a heterocyclyl group is attached to a _C1-4 alkyl group. In other embodiments, a heterocyclyl group is attached to the C _1-2 alkyl group. Such examples include, but are not limited to, 2-pyrrolidinoethyl, 3-azetidinylmethyl, and the like. The heterocyclylalkylene group may be independently unsubstituted or substituted with one or more substituents described herein.

The term "heteroatom" means O, S, N, P and Si, including the form of any oxidation state of N, S and P; in the form of primary, secondary, tertiary and quaternary ammonium salts; or on a nitrogen atom in a heterocycle a form in which hydrogen is substituted, for example, N (like N in 3,4-dihydro-2H-pyrrolyl), NH (like NH in pyrrolidinyl) or NR (like in N-substituted pyrrolidinyl) NR).

The term "halogen" means F, Cl, Br or I.

The term "H" denotes a single hydrogen atom. Such radicals may be attached to other groups, such as to an oxygen atom, to form a hydroxyl group.

The term "D" or ^"2 H" denotes a single deuterium atom. One such atomic group is bonded to a methyl group to form a mono-deuterated methyl group (-CDH ₂ ), two deuterium atoms are bonded to one methyl group to form a bis-deuterated methyl group (-CD ₂ H), and three The ruthenium atom is bonded to a methyl group to form a tri-deuterated methyl group (-CD ₃ ).

The term "N ₃ " means an azide structure. Such a group may be attached to other groups, for example, to a methyl group to form azide methane (MeN ₃ ) or to a phenyl group to form azidobenzene (PhN ₃ ).

The term "aryl" may be used alone or as a large part of "aralkyl", "aralkyloxy" or "aryloxyalkyl", meaning a total of 6 to 14 ring atoms, or 6 to 12 Ring atom, or 6-10 rings a monocyclic, bicyclic, and tricyclic carbocyclic ring system in which at least one ring system is aromatic, wherein each ring system contains a ring of 3-7 atoms and has only one attachment point with the rest of the molecule Partially connected. The term "aryl" may be used interchangeably with the term "aromatic ring", such as an aromatic ring which may include phenyl, naphthyl and anthracene. The aryl group may be independently unsubstituted or substituted with one or more substituents described herein.

The term "arylalkylene" means that the alkyl group may be substituted by one or more aryl groups, wherein the alkyl and aryl groups have the meanings as described herein, some of which are The alkylene group refers to a "lower arylalkylene" group, i.e., an aryl group attached to a _C1-6 alkyl group. In other embodiments, an arylalkylene group refers to a "phenylene group" containing a _C1-4 alkyl group. In other embodiments, an arylalkylene group refers to an aryl group attached to an alkyl group of C _1-2 . Specific examples thereof include a benzyl group, a diphenylmethyl group, a phenethyl group and the like. The arylalkylene group may be independently unsubstituted or substituted with one or more substituents described herein.

The term "heteroaryl" may be used alone or as a large part of "heteroarylalkyl" or "heteroarylalkoxy", meaning a total of 5 to 14 ring atoms, or 5 to 12 ring atoms, Or a monocyclic, bicyclic, and tricyclic ring system of 5-10 ring atoms, wherein at least one ring system is aromatic and at least one ring system comprises one or more heteroatoms, wherein each ring system comprises 5-7 A ring of atoms, and only one attachment point is attached to the rest of the molecule. The term "heteroaryl" can be used interchangeably with the terms "aromatic heterocycle" or "heteroaromatic".

In other embodiments, the aromatic heterocycle includes the following monocyclic rings, but is not limited to these monocyclic rings: 2-furyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5- Imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrole , 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (eg 3-pyridazinyl), 2 -thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (such as 5-tetrazolyl), triazolyl (such as 2-triazolyl and 5-triazolyl), 2-thienyl, 3 -Thienyl, pyrazolyl (such as 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiyl Azyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyridyl Azinyl, 1,3,5-triazinyl; also includes the following bicyclic rings, but is by no means limited to these bicyclic rings: benzimidazolyl, benzofuranyl, benzothienyl, fluorenyl (eg 2-indole) Base, fluorenyl, quinolyl (eg 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and Quino A phenyl group (such as 1-isoquinolyl, 3-isoquinolyl or 4-isoquinolinyl). The heteroaryl group can be independently unsubstituted or substituted with one or more substituents described herein.

The term "heteroarylalkylene" means that the alkyl group may be substituted by one or more heteroaryl groups, wherein the alkyl and heteroaryl groups have the meanings as described herein, some of which are Yes, a heteroarylalkylene group refers to a "lower heteroarylalkylene" group, i.e., a heteroaryl group attached to a _C1-6 alkyl group. In other embodiments, a heteroaryl group is attached to a _C1-4 alkyl group. In other embodiments, a heteroaryl group is attached to the C _1-2 alkyl group. Specific examples thereof include 2-pyridylmethyl, 3-furanethyl and the like. The heteroarylalkylene group may be independently unsubstituted or substituted with one or more substituents described herein.

The term "carboxy", whether used alone or in conjunction with other terms, such as "carboxyalkyl", means -CO ₂ H; the term "carbonyl", whether used alone or in conjunction with other terms, such as "aminocarbonyl" or ""醯oxy", which means -(C=O)-.

The term "alkylamino" includes "N-alkylamino" and "N,N-dialkylamino" wherein the amino groups are each independently substituted with one or two alkyl groups. In some embodiments, the alkylamino group is a lower alkylamino group having one or two _C1-6 alkyl groups attached to the nitrogen atom. In other embodiments, the alkylamino group is a lower alkylamino group of _C1-3 . Suitable alkylamino groups may be monoalkylamino or dialkylamino, examples of which include, but are not limited to, N-methylamino, N-ethylamino, N,N-dimethylamino, N, N - Diethylamino and the like.

The term "arylamino" means that the amino group is substituted by one or two aryl groups, examples of which include, but are not limited to, N-phenylamino. In some of these embodiments, the aromatic ring on the arylamino group can be further substituted.

The term "aminoalkyl" includes _C1-10 straight or branched alkyl groups substituted with one or more amino groups. In some embodiments, the aminoalkyl group is a _C1-6 "lower aminoalkyl group" substituted with one or more amino groups, examples of which include, but are not limited to, aminomethyl, ammonia Ethyl, aminopropyl, aminobutyl and aminohexyl.

The term "unsaturated" as used in the present invention means that the group contains one or more unsaturations.

The term "comprising" is an open expression, that is, includes the content specified by the present invention, but does not exclude it. His content.

Unless otherwise indicated, the structural formulae described herein include all isomeric forms (eg, enantiomeric, diastereomeric, and geometric (or conformational)): for example, containing asymmetric centers The R, S configuration, the (Z), (E) isomers of the double bond, and the conformational isomers of (Z), (E). Thus, individual stereochemical isomers of the compounds of the invention, or enantiomers, diastereomers thereof, or mixtures of geometric isomers (or conformational isomers) are within the scope of the invention.

The term "tautomer" or "tautomeric form" as used in the present invention means that structural isomers having different energies can cross the low energy barrier and thereby transform each other. For example, proton tautomers (ie, proton shifts) include interconversions by proton transfer, such as keto-enol interconversion and imine-enamine isomerization. Valence tautomers include interconversion through some bonding electron recombination.

Unless otherwise indicated, all tautomeric forms of the compounds of the invention are included within the scope of the invention. Additionally, unless otherwise indicated, the structural formulae of the compounds described herein include enriched isotopes of one or more different atoms.

The term "prodrug" as used in the present invention denotes a compound which is converted in vivo to a compound of formula (I) or formula (II). Such transformation is affected by the hydrolysis of the prodrug in the blood or by enzymatic conversion to the parent structure in the blood or tissue. Prodrugs of the compounds of the present invention may be an ester before, in the conventional invention, the ester may be used as prodrugs are phenyl esters, aliphatic (C _1-24) esters, acyl oxymethyl ester, carbonate, Carbamates and amino acid esters. For example, a compound of the invention comprises a hydroxyl group, i.e., it can be deuterated to give a compound in the form of a prodrug. Other prodrug forms include phosphates, such as those obtained by phosphorylation of a hydroxy group on the parent. For a discussion of the completeness of prodrugs, refer to the following documents: T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987 , J. Rautio et al ., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery , 2008 , 7, 255-270, and SJ Hecker et al ., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry , 2008 , 51, 2328-2345.

"metabolite" refers to the production of a specific compound or a salt thereof by metabolism in vivo. Things. Metabolites of a compound can be identified by techniques well known in the art, and the activity can be characterized by experimental methods as described herein. Such a product may be obtained by administering a compound by oxidation, reduction, hydrolysis, hydrazine, deamination, esterification, defatting, enzymatic cleavage and the like. Accordingly, the invention includes metabolites of a compound, including metabolites produced by intimate contact of a compound of the invention with a mammal for a period of time.

The use of the definitions and conventions of stereochemistry in the present invention is generally referred to the following documents: SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S. "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the invention may contain asymmetric centers or chiral centers, and thus different stereoisomers are present. All stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, constitute the present invention. portion. Many organic compounds exist in optically active forms, that is, they have the ability to rotate planes of plane polarized light. In describing an optically active compound, the first code D, L or R, S is used to indicate the absolute configuration of the molecular chiral center. The first code d, l or (+), (-) is used to name the symbol of the rotation of the plane polarized light of the compound, (-) or l means that the compound is left-handed, and the first code (+) or d means that the compound is right-handed. . The chemical structures of these stereoisomers are the same, but their stereostructures are different. A particular stereoisomer can be an enantiomer, and a mixture of isomers is often referred to as a mixture of enantiomers. The 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may result in no stereoselectivity or stereospecificity during the chemical reaction. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that lack optical activity.

The term "tautomer" or "tautomeric form" means that the isomers of the structure of different energies can be converted into each other by a low energy barrier. For example, proton tautomers (i.e., proton-shifted tautomers) include interconversions by proton transfer, such as keto-enol and imine-enamine isomerization. The valence (valence) tautomer includes the interconversion of recombination bond electrons.

The "pharmaceutically acceptable salt" as used in the present invention means an organic salt and an inorganic salt of the compound of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in the literature: SMBerge et al ., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977 , 66: 1-19. Salts formed by pharmaceutically acceptable non-toxic acids include, but are not limited to, mineral acid salts formed by reaction with amino groups, hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, and Organic acid salts such as acetates, oxalates, maleates, tartrates, citrates, succinates, malonates, or by other methods such as ion exchange methods described in the literature. . Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, besylate, benzoate, disulfate, borate, butyrate, camphorate , camphor sulfonate, cyclopentyl propionate, digluconate, lauryl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerol phosphate , gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malic acid Salt, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulphate, 3-benzene Propionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts obtained by appropriate hydrazine include salts of alkali metals, alkaline earth metals, ammonium and N ⁺ (C _1-4 alkyl) ₄ . The present invention also contemplates quaternary ammonium salts formed from any of the compounds comprising a group of N. Water soluble or oil soluble or dispersed products can be obtained by quaternization. Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further comprise suitable amine cation nontoxic ammonium, quaternary ammonium, and the counterion, such as halide, hydroxide, carboxylate, sulfated, phosphorylated compounds, nitrate compounds, C _{1- 8} sulfonate and aromatic sulfonate.

"Solvate" as used herein refers to an association of one or more solvent molecules with a compound of the invention. Solvent-forming solvents include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl hydrazine, ethyl acetate, acetic acid, aminoethanol. The term "hydrate" means that the solvent molecule is an association formed by water.

The term "protecting group" or "Pg" refers to a substituent that is typically used to block or protect a particular functionality when reacted with other functional groups. For example, "protecting group of an amino group" means a substituent which is bonded to an amino group to block or protect the functionality of an amino group in a compound. Suitable amino protecting groups include ethenyl, trifluoroethylidene, tert-butyl Oxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethoxycarbonyl (Fmoc). Similarly, a "hydroxy protecting group" refers to a substituent of a hydroxy group used to block or protect the functionality of a hydroxy group. Suitable protecting groups include ethenyl and carbaryl. "Carboxy protecting group" means a substituent of a carboxy group used to block or protect the functionality of a carboxy group. Typical carboxy protecting groups include -CH ₂ CH ₂ SO ₂ Ph, cyanoethyl, 2-(trimethylnonane) Ethyl, 2-(trimethyldecyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfonyl)ethyl, 2-(di Phenylphosphino)ethyl, nitroethyl, and the like. A general description of protecting groups can be found in the literature: T W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991 ; and PJ Kocienski, Protecting Groups, Thieme, Stuttgart, 2005 .

Description of the compounds of the invention

The present invention relates to substituted pyrazolone compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof, mediated by tyrosine kinase receptors, particularly VEGFR, c-Met, Ron and/or Axl receptors Or the treatment of the condition has potential uses. In particular, the invention relates to a compound of formula (I): Or a stereoisomer, geometric isomer, tautomer, oxynitride, hydrate, solvate, metabolite, pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q in formula (I) The definitions of R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , W, X, Y and Z are as follows.

In some embodiments, in Formula (I): Q is H, NR ^a R ^b , OR ^a , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a W is CR ⁷ or N; each X, Y and Z are independently H, D, C _1-6 alkyl, C _3-8 cycloalkyl, C _3-8 cycloalkyl-C _1-4 alkylene , C _3-7 heterocyclyl, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl, heteroaryl consisting of 5-10 atoms, C _6-10 aryl -C _1-4 alkylene or (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group, wherein the C _1-6 alkyl group, C _3-8 cycloalkyl group, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclic, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl, 5-10 A heteroaryl group of an atom, a C _6-10 aryl-C _1-4 alkylene group and a (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group may optionally be 1,2 , 3, 4 or 5 independently selected from D, F, Cl, Br, CN, C _2-6 alkenyl, C _2-6 alkynyl, OR ^a , NR ^a R ^b , R ^a OC _1-4 alkylene Substituted by a substituent of R ^a R ^b NC _1-4 alkylene; each R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ^{7 are} independently H, D, F, Cl _{, Br, CN, N 3,} oR a, C 1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl or C _2-6 alkynyl group Each R ^a, R ^b and R ^{c are} independently H, C _1-6 aliphatic, C _1-6 haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl, -C _1-4 alkylene , C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-4 alkylene, C _6-10 aryl, heteroaryl group of 5-10 atoms, C _6-10 aryl -C _1-4 alkylene or (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group, when R ^a and R ^{b are} bonded to the same nitrogen atom, R ^a , R ^b , Together with the nitrogen atom to which they are attached, a substituted or unsubstituted heterocyclic ring of 3-8 atoms may be optionally formed, wherein the C _1-6 aliphatic, C _1-6 haloalkyl, C _{3 -6} cycloalkyl, C _3-6 cycloalkyl-C _1-4 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-4 alkylene, C _6-10 Aryl group, heteroaryl group of 5-10 atoms, C _6-10 aryl-C _1-4 alkylene group, (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group and The heterocyclic ring of 3-8 atoms may optionally be 1, 2, 3 or 4 independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _{1 -6} alkoxy or substituted C _1-6 alkyl substituted amino group; and R ^d is H, C _1-6 alkyl, C _3-8 cycloalkyl, -C _1-4 alkylene C _3-7 heterocyclyl, C _3-7 heterocyclyl -C _1-4 alkylene or C _6-10 aryl group, when ^{R 1, R 2, R 3} , R 5 ( or R ^4), R ⁶ and R ^{7 are} both H, and R ⁴ (or R ⁵ ) is F, and R ^{d is} not a C _3-7 heterocyclic group, wherein the C _1-6 alkyl group, C _3-8 cycloalkyl group- C _1-4 alkylene, C _3-7 heterocyclyl, C _3-7 heterocyclyl-C _1-4 alkylene and C _6-10 aryl may optionally be 1, 2, 3 or 4 Individually selected from D, F, Cl, Br, CN, OR ^a , NR ^a R ^b , C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, R ^a OC _1-4 Substituted by a substituent of an alkyl group or R ^a R ^b NC _1-4 alkylene group.

In still other embodiments, Q in formula (I) is NR ^a R ^b , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a .

In still other embodiments, each of X, Y and Z in formula (I) is independently H, D, C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _{1- 2} alkylene, C _3-6 heterocyclic, C _3-6 heterocyclyl-C _1-2 alkylene, phenyl, heteroaryl consisting of 5-10 atoms, phenyl-C _1-2 An alkylene group or a heteroaryl group of 5-10 atoms, a C _1-2 alkylene group, wherein the C _1-4 alkyl group, a C _3-6 cycloalkyl group, a C _3-6 cycloalkane -C _1-2 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-2 alkylene, phenyl-C _1-2 alkylene, (5-10 Heteroaryl group of the atomic composition) -C _1-2 alkylene group, phenyl group and heteroaryl group of 5-10 atoms may optionally be 1, 2, 3 or 4 independently selected from D, F, Cl ,Br,CN,C _2-4 alkenyl, C _2-4 alkynyl, OR ^a , NR ^a R ^b ,R ^a OC _1-2 alkylene or R ^a R ^b NC _1-2 alkylene group substitution Substituted by the base.

In other embodiments, each of R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ^{7 in} formula (I) is independently H, D, F or Cl.

In still other embodiments, each of R ^a , R ^b and R ^c in formula (I) is independently H, C _1-4 alkyl, C _1-4 haloalkyl, C _3-6 cycloalkyl, C _{3- 6} cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl or C _3-6 heterocyclyl-C _1-2 alkylene, when R ^a and R ^{b are} bonded to the same nitrogen atom And R ^a , R ^b , together with the nitrogen atom to which they are attached, may optionally form a substituted or unsubstituted heterocyclic ring of 3-8 atoms, wherein said C _1-4 alkyl group, C _{1 -4} haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-2 The alkyl group and the heterocyclic ring of 3-8 atoms may be optionally 1, 2, 3 or 4 independently selected from the group consisting of D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-3 haloalkyl Substituted with a C _1-3 alkoxy group or a C _1-3 alkylamino group.

In still other embodiments, R ^d in formula (I) is H, D, C _1-4 alkyl, C _3-6 cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl or C _3-6 Heterocyclyl-C _1-2 alkylene group, when R ¹ , R ² , R ³ , R ⁵ (or R ⁴ ), R ⁶ and R ^{7 are} simultaneously H, and R ⁴ (or R ⁵ ) is When F is, R ^{d is} not a C _3-6 heterocyclic group, wherein the C _1-4 alkyl group, C _3-6 cycloalkyl-C _1-2 alkylene group, C _3-6 heterocyclic group or C _3-6 Heterocyclyl-C _1-2 alkylene may be optionally 1, 2, 3 or 4 independently selected from D, F, CN, OR ^a , NR ^a R ^b , C _1-3 alkane Substituent, C _2-4 alkenyl, C _2-4 alkynyl, R ^a OC _1-2 alkylene or R ^a R ^b NC _1-2 alkylene substituent.

In still other embodiments, Q in formula (I) is NH ₂ or -N(R ^c )C(=O)R ^d .

In still other embodiments, each of X, Y and Z in formula (I) is independently H, D, CH ₃ , CH ₂ CH ₃ , phenyl or is 1, _{2, 3} , 4 or 5 independently selected from D a phenyl group substituted with a substituent of F or Cl.

In still other embodiments, Q in formula (I) is:

In still other embodiments, the compounds of the invention have the structure of formula (II): Among them, the definitions of Q, X, Y and Z in the formula (II) are as follows.

In some embodiments, in Formula (II): Q is NR ^a R ^b , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a ; each X,Y And Z are independently H, D, C _1-6 alkyl, C _3-8 cycloalkyl, C _3-7 heterocyclyl, C _6-10 aryl, heteroaryl consisting of 5-10 atoms, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 alkylene, or (5 -10 atomic heteroaryl)-C _1-4 alkylene, wherein said C _1-6 alkyl, C _3-8 cycloalkyl, C _3-7 heterocyclic, C _6-10 Aryl, heteroaryl consisting of 5-10 atoms, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 The aryl-C _1-4 alkylene group and the (5-10 atom heteroaryl group)-C _1-4 alkylene group may be optionally 1, 2, 3, 4 or 5 independently selected from D , F, Cl, Br, CN, C _2-6 alkenyl, C _2-6 alkynyl, OR ^a , NR ^a R ^b , R ^a OC _1-4 alkylene or R ^a R ^b NC _1-4 Substituted by a substituent of an alkyl group; each of R ^a , R ^b and R ^{c is} independently H, C _1-6 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclic, C _6-10 aryl group, composed of 5-10 atoms heteroaryl, C _3-6 cycloalkyl, -C _1-4 alkylene, C _3-6 heterocyclyl -C _1-4 Alkyl, C _6-10 aryl or -C _1-4 alkylene (5-10 atoms heteroaryl) -C _1-4 alkylene, wherein said C _1-6 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclyl, C _6-10 aryl, heteroaryl group of 5-10 atoms, C _3-6 cycloalkyl-C _1-4 alkylene, C _3-6 heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 alkylene and (heteroaryl group of 5-10 atoms)-C _1-4 alkylene The group may be optionally 1, 2, 3 or 4 independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _1-6 alkoxy or C ₁ Substituted by a substituent of a _-6 alkylamino group; and R ^d is a C _1-6 alkyl group, wherein the C _1-6 alkyl group may be optionally 1, 2, 3 or 4 independently selected from D, Substituted by a substituent of F, Cl, OH, NH ₂ , C _1-6 alkoxy or C _1-6 alkylamino.

In still other embodiments, Q in formula (II) is NR ^a R ^b or -N(R ^c )C(=O)R ^d .

In still other embodiments, each of X, Y and Z in formula (II) is independently H, D, C _1-4 alkyl or phenyl, wherein said C _1-4 alkyl and phenyl are optional The ground is replaced by 1, 2, 3, 4 or 5 substituents independently selected from D, F or Cl.

In still other embodiments, each R ^a , R ^b and R ^c in formula (II) is independently H, C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclyl, C _{3 -6} cycloalkyl-C _1-2 alkylene or C _3-6 heterocyclyl-C _1-2 alkylene, wherein said C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 Heterocyclyl, C _3-6 cycloalkyl-C _1-2 alkylene and C _3-6 heterocyclyl-C _1-2 alkylene may be optionally 1, 2, 3 or 4 Substituents independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _1-6 alkoxy or C _1-6 alkylamino are substituted.

In other embodiments, of formula (II), R ^d is Me, Et, n -Pr, i -Pr, n -Bu, i -Bu , or t -Bu.

In still other embodiments, Q in formula (II) is NH ₂ or -N(R ^c )C(=O)R ^d .

In still other embodiments, each of X, Y and Z in formula (II) is independently H, D, Me, CH ₂ D, CHD ₂ , CD ₃ , ethyl, propyl, isopropyl, phenyl or 1, 2, 3, 4 or 5 phenyl groups independently substituted with substituents selected from D, F or Cl.

In still other embodiments, Q in formula (II) is:

In still other embodiments, the invention relates to a compound of any of the following, or a stereoisomer, geometric isomer, tautomer, oxynitride, hydrate, solvate, metabolite thereof, pharmaceutically acceptable Salt or its prodrug, but by no means limited to these compounds:

The invention further encompasses the use of a compound of the invention, and a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical product for the treatment of acute and chronic hyperproliferative diseases and/or angiogenesis-mediated diseases, including those described herein. Use of the compounds of the invention in the manufacture of anticancer drugs. The compounds of the invention are also useful in the manufacture of a medical article to alleviate, arrest, control or treat a disease by inhibiting protein kinase activity. The invention comprises a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or formula (II) in combination with at least one pharmaceutically acceptable carrier, adjuvant or diluent.

The invention also encompasses a method of treating, or responsive to, a disease mediated by an angiogenesis in a patient, the method comprising treating a patient with a therapeutically effective amount of a compound represented by Formula (I) or Formula (II).

Unless otherwise indicated, all stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, salts and pharmaceutically acceptable prodrugs of the compounds of the invention are The scope of the invention.

In particular, the salt is a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" includes that the substance or composition must be chemically or toxicologically relevant to the other components of the formulation and to the mammal being treated.

Salts of the compounds of the invention also include intermediates useful in the preparation or purification of compounds of formula (I) or formula (II) or salts of enantiomers isolated from compounds of formula (I) or formula (II) , but not necessarily a pharmaceutically acceptable salt.

If the compound of the present invention is basic, the desired salt can be prepared by any suitable method provided in the literature, for example, using a mineral acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid or the like. Or use organic acids such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid and salicylic acid; pyranoic acid such as glucuronic acid and galactose Aldehydic acid; alpha-hydroxy acids such as citric acid and tartaric acid; amino acids such as aspartic acid and glutamic acid; aromatic acids such as benzoic acid and cinnamic acid; sulfonic acids such as p-toluenesulfonic acid, ethanesulfonic acid, and many more.

If the compound of the present invention is acidic, the desired salt can be prepared by a suitable method, for example, using an inorganic hydrazine or an organic hydrazine such as ammonia (primary ammonia, secondary ammonia, tertiary ammonia), an alkali metal hydroxide or an alkaline earth. Metal hydroxide, and so on. Suitable salts include, but are not limited to, organic salts derived from amino acids such as glycine and arginine, ammonia such as primary, secondary and tertiary ammonia, and cyclic ammonia such as acridine, morpholine and pyridazine Etc., and inorganic salts are obtained from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

Compositions, formulations and administration of the compounds of the invention

According to another aspect, the pharmaceutical composition of the present invention comprises a compound of formula (I) or formula (II), a specific compound listed herein, or a compound of examples 1-31, and a pharmaceutically acceptable Carrier, adjuvant, or vehicle. The amount of the compound in the composition of the present invention is effective to detectably inhibit protein kinases in biological specimens or patients.

The compounds of the invention exist in free form or, as appropriate, as pharmaceutically acceptable derivatives Things. According to the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable prodrugs, salts, esters, ester salts, or any other agent which can be administered, directly or indirectly, depending on the needs of the patient. An adduct or derivative, a compound described in other aspects of the invention, a metabolite thereof or a residue thereof.

As described herein, the pharmaceutically acceptable compositions of the present invention further comprise a pharmaceutically acceptable carrier, adjuvant, or excipient, as used herein, including any solvent, diluent, or other Liquid excipients, dispersing or suspending agents, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders or lubricants, etc., are suitable for the particular target dosage form. As described in the following literature: In Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. DBTroy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JC Boylan, 1988- 1999, Marcel Dekker, New York, incorporating the contents of the literature, indicates that different carriers are useful in the formulation of pharmaceutically acceptable compositions and their known methods of preparation. In addition to any conventional carrier medium that is incompatible with the compounds of the invention, such as any undesirable biological effects produced or interactions with any other component of a pharmaceutically acceptable composition in a detrimental manner, The use is also within the scope of the invention.

Substances which may be used as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, aluminum, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphate, glycine, sorbic acid, sorbus Potassium acid, a partial glyceride mixture of saturated vegetable fatty acids, water, salt or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal bismuth, magnesium tristearate, polyethylene Pyrrolidone, polyacrylate, wax, polyethylene-polyoxypropylene-blocking polymer, lanolin, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as carboxymethyl Cellulose sodium, ethyl cellulose and cellulose acetate; gum powder; malt; gelatin; talcum powder; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, Olive oil, corn oil and soybean oil; glycol compounds such as propylene glycol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; seaweed acid Pyrogen-free water; isotonic saline; Ringer (s) solution; ethanol, phosphate buffer solution, and other suitable non-toxic lubricants such as sodium lauryl sulfate and magnesium stearate, the Colorants, release agents, coatings, sweeteners, flavorings and fragrances, preservatives and antioxidants.

The composition of the present invention may be administered orally, by injection, by inhalation, topically, rectally, nasally, buccally, vaginally or by an implantable kit. . The term "injected" as used herein includes subcutaneous, venous, intramuscular, intra-articular, intrasynovial, intrasternal, intramembranous, intraocular, intrahepatic, focal Internal, and intracranial injection or infusion techniques. A preferred composition is for oral administration, either intraperitoneally or intravenously. The sterile injectable form of the compositions of the present invention may be a watery or oleaginous suspension. These suspensions may be formulated according to known techniques using suitable dispersing, wetting and suspending agents. The sterile injectable preparation may be a sterile injectable solution or suspension, or a non-toxic acceptable diluent or solvent, such as a solution of 1,3-butanediol. These acceptable excipients and solvents can be water, Ringer's solution and isotonic sodium chloride solution. Still further, sterile, non-volatile oils are conventionally employed as a solvent or suspending medium.

For this purpose, any mild non-volatile oil can be a synthetic mono or di-glycosyl diglyceride. Fatty acids, such as oleic acid and its glyceride derivatives, are useful in the preparation of injectables as natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially their polyoxyethylene derivatives. These oil solutions or suspensions may contain a long-chain alcohol diluent or dispersing agent, such as carboxymethyl cellulose or similar dispersing agents, and pharmaceutical preparations which are generally used in pharmaceutically acceptable dosage forms include emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifiers or bioavailability enhancers, are generally used in pharmaceutically acceptable solid, liquid, or other dosage forms and can be applied to targeted pharmaceutical preparations. Preparation.

The pharmaceutically acceptable compositions of this invention may be orally administered in any acceptable oral dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. For oral administration to tablets, the carriers generally include lactose and corn starch. Lubricants, such as magnesium stearate, are typically added. For oral administration to capsules, suitable diluents include lactose and dried corn starch. When the oral administration is an aqueous suspension, the active ingredient consists of an emulsifier and a suspending agent. If these dosage forms are desired, certain sweeteners, flavoring or coloring agents can also be added.

Additionally, the pharmaceutically acceptable compositions of this invention may be administered rectally in the form of a suppository. These can be prepared by mixing the agent with a suitable non-perfused adjuvant which is solid at room temperature but liquid at the temperature of the rectum to melt and release the drug in the rectum. such The substances include cocoa butter, beeswax, and polyethylene glycols. The pharmaceutically acceptable compositions of the present invention may be administered topically, especially when applied topically, to areas where the therapeutic goals of the area or organ are readily attainable, such as diseases of the eye, skin or lower intestinal tract. Suitable topical formulations can be prepared and applied to these fields or organs.

Rectal suppositories (see above) or suitable enema agents can be applied topically to the lower intestinal tract. Local skin spots can also be used as such. For topical administration, the pharmaceutically acceptable compositions can be formulated into suitable ointments containing the active ingredient suspended or dissolved in one or more carriers. Carrier compounds for topical administration of the present invention include, but are not limited to, mineral oil, liquid paraffin, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Additionally, the pharmaceutically acceptable compositions may be prepared as a suitable lotion or emulsion containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, Span-60 (sorbitan monostearate), Tween 60 (polysorbate 60), cetyl ester wax, palmitol, 2- Octyl dodecanol, benzyl alcohol and water.

For ophthalmic, pharmaceutically acceptable compositions can be prepared as preparations, such as isotonic microparticulate suspensions, pH adjusted sterile saline or other aqueous solutions, preferably, isotonic solutions and pH adjusted sterile saline or other aqueous solutions. A disinfectant preservative such as benzalkonium chloride can be added. Alternatively, for ophthalmology, the pharmaceutically acceptable composition can be formulated into an ointment such as petrolatum oil in a formulation. The pharmaceutically acceptable compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions may be prepared according to well-known techniques of formulation formulations, or may be prepared as a salt solution, using benzyl alcohol or other suitable preservatives, absorption enhancers, fluorocarbons or other conventional solubilizing or dispersing agents to enhance bioavailability. degree.

Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. The liquid dosage form may contain, in addition to the active compound, a conventional inert diluent such as water or other solvents, solubilizers and emulsifiers such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzoic acid. Benzyl ester, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils and fats (especially cottonseed, groundnut, corn, microbes, olives, ramie and sesame oil), glycerin, 2-tetrahydrofuran methanol, polyethylene Alcohol, sorbitan fatty acid esters, and mixtures thereof. Oral compositions may also contain, in addition to inert diluents Adjuvants such as wetting agents, emulsifying or suspending agents, sweetening, flavoring and perfuming agents.

An injection, such as a sterile injectable solution or a oleaginous suspension, can be prepared according to the known formulation using suitable dispersing agents, wetting agents and suspending agents. The sterile injectable preparation may be a sterile injectable solution, suspension or emulsion in the form of a non-toxic injectable acceptable diluent or solvent, for example, a 1,3-butanediol solution. Acceptable excipients and solvents can be water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, non-volatile oils are conventionally employed as a solvent or suspension medium. Any mild non-volatile oil for this purpose may include synthetic mono- or di-glycosyl diglycerides. In addition, fatty acids such as oleic acid find use in injections.

The injection may be sterile, such as by filtration through a bacterial defense screening procedure, or by incorporating a sterilizing agent in the form of a sterile solid composition which may be dissolved or dispersed in sterile water or other sterile injectable medium before use. In order to prolong the effects of the compounds of the invention, it is usually necessary to slow the absorption of the compound by subcutaneous or intramuscular injection. This makes it possible to solve the problem of poor water solubility of crystalline or amorphous materials by using a liquid suspension. The rate of absorption of a compound depends on its dissolution, which in turn depends on the grain size and crystal shape. In addition, delayed absorption of the compound injection administration can be accomplished by dissolving or dispersing the compound in an oil vehicle.

The injectable form of the preparation is accomplished by a biodegradable polymer, such as a microcapsule matrix of a polylactic acid-polyglycolide forming compound. The controlled release ratio of the compound depends on the ratio of the compound forming the polymer and the nature of the particular polymer. Other biodegradable polymers include poly(orthoesters) and poly(anhydrides). The injectable preparation form can also be prepared by embedding the compound in a liposome or microemulsion compatible with body tissues.

In some embodiments, the composition for rectal or vaginal administration is a suppository, and the suppository can be prepared by mixing a compound of the present invention with a suitable non-perfused adjuvant or carrier, such as cocoa butter, polyethylene glycol, Or suppository waxes which are solid at room temperature but liquid at body temperature and therefore melt in the vaginal or sheath lumen to release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these dosage forms, the active compound is mixed with at least one pharmaceutically acceptable inert excipient or carrier, such as sodium citrate or calcium phosphate or a filler or a) fillers such as starch, lactose, sucrose, glucose, mannitol and hydrazine Acid, b) binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic, c) humectants such as glycerin, d) disintegrants such as agar, calcium carbonate, potato starch or wood Potato starch, alginic acid, certain citrates and sodium carbonate, e) retarder solutions such as paraffin, f) absorption enhancers such as quaternary amines, g) wetting agents such as cetyl alcohol and glyceryl monostearate, h) absorbents such as kaolin and bentonite, i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. As for capsules, tablets and pills, these dosage forms may contain a buffer.

A solid composition of a similar type may be a filler filled with a soft or hard capsule, and the excipients used are lactose and high molecular weight polyethylene glycol and the like. The solid dosage forms like tablets, troches, capsules, pills and granules can be prepared by coating, encapsulation, such as enteric coating, and other pharmaceutical preparations. They may optionally contain opacifying agents or, preferably, the only active ingredient in the composition, in a certain portion of the intestinal tract, optionally, in a delayed manner. For example, the implant composition can comprise a multimeric substance and a wax.

The active compound can be combined with one or more excipients described herein to form a microcapsule dosage form. Solid dosage forms like tablets, troches, capsules, pills, and granules can be coated or otherwise, such as enteric coatings, controlled release coatings, and other known pharmaceutical formulations. In these solid dosage forms, the active compound may be mixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as a general application, additional substances other than inert diluents, such as tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. As for capsules, tablets and pills, these dosage forms may contain a buffer. They may optionally contain a sedative, or preferably, in a certain portion of the intestinal tract, release the only active ingredient in the composition in any delayed manner. Applicable implant compositions can include, but are not limited to, multimers and waxes.

The formulations of the present invention for topical or transdermal administration include ointments, pastes, emulsions, lotions, gels, powders, solutions, sprays, inhalants, patches. The active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservative or buffer. Ophthalmic pharmaceutical preparations, ear drops and eye drops are all contemplated by the present invention. In addition, the present invention contemplates the use of transdermal patches which have additional advantages in controlling the delivery of the compound to the body, such dosage forms being prepared by dissolving or dispersing the compound into a suitable medium. Absorption enhancers can increase the flux of the compound across the skin, controlling its rate by rate controlling the film or dispersing the compound in a polymeric matrix or gelatin.

The compounds of the present invention are preferably prepared in dosage unit form in a formulation to reduce the amount administered and Uniformity of dose. The term "dosage unit type" as used herein refers to the physically discrete unit of the drug required for the patient to receive appropriate treatment. However, it is to be understood that the total daily usage of the compounds or compositions of the present invention will be determined by the attending physician based on a reliable medical field judgment. The specific effective dosage level will depend on a number of factors for any particular patient or organism, including the severity of the condition and condition being treated, the activity of the particular compound, the particular composition employed, the patient's age, weight, health, sex And dietary habits, time of administration, route of administration and rate of excretion of the particular compound employed, duration of treatment, administration of the drug in combination or in combination with a compound having a specific effect, and other factors well known in the pharmaceutical arts.

The amount of the compound of the invention which can be combined with the carrier material to produce a single dosage form composition will vary depending upon the attending and the particular mode of administration. In some of these embodiments, the composition can be prepared as an inhibitor at a dose of from 0.01 to 200 mg/kg body weight per day by formulation and administered by the patient receiving the amount of the composition.

The compounds of the present invention may be administered as the sole pharmaceutical agent or in combination with one or more additional therapeutic (pharmaceutical) agents, wherein the combination induces an acceptable adverse reaction, which has a therapeutic effect on a hyperproliferative disease such as cancer. Special meaning. In this case, the compounds of the invention may be combined with known cytotoxic agents, single transduction inhibitors or other anti-cancer agents, as well as mixtures and combinations thereof. As used herein, the additional therapeutic agent is normally administered to treat a particular condition, known as "appropriate treatment of the disease." As used herein, "additional therapeutic agents", including chemotherapeutic drugs or other anti-proliferative drugs, can be combined with the compounds of the invention to treat proliferative diseases or cancer.

Chemotherapeutic drugs or other anti-proliferative drugs include histone deacetylase (HDAC) inhibitors including, but not limited to, SAHA, MS-275, MGO 103, and those described in the following patents: WO 2006/010264, WO 03/024448, WO 2004/069823, US 2006/0058298, US 2005/0288282, WO 00/71703, WO 01/38322, WO 01/70675, WO 03/006652, WO 2004/035525, WO2005/030705, WO 2005/092899, and demethylating agents include, but are not limited to, 5-aza-2'-deoxycytidine (5-aza-dC), azacitidine (Vidaza), decitabine ( </ RTI> <RTIgt; 11/393,380.

In other embodiments, a chemotherapeutic drug or other anti-proliferative drug can be combined with a compound of the invention to treat proliferative diseases and cancer. Known chemotherapeutic drugs include, but are not limited to, other therapies or anticancer agents may be combined with the anticancer agents of the present invention and include surgical, radiation therapy (a few examples such as gamma radiation, neutron beam radiation therapy, electron beam radiation therapy) , proton therapy, brachytherapy and systemic radioisotope therapy), endocrine therapy, taxanes (paclitaxel, docetaxel, etc.), platinum derivatives, biological response modifiers (interferon, interleukin, tumor) Necrosis factor (TNF), TRAIL receptor targeting and vehicle), hyperthermia and cryotherapy, agents that dilute any adverse reactions (eg antiemetics), and other approved chemotherapeutics, including but not limited to, alkanes Chemical drugs (nitrogen mustard, chlorambucil, cyclophosphamide, phenylalanine mustard, ifosfamide), antimetabolites (methotrexate, Pemetrexed, etc.) , 嘌呤 antagonists and pyrimidine antagonists (6-Mercaptopurine, 5-fluorouracil, Cytarabile, Gemcitabine), spindle inhibitors (Changchun, Changchun Xinyi, vinorelbine, paclitaxel), Podophyllotoxin Toposide, Irinotecan, Topotecan, Antibiotics (Doxorubicin, Bleomycin, Mitomycin), Nitroso Urea (Carmustine, Lomustine), inorganic ions (cisplatin, carboplatin), cell division cycle inhibitors (KSP through mitotic kinesin inhibitors, CENP-E and CDK inhibitors) ), enzyme (asparaginase), hormone (Tamoxifen, Leuprolide, Flutamide, Megestrol), Gleevec (GLEEVEC) ^® ), Adriamycin, Dexamethasone, and Cyclophosphamide. Anti-angiogenic factors (Avastin and others). Monoclonal antibodies (Belimumab, BENLYSTA ^® , Brentuximab (ADCETRIS ^® ), Cetuximab (ERBITUX ^® ), Gemtuzumab (MYLOTARG ^® ), Ipilimumab ( ipilimumab, YERVOY ^®), ofatumumab (ofatumumab, ARZERR ^®), panitumumab (panitumumab, VECTIBIX ^®), ranibizumab (ranibizumab, LUCENTIS ^®), rituximab (rituximab, RITUXAN ^® ), Tositumomab (BEXXAR ^® ), Trastuzumab (HERCEPTIN ^® ). Kinase inhibitors (imatinib (Imatinib, GLEEVEC ^®), sunitinib (Sunitinib, SUTENT ^®), sorafenib (Sorafenib, NEXAVAR ^®), cetuximab (Cetuximab, ERBITUX ^®), Trastuzumab Chemizumab (HERCEPTIN ^® ), Erlotinib (TARCEVA ^® ), Dasatinib (SPRYCEL ^® ), tivozanib, dovitinib, axitinib, motesanib, pazopanib, Kyrgyzstan gefitinib ^{(gefitinib, iRESSA ®), cediranib} , brivanib, tipranavir erlotinib (telatinib), masitinib, neratinib (neratinib), lenvatinib, ruxolitinib, linifanib, linsitinib, crizotinib, regorafenib, ponatinib, bosutinib (bosutinib), sacatinib, afatinib, amuvatinib, ponatinib, quizartinib, vemurafenib (ZELBORAF ^® ), vandetanib (CAPRELSA ^® ), olaparib, veliparib, iniparib, irri Sand (Iressa) and others). Drugs inhibit or initiate cancer pathways such as mTOR, HIF (hypoxia-inducible factor) pathways and others. A broader forum for cancer treatment can be found at http://www.nci.nih.gov/, and a list of FDA-approved oncology drugs can be found at http://www.fda.gov/cder/cancer/druglist-rame.htm, and The gram manual, eighteenth edition. 2006, all of which incorporates references.

In other embodiments, the compounds of the invention may bind to a cytotoxic anticancer agent. Such anticancer agents can be found in the thirteenth edition of the Merck Index (2001). These anticancer agents include, but are in no way limited to, Asparaginase, Bleomycin, Carboplatin, Carmustine, Chlorambucil, Cisplatin , L-aspartate (Colaspase), cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Acetomycin (doxorubicin), epirubicin, Etoposide, 5-fluorouracil, hexamethyl melamine, hydroxyurea, ifosfamide, irinotecan, folinic acid, Cyclohexyl nitrosourea, nitrogen mustard, 6-mercaptopurine, Mesna, Methotrexate, Mitomycin C, Mitoxantrone, prednisone Prednisolone, Prednisone, Procarbazine, Raloxifen, Streptozocin, Tamoxifen, Thioguanine, Topotecan, Changchun, Changchun Xinyi, Changchun Dixin.

Other suitable cytotoxic drugs for administration in combination with the compounds of the present invention include, but are not limited to, those compounds which are recognized for their use in the treatment of neoplastic diseases, as described in the following literature: Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition, 1996, McGraw-Hill.); these anticancer agents include, but are in no way limited to, aminoglutethimide (Aminoglutethimide), L-aspartate, azathioprine, 5-azacytidine, Cladribine, Busulfan, diethylstilbestrol, 2',2'-difluorodeoxygenate Diphosphocholine, docetaxel, Erythrohydroxynonyladenine, ethinyl estradiol, 5-fluorouracil deoxynucleoside, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate (Fludarabine) Phosphate, Fluoxymesterone, Flutamide, Hydroxyprogesterone caproate, Idarubicin, Interferon, Medroxyprogesterone acetate, Megestrol acetate, Melphalan ), Mitotane, paclitaxel, pentastatin, N-phosphoryl-L-aspartic acid (PALA), pecamycin (Plicamycin), methylcyclohexylnitrite Semustine, Teniposide, testosterone propionate, Thiotepa, trimethyl melamine, uridine and vinorelbine.

Other suitable cytotoxic anticancer agents for use in combination with the compounds of the present invention include newly discovered cytotoxic substances including, but not limited to, Oxaliplatin, Gemcitabine, Capecitabine (Capecitabine), a macrolide antitumor drug and its natural or synthetic derivative, Temozolomide (Quinn et al ., J. Clin . Oncology, 2003 , 21(4), 646-651) Simuzumab (BEXXAR ^® ), Trabedectin (Vidal et al ., Proceedings of the American Society for Clinical Oncology , 2004 , 23, abstract 3181), and kinesin spindle protein inhibitor Eg5 (Wood et al ., Curr . Opin . Pharmacol. 2001 , 1, 370-377).

In other embodiments, the compounds of the invention may bind to other signal transduction inhibitors. Interestingly, signal transduction inhibitors target the EGFR family, such as EGFR, HER-2 and HER-4 (Raymond et al., Drugs, 2000 , 60 (Suppl.l), 15-23; Harari et al., Oncogene , 2000 , 19(53), 6102-6114) and their respective ligands. Such agents include, but are not limited to, antibody therapies such as Herceptin (trastuzumab), cetuximab (Erbitux), and pertuzumab (Pertuzumab). Such therapies also include, but are in no way limited to, small molecule kinase inhibitors such as Gefitinib, Erlotinib, Tykerb (Lapatinib), CANERTINIB (CI1033), AEE788 (Traxler et al., Cancer Research). , 2004 , 64, 4931-4941).

In other embodiments, the compounds of the invention bind to other signal transduction inhibitors to target receptor kinases in the cleavage kinase family (VEGFR, FGFR, PDGFR, flt-3, c-kit, c-fins, etc. ), and their respective ligands. Such agents include, but are not limited to, antibodies such as bevacizumab (Avastin). Such agents include, but are in no way limited to, small molecule inhibitors such as Gleevec/Imanitib, Sprycel (Dasatinib), Tasigna/Nilotinib, Nexavar (Vandetanib), Vatalanib (PTK787/ZK222584) (Wood et al., Cancer Res. 2000 , 60(8), 2178-2189), Telatinib/BAY-57-9352, BMS-690514, BMS-540215, Axitinib/AG-013736, Motesanib/AMG706, Sutent/Sunitinib/SU-11248, ZD-6474 (Hennequin et Al., 92nd AACR Meeting , New Orleans, Mar. 24-28, 2001 , abstract 3152), KRN-951 (Taguchi et al., 95th AACR Meeting , Orlando, FIa, 2004 , abstract 2575), CP-547, 632 (Beebe Et al., Cancer Res . 2003 , 63, 7301-7309), CP-673, 451 (Roberts et al., Proceedings of the American Association of Cancer Research , 2004 , 45, abstract 3989), CHIR-258 (Lee et al. Proceedings of the American Association of Cancer Research , 2004 , 45, abstract 2130), MLN-518 (Shen et al., Blood , 2003 , 102, 11, abstract 476).

In other embodiments, the compounds of the invention may bind to other signal transduction inhibitors. Interestingly, signal transduction inhibitors target the EGFR family, such as EGFR, HER-2 and HER-4 (Raymond et al., Drugs, 2000 , 60 (Suppl.l), 15-23; Harari et al., Oncogene , 2000 , 19(53), 6102-6114) and their respective ligands. Such agents include, but are not limited to, antibody therapies such as Herceptin (Trastuzumab, HERCEPTIN ^®), cetuximab (Cetuximab, ERBITUX ^®), ipilimumab (Ipilimumab, YERVOY ^®) and pertuzumab Metuzumab (Pertuzumab). Such therapies include, but not limited to, small-molecule kinase inhibitors such as imatinib (Imatinib, GLEEVEC ^®), sunitinib (Sunitinib, SUTENT ^®), sorafenib (Sorafenib, NEXAVAR ^®), Ecuador Erlotinib (TARCEVA ^® ), Gefitinib (IRESSA ^® ), Dasatinib (SPRYCEL ^® ), Nilotinib (TASIGNA ^® ), Lapatinib (Lapatinib, TYKERB ^® ),Crizotinib (XALKORI ^® ), Ruxolitinib (JAKAFI ^® ), Vemurafenib (ZELBORAF ^® ), Vandetanib (CAPRELSA ^® ), Pazopanib (VOTRIENT ^® ), Afatinib (Afatinib), alisertib, amuvatinib, Axitinib (axitinib), bosutinib (brsutinib), brivanib, canertinib, cabozantinib, cedaniib, dabrafenib, dacomitinib, danusertib, dovitinib, foretinib, ganetespib, ibrutinib, iniparib, lenvatinib, linifanib , linsitinib, masitinib, momelotinib, motesanib, neratinib, niraparib, oprozomib, olaparib, pictilisib, ponatinib, quizartinib, regorafeni b, rigosertib, rucaparib, sarkatinib, saridegib, tandutinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vatalanib, veliparib, vismodegib, volasertib, BMS-540215, BMS777607, JNJ38877605, TKI258, GDC- 0941 (Folkes, et al ., J. Med. Chem., 2008, 51, 5522), BZE235, and the like.

In other embodiments, the compounds of the invention may bind to a histone deacetylase inhibitor. Such agents include, but are in no way limited to, octyl aniline oxime acid (SAHA), LAQ-824 (Ottmann et al ., Proceedings of the American Society for Clinical Oncology, 2004 , 23, abstract 3024), LBH-589 (Beck et al ., Proceedings of the American Society for Clinical Oncology , 2004 , 23, abstract 3025), MS-275 (Ryan et al ., Proceedings of the American Association of Cancer Research, 2004 , 45, abstract 2452), FR -901228 (Piekarz et al ., Proceedings of the American Society for Clinical Oncology , 2004 , 23, abstract 3028) and MGCDOI 03 (US 6,897, 220).

In other embodiments, the compounds of the invention may be combined with other anticancer agents such as proteasome inhibitors and m-TOR inhibitors. These include, but are in no way limited to, Bortezomib (Mackay et al., Proceedings of the American Society for Clinical Oncology , 2004 , 23, Abstract 3109), and CCI-779 (Wu et al ., Proceedings of the American Association of Cancer Research , 2004 , 45, abstract 3849). The compounds of the invention may also incorporate other anticancer agents such as topoisomerase inhibitors, including but not limited to camptotheca acuminata.

Those additional therapeutic agents can be administered separately from the compositions comprising the compounds of the invention as part of a multiple dosing regimen. Alternatively, those therapeutic agents can be part of a single dosage form, mixed with the compounds of the invention to form a single composition. If administered as part of a multiple dosing regimen, the two active agents can be delivered to each other either continuously or over a period of time to provide the desired agent activity.

The amount of compound that can be combined with the carrier material to produce a single dosage form and the amount of additional therapeutic agent (such as those comprising an additional therapeutic agent as described herein) will vary depending upon the attending and particular mode of administration. Normally, the amount of additional therapeutic agent of the compositions of the present invention will not exceed the amount normally administered by the composition comprising the therapeutic agent as the sole active agent. On the other hand, the presently disclosed composition is attached The amount of therapeutic agent added will range from about 50% to about 100% of the normal amount of the existing composition, with the included agent being the sole active therapeutic agent. In those compositions comprising additional therapeutic agents, the additional therapeutic agent will act synergistically with the compounds of the invention.

Use of the compounds and compositions of the invention

The pharmaceutical composition of the present invention is characterized by comprising a compound represented by formula (I) or formula (II) or a compound listed in the present invention, and a pharmaceutically acceptable carrier, adjuvant or vehicle. The amount of the compound in the composition of the present invention is effective to detectably inhibit the activity of a protein kinase such as VEGFR, c-Met, Ron or Axl. The compounds of the invention will treat patients as anti-tumor drugs or reduce the deleterious effects of VEGFR, c-Met, Ron and/or Axl receptor signaling.

The compounds of the invention will be, but are not limited to, administered to a patient using an effective amount of a compound or composition of the invention to prevent or treat a proliferative disorder in a patient. Such diseases include cancer, especially metastatic cancer, atherosclerosis, and pulmonary fibrosis.

The compounds of the present invention will be applied to the treatment of tumors including cancer and metastatic cancer, and further include, but are not limited to, cancers such as bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer (including small cell lung cancer), esophageal cancer, Gallbladder cancer, ovarian cancer, pancreatic cancer, gastric cancer, cervical cancer, thyroid cancer, prostate cancer, and skin cancer (including squamous cell carcinoma); lymphoid hematopoietic tumors (including leukemia, acute lymphocytic leukemia, acute lymphoblastic Leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell leukemia and Burkitt's lymphoma); Bone marrow system hematopoietic tumors (including acute and chronic) Myeloid leukemia, myelodysplastic syndrome, and promyelocytic leukemia; tumors of mesenchymal origin (including fibrosarcoma and rhabdomyosarcoma, and other sarcomas such as soft tissue and cartilage); central peripheral neuroma ( Including astrocytoma, neuroblastoma, glioma, and schwannomas; and other tumors (including melanoma, seminoma, teratoma) Cancer, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular tumor and Kaposi's sarcoma.

The compounds of the invention are also useful in the treatment of ophthalmic conditions such as corneal transplant rejection, neovascularization of the eye, neovascularization of the retina including neovascularization following injury or infection; diabetic retinopathy; posterior lens hyperplasia, and neovascularization Glaucoma; retinal ischemia; vitreous hemorrhage; ulcerative diseases such as gastric ulcer; pathological but non-malignant conditions such as hemangioma, including infantile vascular endothelial cell tumor, aneurysm of nasopharyngeal and avascular necrosis; Sexual reproductive system disorders such as endometriosis. These compounds are also used to treat conditions of edema and vascular hyperpermeability.

The compounds of the invention may be used to treat conditions associated with diabetes such as diabetic retinopathy and microangiopathy. The compounds of the invention are also useful in the reduction of blood flow in cancer patients. The compounds of the invention also have beneficial effects on the reduction of tumor metastasis in patients.

In addition to being useful for human therapy, the compounds of the present invention are also useful in veterinary treatment of pets, introduced species of animals, and farm animals, including mammals, rodents, and the like. Other examples of animals include horses, dogs, and cats. Herein, the compounds of the invention include pharmaceutically acceptable derivatives thereof.

In the case where the plural form is applied to a compound, a salt or the like, it also means a single compound, a salt or the like.

The method of treatment comprising administration of a compound or composition of the invention further comprises the administration of an additional therapeutic agent (combination therapy) to the patient, wherein the additional therapeutic agent is selected from the group consisting of: chemotherapy, anti-proliferative or anti-inflammatory agents, wherein the additional treatment The agents are suitable for the condition to be treated, and the additional therapeutic agents can be administered in combination with the compounds or compositions of the invention, either as a single dosage form, or as a separate compound or composition as part of a multiple dosage form. The additional therapeutic agent can be administered simultaneously or not simultaneously with the compounds of the invention. In the latter case, administration can be carried out staggered as 6 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks, 3 weeks, 1 month or 2 months.

The invention likewise encompasses a method of inhibiting the growth of cells expressing VEGFR, c-Met, Ron or Axl, which method comprises contacting a compound or composition of the invention with a cell to inhibit cell growth. Cells that can be inhibited from growth include: breast cancer cells, colorectal cancer cells, lung cancer cells, papillary cancer cells, prostate cancer cells, lymphoma cells, colon cancer cells, pancreatic cancer cells, ovarian cancer cells, cervical cancer cells, Central nervous system cancer cells, osteosarcoma cells, renal cancer cells, hepatocellular carcinoma cells, bladder cancer cells, gastric cancer cells, head or cervical squamous cell carcinoma cells, melanoma cells and leukemia cells.

The invention provides a method of inhibiting the activity of a VEGFR, c-Met, Ron or Axl kinase in a biological sample, the method comprising contacting a compound or composition of the invention with a biological sample. The term "biological specimen" as used in the present invention refers to a specimen external to a living body, including but not limited to, cell culture. Or cell extraction; biopsy material obtained from a mammal or its extract; blood, saliva, urine, feces, semen, tears, or other living tissue fluids and extracts thereof. Inhibition of kinase activity in biological specimens, particularly VEGFR, c-Met, Ron and Axl kinase activities, can be used for a variety of uses well known to those skilled in the art. Such uses include, but are in no way limited to, transfusion methods, organ transplantation, biological specimen storage, and bioassay.

An "effective amount" or "effective amount" of a compound or pharmaceutically acceptable composition of the invention refers to an effective amount to treat or ameliorate the severity of one or more of the conditions mentioned herein. In accordance with the methods of the present invention, the compounds and compositions can be administered in any amount and in any route of administration effective to treat or reduce the severity of the disease. The exact amount required will vary depending on the patient's condition, depending on race, age, general condition of the patient, severity of infection, specific factors, mode of administration, and the like. The compound or composition can be administered in combination with one or more other therapeutic agents, as discussed herein.

The compounds of the present invention or pharmaceutical compositions thereof can be applied to coatings of implantable medical devices such as prostheses, prosthetic valves, artificial blood vessels, stems and urinary catheters. For example, vascular stems have been used to overcome restenosis (recontraction of the vessel wall after injury). However, patients with stems or other implantable devices will be at risk of clot formation or platelet activation. These adverse effects can be prevented or alleviated by the use of a pharmaceutically acceptable composition pre-coating device comprising a compound of the invention.

A general method for the preparation of suitable coatings and coatings for implantable devices is described in the documents US Pat. No. 6,099,562, US Pat. No. 5,886, 026, and US Pat. , polymethyl dimethyl ether, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coating may optionally be further covered by a suitable coating, such as fluorodimethyl hydrazine oil, a polysaccharide enzyme, polyethylene glycol, phospholipids, or combinations thereof, to characterize the controlled release of the composition. Another aspect of the invention includes an implantable device coated with a compound of the invention. The compounds of the present invention may also be applied to medical devices implantable in the body, such as beads, or mixed with a polymer or other molecule to provide a "drug store", thus allowing the drug to be compared to the aqueous drug solution. Release has a longer period of time.

General synthetic process

In general, the compounds of the present invention can be prepared by the methods described herein, unless otherwise stated, wherein the substituents are as defined for formula (I) or formula (II). The following reaction schemes and examples are provided to further illustrate the contents of the present invention.

Those skilled in the art will recognize that the chemical reactions described herein can be used to suitably prepare a number of other compounds of the invention, and that other methods for preparing the compounds of the invention are considered to be within the scope of the invention. Inside. For example, the synthesis of those non-exemplified compounds according to the present invention can be successfully accomplished by modifications by those skilled in the art, such as appropriate protection of the interfering group, by the use of other known reagents in addition to those described herein, or The reaction conditions are subject to some conventional modifications. Additionally, the reactions or known reaction conditions disclosed herein are also recognized to be suitable for the preparation of other compounds of the invention.

The examples described below, unless otherwise indicated, all temperatures are set to degrees Celsius. The reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Arco Chemical Company and Alfa Chemical Company and were used without further purification unless otherwise indicated. General reagents from Shantou Xiqiao Chemical Plant, Guangdong Guanghua Chemical Reagent Factory, Guangzhou Chemical Reagent Factory, Tianjin Haoyuyu Chemical Co., Ltd., Tianjin Fuchen Chemical Reagent Factory, Wuhan Xinhuayuan Technology Development Co., Ltd., Qingdao Tenglong Chemical Reagent Co., Ltd., and Qingdao Ocean Chemical Plant purchased it.

Anhydrous tetrahydrofuran, dioxane, toluene and diethyl ether are obtained by refluxing with sodium metal. Anhydrous dichloromethane and chloroform were obtained by reflux drying of calcium hydride. Ethyl acetate, petroleum ether, n-hexane, N,N-dimethylacetamide and N,N-dimethylformamide were previously dried over anhydrous sodium sulfate.

The following reaction is generally carried out under a positive pressure of nitrogen or argon or on a dry solvent (unless otherwise indicated), the reaction bottle is stoppered with a suitable rubber stopper, and the substrate is driven through a syringe. The glassware is dry.

The column is a silicone column. Silicone rubber (300-400 mesh) was purchased from Qingdao Ocean Chemical Plant. The nuclear magnetic resonance spectrum was measured by CDCl ₃ , DMSO- d ₆ , CD ₃ OD or acetone- d ₆ (in ppm) using TMS (0 ppm) or chloroform (7.25 ppm) as a reference standard. When multiple peaks appear, the following abbreviations are used: s (singlet, single peak), d (doublet, doublet), t (triplet, triplet), m (multiplet, multiplet), br (broadened, wide) Peak), dd (doublet of doublets), dt (doublet of triplets). Coupling constant, expressed in Hertz (Hz).

The conditions for the low-resolution mass spectrometry (MS) data were: Agilent 1200 Series LCMS (Zorbax SB-C18, 2.1 x 30 mm, 4 μm, 10 min, flow rate 0.6 mL/min, 5%-95% (0.1% dissolved in H _{2 )} (0.1% of formic acid in CH ₃ CN) in the formic acid of O), UV detection at 210/254 nm, with low response electrospray mode (ESI).

Pure compounds were characterized by Agilent 1100 Series high performance liquid chromatography (HPLC) with UV detection at 210 nm and 254 nm. The column was operated at 40 °C.

The following abbreviations are used throughout the invention: Ac ₂ O acetic anhydride

ATP adenosine triphosphate

BBr ₃ boron tribromide

BINAP 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl

BSA bovine serum albumin

BOC, Boc tert-butoxycarbonyl

Ca(SO ₃ CF ₃ ) ₂ trifluoromethyl sulfate

Cs ₂ CO ₃ strontium carbonate

CHCl ₃ chloroform

CDCl ₃ deuterated chloroform

CH ₂ Cl ₂ , DCM dichloromethane

Cu copper

CuI cuprous iodide

Et ₂ O ether

EtOH ethanol

DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

D ₂ helium

DIBAL diisobutylaluminum hydride

DIAD diisopropyl azodicarboxylate

DIEA, DIPEA, iPr ₂ Net N, N-diisopropylethylamine

DEAD diethyl azodicarboxylate

DMF N,N-dimethylformamide, dimethylformamide

DMAP 4-dimethylaminopyridine

DMSO dimethyl sulfoxide

DPPA diphenyl phosphate

DTT dimercaptosuitol

EDC, EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

EDTA ethylenediaminetetraacetic acid

EtOAc, EA ethyl acetate

Et ₃ N, TEA triethylamine

FBS fetal bovine serum

g g

h hours

HATU 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate

HBr hydrobromic acid

HCl hydrochloric acid

HOAc acetic acid

HOAT N-hydroxy-7-azabenzotriazole

HOBt 1-hydroxybenzotriazole hydrate

H ₂ hydrogen

H ₂ O water

H ₂ O ₂ hydrogen peroxide

H ₃ PO ₄ phosphate

H ₂ SO ₄ sulfuric acid

HNO ₃ nitric acid

HCOOK potassium formate

Fe iron

LiHMDS hexamethyldidecyl lithium

LDA diisopropylamino lithium

MBP myelin basic protein

MCPBA m-chloroperoxybenzoic acid

MeCN, CH ₃ CN acetonitrile

MgSO ₄ magnesium sulfate

Mg ATP magnesium adenosine triphosphate

MeOH, CH ₃ OH methanol

MeI methyl iodide

MOPS 3-(N-morpholino)propanesulfonic acid

mL, ml ml

N ₂ nitrogen

NMP N-methylpyrrolidone

NaHCO ₃ sodium bicarbonate

NaBH ₄ sodium borohydride

NaBH ₃ CN sodium cyanoborohydride

NaOtBu sodium tert-butoxide

NaOH sodium hydroxide

NaClO ₂ sodium chlorite

NaCl sodium chloride

NaH ₂ PO ₄ sodium dihydrogen phosphate

NaH sodium hydride

NaI sodium iodide

Na ₂ SO ₄ sodium sulfate

NBS N-bromobutanediimine

Nonidet Norit lotion

NH ₃ ammonia

NH ₄ Cl ammonia chloride

Pd/C palladium/carbon

Pd ₂ (dba) ₃ tris(dibenzylideneacetone) dipalladium

Pd(OAc) ₂ palladium acetate

Pd(OH) ₂ palladium hydroxide

Pd(PPh ₃ ) ₄ tetrakis(triphenylphosphine)palladium

Pd(dppf)Cl ₂ 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride

P(t-Bu) ₃ tri(tert-butyl)phosphine

PE petroleum ether (60-90 ° C)

PBS phosphate buffered saline

POCl ₃ phosphorus oxychloride

PhI(OAc) ₂ iodobenzene diacetate

K ₂ CO ₃ potassium carbonate

KOH potassium hydroxide

RT, rt, r.t. room temperature

Rt retention time

SOCl ₂

t -BuOK potassium tert-butoxide

TBTU O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroborate

THF tetrahydrofuran

TFA trifluoroacetic acid

TBAI tetrabutylammonium iodide

TBS Tris buffered saline

TEAC bis(tetraethylammonium) carbonate

Tris Tris

The synthetic schemes 1-4 are typical synthetic schemes for the preparation of the compounds of the following examples. Each of X, Y, Z, W, R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ⁶ has the meanings indicated in the present invention.

Synthetic scheme 1

The compounds of the present invention can be prepared by the above synthesis scheme 1 , and the specific synthesis schemes are described in the examples. In Synthesis Scheme 1 , 6-aminopyridin-3-ol ( 1 ) is first condensed with a substituted pyrazolone compound ( 2 ) to give compound ( 3 ) . Under basic conditions (for example, using potassium t -tert-butoxide or sodium hydride), the pyridine carbenamide ( 4 ) is reacted with the compound ( 3 ) under elevated temperature and a polar solvent (such as DMF) to give the guanamine. Compound ( 5 ) . The guanamine compound ( 5 ) undergoes a rearrangement reaction under the action of the oxidant iodobenzene diacetate or NaClO to obtain an aminopyridine compound ( 6 ) , and the compound ( 6 ) is further acetylated to obtain a target kinase inhibitor ( 7 ) .

Synthetic scheme 2

The compounds of the present invention can also be prepared by the above Synthesis Scheme 2. The specific synthesis schemes are described in the examples. In Synthetic Scheme 2 , the nitro derivative ( 8 ) is reduced to the aniline compound ( 9 ) under catalytic hydrogenation conditions. The substituted aniline compound ( 9 ) and 4-chloropyridin-2-amine ( 10 ) are dissolved in dimethyl hydrazine and placed under microwave conditions to obtain a diaryl ether compound ( 11 ) . The compound ( 11 ) is condensed with a substituted pyrazolone compound ( 2 ) to form an aminopyridine compound ( 12 ) . Under basic conditions, compound ( 12 ) can be further converted to the target kinase inhibitor ( 13 ) under basic conditions.

Synthetic scheme 3

The compounds of the present invention can also be prepared by the above synthesis scheme 3. The specific synthesis schemes are described in the examples. In the synthesis scheme 3 , the aryl compound ( 14 ) is first coupled with the substituted pyridine compound ( 15 ) under elevated temperature to obtain a diaryl ether compound ( 16 ) . The compound ( 16 ) and the substituted pyrazolone compound ( 2 ) undergo a condensation reaction to form a guanamine pyridine compound ( 17 ) . The compound ( 17 ) undergoes a rearrangement reaction under the action of the oxidant iodobenzene diacetate or NaClO to obtain a target kinase inhibitor ( 18 ) .

Synthetic scheme 4

Further compounds of the present invention can also be prepared by the above Synthetic Scheme 4 , and the aminopyridine compound ( 18 ) is deuterated with an acetamidine reagent (e.g., acetic anhydride or ethyl hydrazine chloride) under basic conditions to form a target kinase. Agent ( 19) .

Example Example 1 N -(4-((2-Aminopyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydrogen -1 H -pyrazole-4-carboxamide

Step 1) 4-Aminophenol

4-Nitrophenol (7g, 50.3mmol) and HCOOK (1.8g, 21.48mmol) were dissolved in THF (210mL) and water (70mL), then Pd/C (110mg, 10% Pd content, 53 %~55% water content). The reaction solution was stirred at 50 ° C for 24 hours and then concentrated in vacuo. The residual reaction solution was diluted with dichloromethane (100 mL) and filtered over Celite. The filtrate was concentrated in vacuo to give crystal crystal crystal crystal crystals

MS (ESI, pos.) m/z: 110.1 [M+H] ⁺ .

Step 2) 4-(4-Aminophenoxy)pyridin-2-amine

4-Aminophenol (218 mg, 2 mmol) and 4-chloropyridin-2-amine (256 mg, 2 mmol) were dissolved in dimethyl hydrazine (2.5 mL), then solid sodium methoxide (216 mg, 4 mmol). The reaction solution was placed under microwave at 40 ° C for 40 minutes, then cooled to room temperature and then quenched with water (10 mL). The reaction mixture was extracted with EtOAc (EtOAc m. The residue was purified by silica gel column chromatography _{(DCM / CH 3 OH (v} / v) = 30/1) to give the title compound as a tan solid (103mg, 26%).

MS (ESI, pos.ion) m / z: 202.2 [M + H] +; 1 H NMR (400MHz, CDCl 3): δ (ppm) 3.65 (s, 2H), 4.37 (s, 1H), 5.89- 5.90 (d, J = 2.04 Hz, 1H), 6.25-6.27 (dd, J = 2.08 Hz, 5.88 Hz, 1H), 6.68-6.71 (m, 2H), 6.86-6.89 (m, 2H), 7.88-7.89 (d, J = 5.88 Hz, 1H).

Step 3) N- (4-((2-Aminopyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro -1 H -pyrazole-4-carboxamide

4-(4-Aminophenoxy)pyridin-2-amine (101 mg, 0.5 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H Pyrazole-4-carboxylic acid (118 mg, 0.51 mmol) was dissolved in dichloromethane (5 mL) then EDCI (l. After the reaction mixture was stirred at 45 ° C for 3 hours, the reaction was quenched with water (20 mL). The organic phase was separated and concentrated in vacuo. The residue was purified by silica gel column to give the title compound chromatography _{(DCM / CH 3 OH (v} / v) = 20/1) as a light gray solid (110mg, 49.2%).

MS (ESI, pos.ion) m / z: 416.4 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.71 (s, 3H), 3.36 (s, 3H), 5.80-5.81 (d, J = 2.16 Hz, 1H), 5.92 (s, 2H), 6.12-6.14 (dd, J = 2.24 Hz, 5.8 Hz, 1H), 7.08-7.10 (m, 2H), 7.42-7.45 (m, 2H), 7.51-7.53 (m, 1H), 7.57-7.61 (m, 2H), 7.65-7.67 (m, 2H), 7.77-7.79 (d, J = 5.8 Hz, 1H).

Example 2 N- (4-((2-Amino-3-chloropyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) N- (4-Hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

4-Aminophenol (1.09 g, 10 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxylic acid (2.37 g , 10.2 mmol) was dissolved in dichloromethane (30 mL) then EDCI (2.3 g, 12 mmol) and HOAT (0.27 g, 2mmol). After the reaction mixture was stirred at 46 ° C for 4 hr, cooled to room temperature and diluted with ethyl acetate (10 mL) and water (10 mL). After the reaction mixture was stirred at room temperature for 1 hr.

MS (ESI, pos.ion) m / z: 324.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.68 (s, 3H), 3.32 (s, 3H), 6.72 (d, J = 8.8 Hz, 2H), 7.36-7.42 (m, 4H), 7.49 (t, J = 7.4 Hz, 1H), 7.57 (t, J = 7.6 Hz, 2H), 9.21 (s, 1H) ), 10.46 (s, 1H).

Step 2) 3,4-Dichloro-2-pyridinecarboxamide

2,2,6,6-Tetramethyl acridine (6.2 mL, 37.2 mmol) was dissolved in diethyl ether (50 mL) then taken in hexanes (2.5 M, 23 mL, 57.5 mmol) of n-butyllithium. After the reaction solution was stirred at 0 ° C for 0.5 hour, it was kept at -78 ° C for 0.5 hour, and then 3,4-dichloropyridine (5.00 g, 33.8 mmol) dissolved in diethyl ether (20 mL) was added to the reaction mixture over 15 minutes by syringe. ) solution. After the reaction mixture was stirred at -78 ° C for 2 hours, trimethyl decane isocyanate (94% purity, 6.7 mL, 50.7 mmol). The reaction mixture was warmed to room rt and stirred for 2 h then quenched with EtOAc (EtOAc &lt Stirring was continued overnight, a white solid precipitated and collected by filtration. The filtrate was extracted with EtOAc (EtOAc (EtOAc)EtOAc. The resulting solid was combined with EtOAc EtOAcjjjjjjj

MS (ESI, pos.ion) m / z: 191.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 8.48 (d, J = 5.2Hz, 1H), 8.09 ( Br s, 1H), 7.82 (s, 1H), 7.81 (d, J = 5.2 Hz, 1H).

Step 3) 3-Chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide) Phenoxy)pyridinium

N- (4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide (356 mg, 1.1 mmol) was dissolved in dimethyl hydrazine (4 mL) and placed in a microwave vial, then NaH (88 mg, 2.2 mmol, 60% disperse in mineral oil) was added at room temperature. After the reaction mixture was stirred at room temperature for 30 minutes, 3,4-dichloro-2-pyridinecarbamide (191 mg, 1.0 mmol) was added. The reaction mixture was placed under microwave at 160 ° C for 2 hours, cooled to room temperature and diluted with water (10 mL). The resulting mixture was extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with brine (30 mL EtOAc) The residue was purified by EtOAc EtOAc EtOAc EtOAc

MS (ESI, pos.ion) m / z: 478.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.71 (s, 3H), 3.35 (s, 3H), 6.82 (d, J = 5.4 Hz, 1H), 7.19 (d, J = 9.0 Hz, 2H), 7.44 (d, J = 7.5 Hz, 2H), 7.53 (m, 1H), 7.59 (m, 2H), 7.74 (m, 3H), 8.02 (s, 1H), 8.33 (d, J = 5.4 Hz, 1H), 10.84 (s, 1H).

Step 4) N- (4-((2-Amino-3-chloropyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

3-Chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)benzene Ethyl pyridinamine (140 mg, 0.29 mmol) was dissolved in a mixed solution of ethyl acetate (2.5 mL), acetonitrile (2.5 mL) and water (1.3 mL), then iodobenzene diacetate (113 mg, 0.35 mmol). After the reaction solution was stirred at 0 ° C for 30 minutes, the mixture was further stirred at room temperature for 4 hours. The reaction mixture was diluted with dichloromethane (30 mL)EtOAc. The residue was purified by EtOAc EtOAc EtOAc (EtOAc:

MS (ESI, pos.ion) m / z: 450.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.70 (s, 3H), 3.37 (s, 3H), 5.95 (d, J = 5.6 Hz, 1H), 6.36 (s, 2H), 7.10 (d, J = 8.5 Hz, 2H), 7.44 (d, J = 7.6 Hz, 2H), 7.51 (m, 1H), 7.59 (m, 2 H), 7.66 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 5.6 Hz, 1H), 10.79 (s, 1H).

Example 3 N -(4-((2-Amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-benzene Base-2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 4-(4-Amino-2-fluorophenoxy)-3-chloropyridiniumamine

4-Amino-2-fluorophenol (254 mg, 2.0 mmol) was dissolved in dimethylformamide (5 mL) and potassium tert-butoxide (359 mg, 3.2 mmol). The reaction was stirred at room temperature for 30 min then 3,4-dichloro-2-pyridinecarbamide (420 mg, 2.2 mmol). The reaction mixture was placed under microwave at 120 ° C for 2 hours, cooled to room temperature and diluted with 25 mL of water. The mixture was extracted with EtOAc (EtOAc (EtOAc)EtOAc. The residue was purified by EtOAc EtOAc EtOAc (EtOAc)

MS (ESI, pos.ion) m / z: 282.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): (ppm) δ 8.30 (d, J = 5.6Hz, 1H), 8.03 ( s, 1H), 7.73 (s, 1H), 7.03 (t, J = 9.0 Hz, 1H), 6.72 (dd, J = 0.8 Hz, 5.6 Hz, 1H), 6.53 (dd, J = 2.4 Hz, 13.2 Hz , 1H), 6.44 (dd, J = 1.8 Hz, 8.7 Hz, 1H), 5.55 (s, 2H).

Step 2) 3-Chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide) )-2-fluorophenoxy)pyridinium

4-(4-Amino-2-fluorophenoxy)-3-chloropyridiniumamine (306 mg, 1.40 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3 -Dihydro-1 H -pyrazole-4-carboxylic acid (390 mg, 1.68 mmol) was suspended in dichloromethane (6 mL) then EDCI ( 322 g, 1.68 mmol) and HOAT (38 mg, 0.28 mmol). After the reaction mixture was stirred at 45 ° C for 14.5 hours, cooled to room temperature and quenched with 5 mL water. The reaction mixture was extracted with EtOAc (EtOAc m. The residue was purified by EtOAc EtOAc EtOAc (EtOAc:EtOAc

MS (ESI, pos.) m/z: 496.1 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 10.98 (s, 1H), 8.33 (d, J = 5.6 Hz, 1H), 8.06 (br s, 1H), 7.99 (dd, J = 2.2 Hz, 13.2 Hz, 1H), 7.75 (br s, 1H), 7.60 (t, J = 7.2 Hz, 2H), 7.52 ( m, 1H), 7.45 (d, J = 5.6 Hz, 2H), 7.35 (m, 2H), 6.84 (d, J = 5.5 Hz, 1H), 3.37 (s, 3H), 2.71 (s, 3H).

Step 3) N- (4-((2-Amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-benzene Base-2,3-dihydro-1 H -pyrazole-4-carboxamide

3-Chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)- 2-Fluorophenoxy)pyridiniumamine (437 mg, 0.88 mmol) was suspended in a mixed solution of ethyl acetate (5 mL), acetonitrile (5 mL) and water (2.5 mL), and then, iodobenzene diacetate was added at 0 ° C ( 341 mg, 1.06 mmol). After the reaction mixture was stirred at 0 ° C for 30 minutes, it was allowed to warm to room temperature and stirring was continued for 3 hours. The reaction mixture was concentrated with EtOAc EtOAc m.

MS (ESI, pos.) m/z: 468.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 10.93 (s, 1H), 7.92 (d, J =12.6) Hz, 1H), 7.74 (d, J = 5.7 Hz, 1H), 7.59 (t, J = 7.4 Hz, 2H), 7.52 (m, 1H), 7.43 (d, J = 7.6 Hz, 2H), 7.28 ( d, J = 4.3 Hz, 2H), 6.40 (s, 2H), 5.92 (d, J = 5.6 Hz, 1H), 5.86 (d, J = 1.9 Hz, 1H), 3.36 (s, 3H), 2.70 ( s, 3H).

Example 4 N -(4-((2-Ethylamino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2 -phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) N- (4-((2-(N-Ethylethylamino)-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl -3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

Compound N -(4-((2-Amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-dihydro -1 H - pyrazole-4-acyl-amine (0.22g, 0.47mmol), acetic anhydride (1.3mL, 13.75mmol) and Et ₃ N (0.51g, 5.04mmol) in a mixture of 60 after ℃ reaction was stirred for 24 hours, saturated Na ₂ CO ₃ solution (50mL) was quenched reaction mixture was extracted with EtOAc (50mL x 3), the combined organic phase was washed with brine (50mL x 3) washed, dried over anhydrous Na ₂ SO _{4 was} dried, then concentrated under reduced pressure, and the obtained crude product was applied to the next step without further purification.

MS (ESI, pos.ion) m / z: 552.1 [M + H] +.

Step 2) N- (4-((2-Ethylamino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2 -phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

Compound N -(4-((2-( N -Ethylethylamino)-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl- 3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide (259 mg, 0.47 mmol) was dissolved in CH ₃ OH (20 mL) and then added to the reaction mixture A solution of Na ₂ CO ₃ (59.8 mg, 0.56 mmol) in water (1 mL). After the reaction stirred for 15 minutes at room temperature, and concentrated to give the residue _{(CH 3 OH / EtOAc (v} / v) = 1/50) was purified by silica gel column chromatography to give the title compound as a beige solid (160 mg reduced pressure, 66.7 %).

MS (ESI, pos.ion) m / z: 510.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 10.97 (s, 1H), 10.27 (s, 1H), 8.20 (d, J = 5.6 Hz, 1H), 7.98 (dd, J = 2.3 Hz, 13.2 Hz, 1H), 7.60 (m, 2H), 7.54 (m, 1H), 7.44 (d, J = 7.3 Hz, 2H), 7.38 (m, 1H), 7.33 (dd, J = 2.0 Hz, 9.0 Hz, 1H), 6.67 (d, J = 5.4 Hz, 1H), 3.40 (s, 3H), 2.71 (s, 3H) , 2.08 (s, 3H).

Example 5 N -(4-((2-Aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 1-(Benzyloxy)-2,3-difluoro-4-nitrobenzene

2,4,5-trifluoronitrobenzene (5.00 g, 28.2 mmol) and benzyl alcohol (3.07 g, 28.4 mmol) were dissolved in dimethylformamide (10 mL), then potassium carbonate (5.87 g, 42.5 mmol). After the reaction mixture was stirred at room temperature for 72 hr, diluted with water (35 mL) Filtration and EtOAc (EtOAc) (EtOAc:EtOAc.

_{^{1 H NMR (400MHz, CDCl 3}} ): δ (ppm) 7.90 (m, 1H), 7.43 (s, 2H), 7.42 (s, 2H), 7.39 (m, 1H), 6.86 (m, 1H), 5.27 (s, 2H).

Step 2) 4-Amino-2,3-difluorophenol

1-(Benzyloxy)-2,3-difluoro-4-nitrobenzene (1.93 g, 0.73 mmol) was suspended in a mixed solution of methanol (45 mL) and tetrahydrofuran (9 mL), then Pd/C ( 333 mg, 6% Pd content, 53% to 55% water content). After the reaction mixture was stirred at 32 ° C for 13 hr under H ₂ , filtered over Celite, and filtered. The title compound was obtained as a dark brown solid (yield: <RTIgt;

MS (ESI, pos.ion) m / z: 146.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 6.49 (m, 1H), 6.38 (m, 1H), 4.71 (s, 2H).

Step 3) 4-(4-Amino-2,3-difluorophenoxy)pyridinium

4-Amino-2,3-difluorophenol (208 mg, 1.43 mmol) was dissolved in dimethylformamide (4 mL) then potassium t-butoxide (257 mg, 2.29 mmol). After the reaction mixture was stirred at room temperature for 30 minutes, 4-chloropyridylcarbamide (249 mg, 1.59 mmol) was added. The reaction mixture was placed under microwave at 120 ° C for 3 hours, cooled to room temperature and diluted with 25 mL of water. The resulting mixture was extracted with EtOAc (EtOAc)EtOAc. The residue was purified by EtOAc EtOAc EtOAc (EtOAc)

MS (ESI, pos.) m/z: 266.0 [M+H] ⁺ , 283.2 [M+NH ₄ ] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 8.42 (d, J = 5.6 Hz, 1H), 7.84 (br s, 1H), 7.65 (d, J = 2.5 Hz, 1H), 7.03 (m, 1H), 6.77 (m, 1H), 6.56 (m, 1H), 5.56 ( Br s, 1H), 3.08 (s, 2H).

Step 4) 4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-2, 3-difluorophenoxy)pyridinium

4-(4-Amino-2,3-difluorophenoxy)pyridiniumamine (180 mg, 0.68 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3- Dihydro-1 H -pyrazole-4-carboxylic acid (161 mg, 0.69 mmol) was suspended in dichloromethane (4 mL), then EDCI (157 mg, 0.82 mmol) and HOAT (19 mg, 0.14 mmol). After the reaction mixture was stirred at 45 ° C for 12 hours, 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxylic acid (87 mg was further added. After the reaction mixture was stirred at 45 ° C for 5 hours, cooled to room temperature, then quenched with 5 mL of water and ethyl acetate (10 mL x 3). The combined organic phases were washed with EtOAcq. The residue was purified by EtOAc EtOAc EtOAc EtOAc

MS (ESI, pos.ion) m / z: 480.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 11.2 (s, 1H), 8.55 (d, J = 5.7 Hz, 1H), 8.34 (m, 1H), 8.16 (br s, 1H), 7.76 (br s, 1H), 7.64 (m, 3H), 7.59 (d, J = 7.8 Hz, 1H), 7.46 (m) , 3H), 7.28 (m, 1H), 3.38 (s, 3H), 2.71 (s, 3H).

Step 5) N- (4-((2-Aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-dihydro-1 H -pyrazole-4-carboxamide

4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-2,3- Difluorophenoxy)pyridiniumamine (108 mg, 0.22 mmol) was suspended in a mixed solution of ethyl acetate (2.5 mL), acetonitrile (2.5 mL) and water (1.5 mL), and then, iodobenzene diacetate was added at 0 ° C. (96 mg, 0.30 mmol). After the reaction mixture was stirred at 0 ° C for 30 minutes, it was allowed to warm to room temperature and stirring was continued for 4 hours. The reaction mixture was concentrated in vacuo, the residue was purified by silica gel column chromatography _{(EtOAc / CH 3 OH (v} / v) = 10/1) to give the title compound as a pale yellow solid (32mg, 32.3%).

MS (ESI, pos.ion) m / z: 452.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 11.12 (s, 1H), 8.27 (m, 1H), 7.81 (d, J = 5.8 Hz, 1H), 7.60 (m, 2H), 7.54 (m, 1H), 7.44 (d, J = 7.4 Hz, 2H), 7.16 (m, 1H), 6.19 (m, 1H) ), 5.98 (s, 2H), 5.86 (d, J = 1.9 Hz, 1H), 3.34 (s, 3H), 2.70 (s, 3H).

Example 6 N -(4-((2-Ethylaminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2- Phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-Dihydro-1 H -pyrazole-4-carboxamide (135 mg, 0.3 mmol) was suspended in acetic anhydride (6 mL), then triethylamine (0.4 mL, 2.9 mmol) was added to the reaction mixture. after stirring the reaction at 35 ℃ 4 hours and filtered off with suction, the filter cake was washed with PE (5mL), EtOAc (5mL ) and CH ₃ OH (2mL) wash to afford the title compound as a beige solid (102mg, 68.9%).

MS (ESI, pos.ion) m / z: 494.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): (ppm) δ 11.16 (s, 1H), 10.60 (s, 1H), 8.31(m,1H), 8.20 (d, J = 5.8 Hz, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.61 (m, 2H), 7.52 (m, 1H), 7.45 (m, 2H) ), 7.22 (m, 1H), 6.73 (dd, J = 2.4 Hz, 5.7 Hz, 1H), 3.38 (s, 3H), 2.71 (s, 3H), 2.04 (s, 3H).

Example 7 N -(4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) -2,3-difluorophenoxy)pyridin-2-yl)morpholine-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-Dihydro-1 H -pyrazole-4-carboxamide (224 mg, 0.50 mmol) was suspended in THF (3 mL), then triethylamine (0.138 mL, 0.99 mmol) was added to the reaction mixture. Then, phenyl chloroformate (0.125 mL, 1.00 mmol) was added dropwise, and the mixture was stirred at room temperature for 2 hr, then morpholine (0.4 mL, 5.00 mmol) was added, and the mixture was stirred at room temperature for 36 hours. , saturated aqueous NH ₄ Cl (20mL) and CH ₂ Cl ₂ (20mL) was quenched reaction mixture was extracted, combined with _{CH 2 Cl 2 (20mL x 3} ) with stirring at room temperature for 10 minutes the organic phase was washed with brine (20mL x 3) washed, dried with anhydrous ₂ SO ₄ Na, and then concentrated under reduced pressure to give the residue (20/1 EtOAc / PE ( v / v) =) was purified by silica gel column chromatography to give the title The compound was an orange solid (148 mg, 52.5%).

MS (ESI, pos.ion) m / z: 565.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 11.16 (s, 1H), 9.32 (s, 1H), 8.30 (m, 1H), 8.14 (d, J = 5.8 Hz, 1H), 7.60 (m, 2H), 7.53 (m, 1H), 7.44 (m, 3H), 7.20 (m, 1H), 6.66 (dd , J = 2.4 Hz, 5.7 Hz, 1H), 3.55 (dd, J = 4.4 Hz, 5.1 Hz, 4H), 3.41 (dd, J = 4.1 Hz, 4.8 Hz, 4H), 3.38 (s, 3H), 2.71 (s, 3H).

Example 8 N -(4-((2-Aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 1-(Benzyloxy)-2,5-difluoro-4-nitrobenzene

A mixed solution of 2,4,5-trifluoronitrobenzene (5.4 g, 30.5 mmol) and benzyl alcohol (3.2 mL, 30.5 mmol) was dissolved in dimethylformamide (20 mL), then potassium carbonate (6.33 g) , 46.1 Mm). The reaction solution was stirred at room temperature for 72 hours. After adding water (60 mL) at 0 ° C, the resulting reaction mixture was stirred at 4 ° C for 24 hours. The solid was collected by EtOAc (EtOAc)EtOAc.

¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 5.22 (s, 2H), 6.85-6.89 (m, 1H), 7.40-7.43 (m, 5H), 7.89-7.94 (m, 1H).

Step 2) 4-Amino-2,5-difluorophenol

1-(Benzyloxy)-2,5-difluoro-4-nitrobenzene (1.06 g, 4 mmol) was suspended in a mixed solution of methanol (25 mL) and tetrahydrofuran (5 mL), then Pd/C (50) % Pd content, 185 mg). The reaction solution was stirred at 32 ° C for 10 hours under H ₂ conditions. The reaction mixture was filtered through celite, and filtrate was concentrated in vacuo. The residue was washed with EtOAc (EtOAc)

MS (ESI, pos. ion) m/z: 146.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 4.68 (s, 2H), 6.53-6.65 (m, 2H) ), 9.06 (br, 1H).

Step 3) 4-(4-Amino-2,5-difluorophenoxy)pyridinium

4-Amino-2,5-difluorophenol (100 mg, 0.64 mmol) and 4-chloropyridylcarzamide (110 mg, 0.71 mmol) were dissolved in dimethylformamide (2 mL) then NaH (80 mg, 1.3 mmol, 60% dispersed in mineral oil). The reaction solution was placed under microwave and reacted at 120 ° C for 1.5 hours. The reaction mixture was cooled to room temperature, diluted with water (20 mL) The combined organic phases were washed with EtOAc EtOAc m. The residue was purified by flash chromatography eluting elut elut elut elut elut elut

MS (ESI, pos.) m/z: 266.2 [M+H] ⁺ .

Step 4) 4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-2, 5-difluorophenoxy)pyridiniumamine

4-(4-Amino-2,5-difluorophenoxy)pyridiniumamine (200 mg, 0.76 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3- A mixed solution of dihydro-1 H -pyrazole-4-carboxylic acid (165 mg, 0.75 mmol) was dissolved in dichloromethane (10 mL), then EDCI (175 mg, 0.93 mmol) and HOAT (26 mg, 0.15 mmol). The reaction was stirred at 45 &lt;0&gt;C for 16 h then cooled to EtOAc. Filtration, the resulting solid was dried in vacuo tolululu

MS (ESI, pos. ion) m/z: 480.1 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 11.24 (s, 1H), 8.53 - 8.57 (m, 2H) ), 8.15 (s, 1H), 7.75 (s, 1H), 7.53 - 7.59 (m, 4H), 7.44 - 7.45 (m, 3H), 7.24 - 7.25 (d, J = 5.2 Hz, 1H), 3.43 ( s, 3H), 2.70 (s, 3H).

Step 5) N- (4-((2-Aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-dihydro-1 H -pyrazole-4-carboxamide

4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-2,5- Difluorophenoxy)pyridiniumamine (80 mg, 0.17 mmol) was dissolved in a mixed solution of ethyl acetate (2 mL), acetonitrile (2 mL) and water (1 mL), then iodobenzene diacetate (70 mg, 1.2 mmol) . After the reaction mixture was stirred at 0 ° C for 30 minutes, it was allowed to warm to room temperature and stirring was continued for 8 hours. The reaction mixture was filtered through EtOAc (EtOAc)EtOAc. The filtrate was concentrated in vacuo, the resulting residue was purified by silica gel column chromatography _{(DCM / CH 3 OH (v} / v) = 20/1) to give the title compound as a white solid (51mg, 68%).

MS (ESI, pos. ion) m/z: 4521. [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 11.18 (s, 1H), 8.45-8.50 (dd, J = 7.4 Hz, 12.8 Hz, 1H), 7.79-7.81 (d, J = 5.76 Hz, 1H), 7.57-7.61 (m, 2H), 7.43-7.54 (m, 4H), 6.16-6.18 (m, 1H) , 5.96 (s, 2H), 5.83-5.83 (d, J = 2.16 Hz, 1H), 3.37 (s, 3H), 2.70 (s, 3H).

Example 9 N -(4-((2-Ethylaminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2- Phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-Dihydro-1 H -pyrazole-4-carboxamide (220 mg, 0.48 mmol) was dissolved in acetic acid (8 mL), then Et ₃ N (0.5 mL, 1. After the reaction was stirred at room temperature for EtOAc ( ₃ mL), EtOAc (EtOAc) .

MS (ESI, pos.ion) m / z: 494.0 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 11.21 (s, 1H), 10.58 (s, 1H), 8.49-8.54 (dd, J = 7.3 Hz, 12.8 Hz, 1H), 8.18-8.20 (d, J = 5.7 Hz, 1H), 7.67-7.68 (m, 1H), 7.51-7.61 (m, 4H), 7.43 - 7.45 (m, 2H), 6.70-6.72 (dd, J = 2.4 Hz, 5.7 Hz, 1H), 3.32 (s, 3H), 2.70 (s, 3H), 2.04 (s, 3H).

Example 10 N -(4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) -2,5-difluorophenoxy)pyridin-2-yl)morpholine-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-Dihydro-1 H -pyrazole-4-carboxamide (250 mg, 0.56 mmol) and Et ₃ N (0.25 mL, 1.68 mmol) were suspended in THF (10.0 mL) and then added to the reaction mixture phenyl chloroformate (0.25mL, 1.68mmol), was stirred at room temperature for 2 hours, morpholine (0.35mL, 3.46mmol), the reaction mixture was stirred for 24 hours at room temperature, NH ₄ Cl aq (40 mL) and DCM (40 mL), separated, the aqueous phase was extracted with DCM (40mL x 3), dried Na ₂ SO ₄ the combined organic phases were dried over anhydrous, and then concentrated under reduced pressure, the resulting residue was purified by silica gel column chromatography PE (EtOAc / (v The title compound was obtained as a white solid (70 mg, 21%).

MS (ESI, pos.ion) m / z: 565.0 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 11.20 (s, 1H), 9.28 (s, 1H), 8.47-8.52 (dd, J = 7.3 Hz, 12.8 Hz, 1H), 8.12-8.14 (d, J = 5.7 Hz, 1H), 7.57-7.61 (m, 2H), 7.50-7.54 (m, 2H), 7.39 -7.45 (m, 3H), 6.63-6.65 (dd, J = 2.5 Hz, 5.6 Hz, 1H), 3.53-3.56 (m, 4H), 3.40-3.41 (m, 4H), 3.35 (s, 3H), 2.70 (s, 3H).

Example 11 N -(4-((2-Amino-3-chloropyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo- 2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 3-Chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide) )-2,5-difluorophenoxy)pyridinium

The compound N -(2,5-difluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole- 4-Mercaptoamine (395 mg, 1.1 mmol) was dissolved in DMF (5.0 mL), then t- BuOK (202 mg, 1.8 mmol) was added to the reaction mixture, and stirred at room temperature for 30 minutes, then 3,4-dichlorobenzene was added. 2-Pyridylcaroxime (190 mg, 1.0 mmol), the mixture was stirred at EtOAc EtOAc (EtOAc) EtOAc. and the combined organic phase was washed with brine (50mL x 3), dried over anhydrous Na ₂ SO _4, then concentrated under reduced pressure, the resulting residue was purified by silica gel column chromatography (MeOH / DCM (v / v ) = 1 / The title compound was obtained as a pale yellow solid (d.

MS (ESI, pos.ion) m / z: 514.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.70 (s, 3H), 3.38 (s, 3H), 6.96 (d, J = 5.5 Hz, 1H), 7.45 (d, J = 7.0 Hz, 2H), 7.51-7.55 (m, 1H), 7.58-7.66 (m, 3H), 7.75 (s, 1H), 8.05 (s, 1H), 8.34 (d, J = 5.5 Hz, 1H), 8.53 - 8.58 (m, 1H), 11.25 (s, 1H).

Step 2) N- (4-((2-Amino-3-chloropyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo- 2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound 3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) 2,5-difluorophenoxy) pyridin-acyl amine (310mg, 0.60mmol) was suspended in the _{EtOAc (6.0mL), CH 3 CN} (6.0mL) and H ₂ O (3.0mL) in the mixed solvent was cooled to At 0 ° C, PhI(OAc) ₂ (234 mg, 0.72 mmol) was added to the reaction mixture, and the mixture was stirred at 0 ° C for 30 minutes, then warmed to room temperature and stirred for 4 hours, then concentrated under reduced pressure. Purification by column chromatography (MeOH/EtOAc (EtOAc)

MS (ESI, pos.ion) m / z: 486.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.70 (s, 3H), 3.38 (s, 3H), 6.01 (d, J = 5.6 Hz, 1H), 6.42 (s, 2H), 7.43 (d, J = 7.2 Hz, 2H), 7.50-7.55 (m, 2H), 7.60 (t, J = 7.4 Hz, 2H) ), 7.75 (d, J = 5.6 Hz, 1H), 8.48-8.53 (m, 1H), 11.19 (s, 1H).

Example 12 N- (4-((2-Aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 4-(4-Amino-3-chlorophenoxy)pyridinium

4-Amino-2-chlorophenol hydrochloride (446 mg, 2.4 mmol) was dissolved in dimethyl hydrazine (4 mL) then NaH (280 mg, 7.0 mmol, 60% disperse in mineral oil). After the reaction mixture was stirred at room temperature for 30 minutes, 4-chloropyridylcarbamide (345 mg, 2.2 mmol) was added. The reaction solution was placed under microwave at 160 ° C for 2 hours, cooled to room temperature and diluted with water (20 mL). The mixture was extracted with EtOAc (EtOAc)EtOAc. The residue was purified by EtOAc EtOAc EtOAc (EtOAc)

MS (ESI, pos.ion) m / z: 264.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 5.45 (s, 2H), 6.89 (d, J = 8.7 Hz, 1H), 6.92 (m, 1H), 7.11 (m, 1H), 7.16 (d, J = 2.6 Hz, 1H), 7.34 (d, J = 2.6 Hz, 1H), 7.68 (s, 1H), 8.10 (s, 1H), 8.47 (d, J = 5.6 Hz, 1H).

Step 2) 4-(3-Chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide) Phenoxy)pyridinium

4-(4-Amino-3-chlorophenoxy)pyridiniumamine (191 mg, 0.72 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro- 1H -pyrazole-4-carboxylic acid (168 mg, 0.72 mmol) was suspended in dichloromethane (10 mL) then EDCI (166 mg, <RTIgt; After the reaction mixture was stirred at 46 ° C for 6 hours, 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxylic acid (32 mg, 0.14) was added. Methyl) and EDCI (27 mg, 0.14 mmol). The reaction mixture was stirred at 46 ° C for further 13 hours, cooled to room temperature and diluted with water (10 mL). The mixture was extracted with EtOAc (EtOAc)EtOAc. The residue was purified by EtOAc EtOAc EtOAc (EtOAc:

MS (ESI, pos.ion) m / z: 478.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.71 (s, 3H), 3.37 (s, 3H), 7.19 (m, 1H), 7.23 (m, 1H), 7.43 (m, 3H), 7.50 (m, 2H), 7.60 (m, 2H), 7.72 (s, 1H), 8.13 (s, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.63 (d, J = 9.1 Hz, 1H), 11.19 (s, 1H).

Step 3) N- (4-((2-Aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

4-(3-Chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)benzene Oxy)pyridiniumamine (160 mg, 0.33 mmol) was dissolved in a mixed solution of ethyl acetate (3 mL), acetonitrile (2.5 mL) and water (1.3 mL), then iodobenzene diacetate (130 mg, 0.40) at 0 ° C Mm). After the reaction mixture was stirred at 0 ° C for 30 minutes, it was allowed to warm to room temperature and stirring was continued for 3 hours. The reaction mixture was concentrated with EtOAc EtOAc m.

MS (ESI, pos.ion) m / z: 450.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.71 (s, 3H), 3.43 (s, 3H), 5.83 (d, J = 2.1 Hz, 1H), 5.95 (s, 2H), 6.16 (m, 1H), 7.14 (m, 1H), 7.45 (d, J = 7.3 Hz, 2H), 7.52 (t, J = 7.3 Hz, 1H), 7.60 (t, J = 7.3 Hz, 2H), 7.80 (d, J = 5.8 Hz, 2H), 8.56 (d, J = 9.1 Hz, 1H), 11.12 (s, 1H).

Example 13 N -(4-((2-Ethylaminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3 -Dihydro-1 H -pyrazole-4-carboxamide (125 mg, 0.28 mmol) was suspended in acetic anhydride (6.0 mL), then triethylamine (0.4 mL) was added to the reaction mixture, and the reaction was stirred at 35 ° C. After </ RTI></RTI><RTIgt;</RTI><RTIgt;</RTI><RTIgt;</RTI><RTIgt;</RTI><RTIgt;

MS (ESI, pos.ion) m / z: 492.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.04 (s, 3H), 2.72 (s, 3H), 3.37 (s, 3H), 6.68 (m, 1H), 7.18 (m, 1H), 7.44 (m, 3H), 7.52 (t, J = 7.4 Hz, 1H) 7.60 (t, J = 7.5 Hz, 2H) , 7.67 (d, J = 2.0 Hz, 1H), 8.18 (d, J = 5.7 Hz, 1H), 8.60 (d, J = 9.1 Hz, 1H), 10.55 (s, 1H), 11.16 (s, 1H) .

Example 14 N -(4-(3-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-methyl) Amidino)phenoxy)pyridin-2-yl)morpholine-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3 -Dihydro-1 H -pyrazole-4-carboxamide (125 mg, 0.28 mmol) and Et ₃ N (0.12 mL, 0.84 mmol) were suspended in THF (4.0 mL), and then benzene chloroformate was added to the reaction mixture. ester (0.10 mL, 0.84 mmol), after stirring 22 hours at room temperature, was added an aqueous solution of NH ₄ Cl (20mL) and DCM (20mL), separated, the aqueous phase was extracted with DCM (20mL x 3), the combined organic phases dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure, purified by silica gel column chromatography (EtOAc / PE (v / v ) = 20/1) the residue with methanol (4mL) wash to afford the title compound as a beige Solid (60 mg, 38%).

MS (ESI, pos.ion) m / z: 563.2 [M + H] +; 1 H NMR (400MHz, CDCl 3): δ (ppm) 2.80 (s, 3H), 3.35 (s, 3H), 3.50 ( t, J = 4.8 Hz, 4H), 3.73 (t, J = 4.8 Hz, 4H), 6.50 (m, 1H), 7.02 (m, 1H), 7.14 (d, J = 2.7 Hz, 1H), 7.29 ( s, 1H), 7.39 (d, J = 7.2 Hz, 2H), 7.46 (m, 1H), 7.55 (m, 2H), 7.65 (s, 1H), 8.02 (d, J = 5.9 Hz, 1H), 8.60 (d, J = 9.0 Hz, 1H), 11.03 (s, 1H).

Example 15 N- (4-((2-Aminopyridin-4-yl)oxy)-2-indolephenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3 -Dihydro-1 H -pyrazole-4-carboxamide (200 mg, 0.44 mmol) and triethylamine (0.10 mL, 0.66 mmol) were suspended in methanol (8.0 mL), then Pd/C was added to the reaction mixture. (40 mg, 20%), the mixture was stirred for 12 hours at 62 ° C under a helium atmosphere, cooled to room temperature, filtered with suction, and the filtrate was concentrated under reduced pressure. After purification by EtOAc (EtOAc/EtOAc)

MS (ESI, pos.ion) m / z: 417.3 [M + H] +; 1 H NMR (400MHz, CDCl 3): δ (ppm) 2.80 (s, 3H), 3.36 (s, 3H), 4.75 ( s, 2H), 5.93 (d, J = 1.8 Hz, 1H), 6.31 (m, 1H), 7.04 (d, J = 8.8 Hz, 2H), 7.37 (d, J = 7.4 Hz, 2H), 7.47 ( m, 1H), 7.56 (m, 2H), 7.68 (d, J = 8.8 Hz, 2H), 10.73 (s, 1H).

Example 16 N -(5-((2-Aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3 -dihydro-1 H -pyrazole-4-carboxamide

Step 1) 4-((6-Aminopyridin-3-yl)oxy)pyridinium

6-Aminopyridin-3-ol (220 mg, 2 mmol) and t- BuOK (225 mg, 2.16 mmol) were dissolved in dimethylformamide (2.5 mL) then 4-chloropyridinecarbamide (315 mg, 2 mmol) ). The reaction mixture was heated at 80 ° C for 5 hr, then cooled to room temperature and diluted with ethyl acetate (50mL) and water (50mL). The organic phase was concentrated in vacuo, the resulting residue was purified by silica gel column to give the title compound chromatography _{(DCM / CH 3 OH (v} / v) = 30/1) as a brown solid (230mg, 50%).

MS (ESI, pos. ion) m/z: 231.1 [M+H] ⁺ ; ¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 6.09 (s, 2H), 6.53-6.56 (d, J = 8.88) Hz, 1H), 7.12-7.14 (dd, J = 2.64 Hz, 5.6 Hz, 1H), 7.31-7.34 (dd, J = 2.92 Hz, 8.88 Hz, 1H), 7.35-7.36 (d, J = 2.48 Hz, 1H), 7.70 (s, 1H), 7.83-7.84 (d, J = 2.8 Hz, 1H), 8.11 (s, 1H), 8.46-8.49 (d, J = 5.6 Hz, 1H).

Step 2) 4-((6-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)pyridine- 3-yl)oxy)pyridinium

4-((6-Aminopyridin-3-yl)oxy)pyridiniumamine (230 mg, 1 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro -1 H - pyrazole-4-carboxylic acid (237mg, 1.02mmol) was suspended in dichloromethane (5mL), followed by addition of EDCI (230mg, 1.2mmol) and HOAT (27mg, 0.2mmol). The reaction mixture was stirred at 45 ° C for 28 hours, cooled to room temperature and diluted with water (10 mL) and dichloromethane (20 mL). The organic phase was concentrated in vacuo, the resulting residue was purified by silica gel column chromatography the title compound _{(DCM / CH 3 OH (v} / v) = 40/1) by a light gray solid (111mg, 25%).

MS (ESI, pos.ion) m / z: 445.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.72 (s, 3H), 3.33 (s, 3H), 7.20-7.22 (dd, J = 2.64 Hz, 5.64 Hz, 1H), 7.43-7.46 (m, 3H), 7.52-7.54 (m, 1H), 7.58-7.62 (m, 2H), 7.72 (s, 3H) , 7.75-7.78 (dd, J = 2.88 Hz, 8.96 Hz, 1H), 8.13 (s, 1H), 8.27-8.28 (d, J = 2.68 Hz, 1H), 8.34 - 8.36 (d, J = 9.08 Hz, 1H), 8.52 - 8.54 (d, J = 5.6 Hz, 1H).

Step 3) N- (5-((2-Aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3 -dihydro-1 H -pyrazole-4-carboxamide

4-((6-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)pyridine-3- Alkyloxy)pyridiniumamine (111 mg, 0.25 mmol) was dissolved in a mixed solution of ethyl acetate (2 mL), acetonitrile (2 mL) and water (1 mL), and then iodobenzene diacetate (97 mg, 0.3 mmol). After the reaction mixture was stirred at 0 ° C for 30 minutes, it was allowed to warm to room temperature and stirring was continued for 12 hours. The reaction mixture was concentrated in vacuo, the resulting residue was purified by silica gel column to give the title compound chromatography _{(DCM / CH 3 OH (v} / v) = 40/1) was purified as a pale beige solid (85mg, 81.7%).

MS (ESI, pos.ion) m / z: 417.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.71 (s, 3H), 3.38 (s, 3H), 5.83 (s, 1H), 5.98 (s, 2H), 6.17 (s, 1H), 7.08-7.10 (m, 2H), 7.42-7.81 (m, 6H), 7.80-7.81 (d, J = 5.8 Hz, 1H), 8.17 (s, 1H), 8.29-8.31 (d, J = 8.56 Hz, 1H), 11.19 (s, 1H).

Example 17 N- (5-((2-Ethylaminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo -2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound N- (5-((2-aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3- Dihydro-1 H -pyrazole-4-carboxamide (300 mg, 0.72 mmol) was dissolved in acetic anhydride (4 mL), then Et ₃ N (400 mg, 4 mmol) was added to the reaction mixture, and the reaction was stirred at 30 ° C for 12 hours. after concentrated under reduced pressure, the residue was purified by silica gel to give the title compound by chromatography _{(DCM / CH 3 OH (v} / v) = 40/1) as a pale yellow solid (197mg, 60.1%).

MS (ESI, pos.ion) m / z: 459.0 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 11.23 (s, 1H), 10.57 (s, 1H), 8.34-8.31 (d, J = 9.1 Hz, 1H), 8.22-8.21 (d, J = 2.8 Hz, 1H), 8.20-8.19 (d, J = 5.7 Hz, 1H), 7.72-7.69 (dd, J = 9.0 Hz, 2.8 Hz, 1H), 7.67-7.67 (d, J = 1.6 Hz, 1H), 7.62-7.59 (m, 2H), 7.54-7.51 (m, 1H), 7.46 (s, 1H), 7.44 ( s, 1H), 3.37 (s, 3H), 2.72 (s, 3H), 2.05 (s, 3H).

Example 18 N -(4-((6-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) Pyridin-3-yl)oxy)pyridin-2-yl)morpholine-4-carboxamide

The compound N- (5-((2-aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3- Dihydro-1 H -pyrazole-4-carboxamide (171 mg, 0.41 mmol) and Et ₃ N (0.17 mL, 1.23 mmol) were suspended in THF (8.0 mL), then phenyl chloroformate was added to the reaction mixture. (0.15mL, 1.23mmol), was stirred at room temperature for 2 hours, morpholine (0.21 mL, 2.46 mmol), stirred for 24 hours at room temperature, was added aqueous NH ₄ Cl (40 mL) and DCM (40mL), liquid separation the aqueous phase was extracted with DCM (40mL x 3) and dried. the combined organic phases were dried over anhydrous Na ₂ SO _4, then concentrated under reduced pressure, the resulting residue was purified by silica gel column chromatography (MeOH / EtOAc (v / v ) = 1 / 50) After purification, EtOAc EtOAc (EtOAc)

MS (ESI, pos.) m/z: 530.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 2.79 (s, 3H), 3.36 (s, 3H), 3.50 ( t, J = 4.8 Hz, 4H), 3.72 (t, J = 4.8 Hz, 4H), 6.49-6.51 (m, 1H), 7.36-7.38 (m, 3H), 7.42-7.46 (m, 2H), 7.52 -7.56 (m, 2H), 7.66 (s, 1H), 8.03 (d, J = 5.6 Hz, 1H), 8.14 (d, J = 2.7 Hz, 1H), 8.34 (d, J = 9.0 Hz, 1H) , 11.19 (s, 1H).

Example 19 N -(5-((2-Amino-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) N- (5-Hydroxypyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-methyl Guanamine

6-Aminopyridin-3-ol (330 mg, 3 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxylic acid (710 mg, 306 mmol) was suspended in dimethylformamide (10 mL), then EDCI (690 mg, 3.6 mmol) and HOAT (80 mg, 0.6 mmol). The reaction was stirred at 60 &lt;0&gt;C for 4 h, cooled to rt and diluted with water &lt The reaction mixture was cooled to 0 ° C and stirred overnight. The title compound was obtained as a light brown solid (yield: 680mg, 70%).

MS (ESI, pos.ion) m / z: 325.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.50 (s, 3H), 3.33 (s, 3H), 7.18-7.20 (dd, J = 2.3 Hz, 8.8 Hz, 1H), 7.40-7.42 (d, J = 7.5 Hz, 2H), 7.48-7.52 (m, 1H), 7.56-7.60 (m, 2H), 7.81 - 7.82 (d, J = 2.2 Hz, 1H), 7.95 (s, 1H), 8.04-8.06 (d, J = 8.8 Hz, 1H), 9.61 (s, 1H), 10.85 (s, 1H).

Step 2) 3-Chloro-4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide) Pyridin-3-yl)oxy)pyridinium

6-Aminopyridin-3-ol (324 mg, 1 mmol) and t- BuOK (135 mg, 1.2 mmol) were dissolved in dimethylformamide (2 mL) then 3,4-dichloro-2-pyridinecarboxamide Amine (191 mg, 1 mmol). The reaction mixture was heated at 80 ° C for 15 hr, then cooled to room temperature and diluted with ethyl acetate (1mL) and water (20mL). The reaction mixture was stirred with EtOAc EtOAc m.

MS (ESI, pos.ion) m / z: 479.2 [M + H] +; 1 H NMR (400MHz, CDCl 3): δ (ppm) 2.72 (s, 3H), 3.35 (s, 3H), 6.91- 6.92 (d, J = 5.5 Hz, 1H), 6.09 (s, 2H), 7.43-7.45 (m, 2H), 7.50-7.54 (m, 1H), 7.58-7.62 (m, 2H), 7.73-7.76 ( m, 2H), 8.03 (s, 1H), 8.26-8.27 (d, J = 2.7 Hz, 1H), 8.33 - 8.36 (m, 2H), 11.26 (s, 1H).

Step 3) N- (5-((2-Amino-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-dihydro-1 H -pyrazole-4-carboxamide

3-Chloro-4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) Pyridin-3-yl)oxy)pyridiniumamine (290 mg, 0.6 mmol) was dissolved in a mixed solution of ethyl acetate (4 mL), acetonitrile (4 mL) and water (2 mL), and then, iodobenzene diacetate (234 mg, 0.72) Mm). After the reaction mixture was stirred at 0 ° C for 30 minutes, it was allowed to warm to room temperature and stirring was continued for 12 hours. The reaction mixture was filtered through EtOAc (EtOAc)EtOAc. The filtrate was washed with water (20 mL) and evaporated. The residue was purified by silica gel column to give the title compound chromatography _{(DCM / CH 3 OH (v} / v) = 50/1) as a pale beige solid (120mg, 44.7%).

MS (ESI, pos.ion) m / z: 451.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.71 (s, 3H), 3.36 (s, 3H), 5.99-6.01 (d, J = 5.6 Hz, 1H), 6.42 (s, 2H), 7.42-7.44 (m, 2H), 7.51-7.53 (m, 1H), 7.57-7.61 (m, 2H), 7.63 7.66 (dd, J = 2.9 Hz, 9.0 Hz, 1H), 7.76-7.77 (d, J = 5.6 Hz, 1H), 8.18-8.19 (d, J = 2.8 Hz, 1H), 8.28-8.30 (d, J = 9.1 Hz, 1H), 11.21 (s, 1H).

Example 20 N -(5-((2-Ethylamino-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2- Phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

N- (5-((2-Amino-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2 , 3-dihydro-1 H -pyrazole-4-carboxamide (60 mg, 0.13 mmol) and triethylamine (26.3 mg, 0.26 mmol) were dissolved in methanol (1 mL) and tetrahydrofuran (2 mL). Then acetonitrile (20.3 mg, 0.26 mmol) was added. The reaction mixture was stirred at room temperature for 3 hr then concentrated in vacuo. The residue was treated with sodium carbonate solution, stirred at room temperature for 5 min and concentrated in vacuo. The resulting residue was purified by silica gel column to give the title compound chromatography _{(DCM / CH 3 OH (v} / v) = 50/1) as a pale beige solid (15mg, 22.7%).

MS (ESI, pos.ion) m / z: 493.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): (ppm) δ 2.08 (s, 3H), 2.71 (s, 3H), 3.35 (s, 3H), 6.72-6.74 (d, J = 5.6 Hz, 1H), 7.43-7.45 (m, 2H), 7.50-7.54 (m, 1H), 7.58-7.62 (m, 2H), 7.63 7.66 (dd, J = 2.9 Hz, 9.0 Hz, 1H), 8.19-8.20 (d, J = 5.6 Hz, 1H), 8.26-8.27 (d, J = 2.8 Hz, 1H), 8.33 - 8.35 (d, J = 9.1 Hz, 1H), 10.24 (s, 1H), 11.25 (s, 1H).

Example 21 N- (4-((2-Ethylamino-3-chloropyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-dihydro-1 H -pyrazole-4-carboxamide

3-Chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)benzene Oxy)pyridiniumamine (124 mg, 0.28 mmol) was dissolved in acetic anhydride (8.0 mL) then triethylamine (0.4 mL). After the reaction mixture was stirred at 40 ° C for 26 hours, the reaction mixture was washed with a saturated solution of sodium carbonate (60 mL x 3), and then extracted with dichloromethane (60 mL x 3). The combined organic layers were dried with anhydrous sodium The residue was purified by EtOAc EtOAc EtOAc (EtOAc)

MS (ESI, pos.ion) m / z: 492.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.07 (s, 3H), 2.70 (s, 3H), 3.37 (s, 3H), 6.64 (d, J = 5.6 Hz, 1H), 7.20 (d, J = 9.0 Hz, 2H), 7.44 (d, J = 7.2 Hz, 2H), 7.51 (m, 1H), 7.59 (m, 2H), 7.72 (d, J = 9.0 Hz, 2H), 8.18 (d, J = 5.6 Hz, 1H), 10.21 (s, 1H), 10.83 (s, 1H).

Example 22 N- (4-((2-Aminopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) N- (3-Fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4- Formamide

4-Amino-2-fluorophenol (2.54 g, 20 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxylate The acid (4.74 g, 20.4 mmol) was suspended in DCM (60 mL) and EDCI (4.6 g, 24 mmol) and HOAT (0.54 g, 4mmol). The reaction was stirred at 45 &lt;0&gt;C for 12 h then cooled to EtOAc EtOAc >EtOAc. The mixture was stirred for 4 hours, filtered, and EtOAc was evaporated.jjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj

MS (ESI, pos.ion) m / z: 342.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 10.59 (s, 1H), 9.58 (s, 1H), 7.64 (dd, J = 2.4 Hz, 13.5 Hz, 1H), 7.60 (m, 2H), 7.50 (m, 1H), 7.42 (m, 2H), 6.97 (m, 1H), 6.88 (dd, J = 9.6) Hz, 8.8 Hz, 1H), 3.34 (s, 3H), 2.70 (s, 3H).

Step 2) 4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-2- Fluorophenoxy)pyridinium

N- (3-Fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamidine The amine (2.2 g, 6.4 mmol) and 4-chloropyridinecarbamide (1 g, 6.39 mmol) were dissolved in DMSO (12 mL), and NaH (615 mg, 12.3 mmol, 50% dispersion in mineral oil) was added. The reaction mixture was stirred at 160 ° C for 20 hr then cooled to EtOAc. The mixture (100mL x 3) and extracted with EtOAc, and the combined organic phase was washed with brine (100 mL) wash, dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure. The residue was purified with EtOAc EtOAc EtOAc (EtOAc:

MS (ESI, pos. ion) m/z: 4621. [M+H] ⁺ ; ¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 10.87 (s, 1H), 8.40-8.41 (d, J = 5.6 Hz, 1H), 7.88-7.92 (dd, J = 2.4 Hz, 12.6 Hz, 1H), 7.82-7.83 (d, J = 3.9 Hz, 1H), 7.71-7.71 (d, J = 2.5 Hz, 1H), 7.54-7.58 (m, 2H), 7.46-7.49 (m, 1H), 7.35-7.37 (d, J = 8.6 Hz, 2H), 7.07-7.11 (m, 1H), 6.96-6.98 (dd, J = 2.5 Hz, 5.6 Hz, 1H), 5.56 (s, 1H), 3.37 (s, 3H), 2.79 (s, 3H).

Step 3) N- (4-((2-Aminopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-2-fluorobenzene oxy) pyridin-acyl amine (0.4g, 0.86mmol) and _{PhI (OAc) 2 (419mg,} 1.5mmol) was dissolved in EtOAc (8mL) MeCN (8mL) and H ₂ O (4mL) the mixture was cooled to Stir at 0 ° C for 30 minutes. The reaction solution was returned to room temperature and stirring was continued for 8 hours. The mixture was diluted with aqueous NaHCO ₃ (60mL), and extracted with EtOAc (100mL x 3). The combined organic phase was washed with brine (100 mL) wash, dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure, the resulting residue (10/1 DCM / MeOH ( v / v) =) was purified by silica gel column chromatography to give the title The compound was a white solid (0.21 g, 56%).

MS (ESI, pos.) m/z: 434.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 10.83 (s, 1H), 7.91 - 7.92 (d, J = 5.9 Hz, 1H), 7.83-7.86 (dd, J = 2.4 Hz, 10.1 Hz, 1H), 7.56-7.58 (m, 2H), 7.46-7.52 (d, J = 5.9 Hz, 2H), 7.35-7.37 (d , J = 8.6 Hz, 2H), 7.04-7.09 (m, 1H), 6.29-6.31 (m, 1H), 5.92-5.93 (d, J = 2.1 Hz, 1H), 4.45 (s, 2H), 3.37 ( s, 3H), 2.79 (s, 3H).

Example 23 N -(4-((2-Ethylaminopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-dihydro-1 H -pyrazole-4-carboxamide

N- (4-((2-Aminopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3- Dihydro-1 H -pyrazole-4-carboxamide (90 mg, 0.21 mmol) was dissolved in acetic acid (6 mL), and Et ₃ N (0.3 mL) was added. The reaction solution was stirred at room temperature for 8 hr and then evaporated. The residue was purified with EtOAc EtOAcjjjjjjj

MS (ESI, pos.ion) m / z: 476.1 [M + H] +; 1 H NMR (400MHz, CDCl 3): δ (ppm) 10.83 (s, 1H), 8.15 (s, 1H), 8.05- 8.07 (d, J = 5.8 Hz, 1H), 7.84 - 7.89 (m, 2H), 7.54 - 7.58 (m, 2H), 7.47 - 7.49 (d, J = 7.3 Hz, 1H), 7.35-7.37 (d, J = 7.4 Hz, 2H), 7.25 (s, 1H), 7.06-7.11 (m, 1H), 6.53 - 6.54 (dd, J = 2.2 Hz, 5.7 Hz, 1H), 3.36 (s, 3H), 2.79 ( s, 3H), 2.16 (s, 3H).

Example 24 N -(4-((2-Aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-oxo-2-benzene Base-2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 1-Chloro-4,5-difluoro-2-nitrobenzene

4-Chloro-1,2-difluorobenzene (8.97 g, 60.4 mmol) was added to the reaction flask, cooled to 0 ° C, then 98% concentrated H ₂ SO ₄ (16.1 mL, 302 mmol) and then 65%. after concentrated HNO ₃ (5.0mL, 66.4mmol), stirred at room temperature for 5 hours, poured into ice water, and the mixture was extracted with EtOAc (200mL x 2), the combined organic phases are washed with saturated aqueous NaHCO ₃ ( 200mL x 2) and brine (200mL) washed, dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure to give the title compound as a yellow liquid (11.31g, 96.7%).

¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 7.41 - 7.45 (m, 1H), 7.86 - 7.90 (m, 1H).

Step 2) Potassium 5-chloro-2-fluoro-4-nitrophenolate

A mixture of the compound 1-chloro-4,5-difluoro-2-nitrobenzene (5.12 g, 26.5 mmol) and 15% KOH (19.9 g, 0.35 mol) was stirred and refluxed for 3 hr then cooled to room temperature. The title compound was obtained as a yellow solid (5.67 g, 93.3%).

¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 6.20 (d, J = 13.2 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H).

Step 3) 4-Amino-5-chloro-2-fluorophenol

The compound 5-chloro-2-fluoro-4-nitrophenol potassium (1.0 g, 4.35 mmol) was dissolved in a mixed solvent of EtOH (22 mL, 95%) and H ₂ O (8 mL), and then added to the reaction mixture. Iron powder (0.97 g, 17.4 mmol) and NH ₄ Cl (1.86 g, 34.8 mmol), the mixture was stirred at room temperature for 10 hours, then the mixture was diluted with methanol (25 mL) and ethyl acetate (25 mL) and filtered. concentrated under reduced pressure, diluted with ethyl acetate (40 mL) The residue was washed with brine (25 mL), dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure to give the title compound as an off-white solid (0.6g, 85.3%).

^{1 H NMR (400MHz, DMSO- d} 6): δ (ppm) 4.90 (s, 2H), 6.60 (d, J = 12.9Hz, 1H), 6.79 (d, J = 8.8Hz, 1H), 9.11 (s , 1H).

Step 4) N- (2-chloro-5-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyridyl Oxazol-4-carboxamide

The compound 4-amino-5-chloro-2-fluorophenol (0.97 g, 6 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyridyl The azole-4-carboxylic acid (1.42 g, 6.12 mmol) was suspended in DMF (20 mL), then EDCI (0.38 mg, 7.2 mmol) and HOAT (0.16 g, 1.2 mmol). after the reaction stirred for 24 hours, cooled to 0 deg.] C, then the mixture was diluted with H ₂ O (200mL) and EtOAc (2mL), filtered off with suction, and dried in vacuo to give the title compound as a light brown solid (1.2g, 53.2%).

MS (ESI, pos.ion) m / z: 376.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 2.68 (s, 3H), 3.34 (s, 3H), 7.03 (d, J = 8.8 Hz, 1H), 7.41-7.43 (m, 2H), 7.48-7.52 (m, 1H), 7.56-7.60 (m, 2H), 8.31 (d, J = 13.8 Hz, 1H) , 10.08 (s, 1H), 10.95 (s, 1H).

Step 5) 4-(5-Chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide) )-2-fluorophenoxy)pyridinium

The compound N -(2-chloro-5-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole 4-Methylguanamine (751.6 mg, 2 mmol) and t- BuOK (224.4 mg, 2 mmol) were suspended in DMF (4 mL), then heated to 4-chloropyridylcarbamide (313.2 mg, 2 mmol). to 120 deg.] C and the reaction was stirred for 15 hours and then cooled to room temperature, H ₂ O (40mL), the resulting mixture was stirred overnight at room temperature, filtered off with suction, the filter cake by silica gel column chromatography _{(DCM / CH 3 OH (v} / The title compound was obtained as a pale yellow solid (290 mg, 60.5%).

MS (ESI, pos.) m/z: 496.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 11.37 (s, 1H), 8.69-8.66 (d, J =13.4 Hz, 1H), 8.55-8.54 (d, J = 5.6 Hz, 1H), 8.15 (s, 1H), 7.78-7.75 (m, 2H), 7.62-7.58 (m, 2H), 7.55-7.51 ( m, 1H), 7.46-7.43 (m, 3H), 7.26-7.24 (dd, J = 5.6 Hz, 2.6 Hz, 1H), 3.38 (s, 3H), 2.72 (s, 3H).

Step 6) N- (4-((2-Aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-oxo-2-benzene Base-2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound 4-(5-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) 2-fluorophenoxy) pyridin-acyl amine (297.6mg, 0.6mmol) was suspended in _{EtOAc (4mL), CH 3 CN} (4mL) and H ₂ O (2mL) in a mixed solvent, was cooled to 0 deg.] C, was added PhI (OAc) ₂ (97 mg, 0.3 mmol), the mixture was stirred at 0 ° C for a half hour, then warmed to room temperature and stirred for 12 hr then concentrated under reduced pressure and the residue was purified by chromatography (DCM/CH ₃ OH Purification of (v/v) = 20/1) gave the title compound as a pale brown solid (220 mg, 78.3%).

MS (ESI, pos.) m/z: 468.0 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 11.32 (s, 1H), 8.63 - 8.60 (d, J =13.4 Hz, 1H), 7.82-7.81 (d, J = 5.9 Hz, 1H), 7.64-7.62 (m, 3H), 7.55-7.54 (m, 1H), 7.46-7.44 (m, 2H), 6.22 6.20 (dd, J = 5.8 Hz, 2.2 Hz, 1H), 6.05 (s, 2H), 5.85-5.84 (d, J = 2.0 Hz, 1H), 3.33 (s, 3H), 2.71 (s, 3H).

Example 25 N -(4-((2-Ethylaminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-oxo-2 -phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-Dihydro-1 H -pyrazole-4-carboxamide (200 mg, 0.43 mmol) was dissolved in acetic anhydride (4 mL), and then Et ₃ N (400 mg, 2.6 mmol) was added to the reaction mixture. after stirring the reaction at 30 ℃ 12 hours and concentrated under reduced pressure, the resulting residue was purified by silica gel column chromatography _{(DCM / CH 3 OH (v} / v) = 40/1) to give the title compound as a pale yellow solid (110mg, 50.5 %).

MS (ESI, pos.ion) m / z: 510.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 12.15 (s, 1H), 11.38 (s, 1H), 9.45-9.42 (d, J = 13.4 Hz, 1H), 9.00-8.98 (d, J = 5.7 Hz, 1H), 8.50-8.48 (m, 2H), 8.42 - 8.38 (m, 2H), 8.34 - 8.31 ( m,1H), 8.26-8.24 (m, 2H), 7.52-7.50 (dd, J = 5.7 Hz, 1.3 Hz, 1H), 4.14 (s, 3H), 3.51 (s, 3H), 2.84 (s, 3H) ).

Example 26 N- (4-(5-Chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-methyl) Amidino)-2-fluorophenoxy)pyridin-2-yl)morpholine-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl -2,3-Dihydro-1 H -pyrazole-4-carboxamide (234 mg, 0.5 mmol) and Et ₃ N (0.1 mg, 1 mmol) were suspended in THF (5 mL), then chloroformic acid was added to the reaction mixture. The phenyl ester (0.16 mg, 1 mmol) was stirred at room temperature for 2 hours, then morpholine (0.44 mL, 5 mmol) was added, and the mixture was stirred at room temperature for 24 hours, then added NH ₄ Cl (30 mL) and DCM (30 mL) solution, the organic phase was washed with DCM (30mL x 3). the combined organic phases were dried over anhydrous Na ₂ SO _4, then concentrated under reduced pressure, the resulting residue was purified by silica gel column chromatography _{(DCM / CH 3 OH (v} / v) The title compound was obtained as a white solid (145 mg, 49.9%).

MS (ESI, pos.ion) m / z: 581.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 11.35 (s, 1H), 9.30 (s, 1H), 8.65-8.61 (d, J = 13.4 Hz, 1H), 8.14 - 8.13 (d, J = 5.7 Hz, 1H), 7.69-7.67 (d, J = 8.1 Hz, 1H), 7.62 - 7.58 (m, 2H) , 7.54 - 7.51 (m, 1H), 7.45 - 7.40 (m, 3H), 6.65 - 6.63 (dd, J = 5.7 Hz, 2.2 Hz, 1H), 3.55 - 3.53 (m, 4H), 3.43 - 3.36 (m , 7H), 2.71 (s, 3H).

Example 27 N- (4-((2-Aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) N- (3-Chloro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4- Formamide

The compound 4-amino-2-chlorophenol (4.0 g, 28.00 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4 The carboxylic acid (7.4 g, 30.11 mmol) was suspended in DCM (70 mL), then EDCI (6.65 g, 30.11 mmol) and HOAT (0.76 g, 5.68 mmol) were added to the reaction mixture, heated to 45 ° C and stirred for reaction 20 </ RTI></RTI></RTI><RTIgt;</RTI><RTIgt;</RTI></RTI></RTI></RTI></RTI></RTI></RTI><RTIgt;

MS (ESI, pos.ion) m / z: 358.1 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 10.56 (s, 1H), 9.92 (s, 1H), 7.59 (m, 2H), 7.50 (m, 1H), 7.42 (m, 2H), 7.83 (dd, J = 2.6 Hz, 8.7 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H), 6.88 ( Dd, J = 9.6 Hz, 8.8 Hz, 1H), 3.33 (s, 3H), 2.68 (s, 3H).

Step 2) 4-(2-Chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido) Phenoxy)pyridinium

The compound N -(3-chloro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-methyl The decylamine (1.074 g, 3.0 mmol) was suspended in DMF (12 mL), and then t- BuOK (539 mg, 4.8 mmol) was added to the reaction mixture, and stirred at room temperature for 30 minutes, then 4-chloropyridinamide (517 mg, 3.3 mmol), warmed to 120 ° C and stirred for 36 hours, then cooled to room temperature, quenched with water (50 mL), and the mixture was extracted with EtOAc (50 mL×3) ), dried over anhydrous sulfate SO ₄ Na _2, and then concentrated under reduced pressure, the resulting residue was purified by silica gel column chromatography (EtOAc / PE (v / v ) = 3/1) to give the title compound as a white solid (580mg, 40.4 %).

MS (ESI, pos.) m/z: 478.0 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 10.95 (s, 1H), 8.53 (d, J = 5.6 Hz, 1H), 8.16 (d, J = 2.4 Hz, 1H), 8.13 (br s, 1H), 7.72 (br s, 1H), 7.60 (m, 2H), 7.51 (m, 2H), 7.44 (d) , J = 7.3 Hz, 2H), 7.38 (d, J = 8.8 Hz, 1H), 7.32 (d, J = 2.6 Hz, 1H), 7.17 (dd, J = 2.6 Hz, 5.6 Hz, 1H), 3.16 ( d, J = 5.2 Hz, 3H), 2.70 (s, 3H).

Step 3) N- (4-((2-Aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

The compound 4-(2-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) phenoxy) pyridin-acyl amine (540mg, 1.13mmol) was suspended in _{EtOAc (6mL), CH 3 CN} (6mL) and H ₂ O (3mL) mixed solvent, was cooled to 0 deg.] C, then added to the reaction solution PhI (OAc) ₂ (438 mg, 1.36 mmol), EtOAc / EtOAc (EtOAc) The title compound was obtained as a beige solid (265 mg, 52.2%).

MS (ESI, pos. ion) m/z: 450.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, DMSO- d ₆ ): δ (ppm) 10.89 (s, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.79 (d, J = 5.8 Hz, 1H), 7.59 (m, 2H), 7.52 (m, 1H), 7.43 (d, J = 5.7 Hz, 3H), 7.25 (d, J = 8.8 Hz, 1H), 6.13 (dd, J = 2.3 Hz, 5.8 Hz, 1H), 5.93 (s, 2H), 5.72 (d, J = 2.2 Hz, 1H), 3.36 (s, 3H), 2.70 (s, 3H).

Example 28 N -(4-((2-Ethylaminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl- 2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3 - dihydro - -1 H - pyrazole-4-acyl-amine (120mg, 0.27mmol) was dissolved in acetic anhydride (5mL), followed by addition of Et ₃ N (0.4mL, 1.12mmol) to the reaction mixture, stirred at room temperature after 8 hours of reaction, concentrated under reduced pressure, the resulting residue was purified by silica gel column to give the title compound chromatography _{(DCM / CH 3 OH (v} / v) = 40/1) as a white solid (65mg, 49%).

MS (ESI, pos.ion) m / z: 492.0 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 10.92 (s, 1H), 10.53 (s, 1H), 8.16-8.17 (d, J = 5.7 Hz, 1H), 8.12 - 8.13 (d, J = 2.4 Hz, 1H), 7.49 - 7.61 (m, 4H), 7.42 - 7.47 (m, 3H), 7.29 - 7.32 ( d, J = 8.7 Hz, 1H), 6.60-6.62 (dd, J = 2.4 Hz, 5.7 Hz, 1H), 3.36 (s, 3H), 2.70 (s, 3H), 2.03 (s, 3H).

Example 29 N -(4-(2-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-methyl) Amidino)phenoxy)pyridin-2-yl)morpholine-4-carboxamide

The compound N -(4-((2-aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3 - dihydro - -1 H - pyrazole-4-acyl-amine (135mg, 0.3mmol) was suspended in THF (3mL), and then added to the reaction mixture before _{Et 3 N (0.080mL, 0.6mmol)} , followed by Phenyl chloroformate (0.075 mL, 0.6 mmol) was added dropwise, and the mixture was stirred at room temperature for 2 hours, then morpholine (0.250 mL, 3.0 mmol) was added, and the mixture was stirred at room temperature for 22 hours, then saturated aqueous NH ₄ Cl (20 mL) and CH ₂ Cl ₂ (20mL), after stirring for 10 minutes, the mixture was extracted with _{CH 2 Cl 2 (20mL x 3} ), the combined organic phase was washed with brine (20mL x 3) washed, dried over anhydrous Na ₂ SO _4, and then After concentrating under reduced pressure, EtOAc EtOAc m.

MS (ESI, pos.ion) m / z: 563.2 [M + H] +; 1 H NMR (400MHz, DMSO- d 6): δ (ppm) 10.92 (s, 1H), 9.25 (s, 1H), 8.12(s,1H), 8.11 (d, J = 3.9 Hz, 1H), 7.59 (m, 2H), 7.52 (m, 1H), 7.44 (m, 3H), 7.31 (m, 2H), 6.56 (dd , J = 2.3 Hz, 5.7 Hz, 1H), 3.54 (t, J = 4.4 Hz, 5.0 Hz, 4H), 3.37 (br s, 7H), 2.70 (s, 3H).

Example 30 N- (4-((2-Aminopyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 4-Amino-3-fluorophenol

Suspension of compound 3-fluoro-4-nitrophenol (2.0 g, 12.73 mmol), 10% Pd/C (0.4 g), HCOOK (8.75 g, 101.85 mmol) and THF/H ₂ O (70 mL / 20 mL) after stirring the reaction at 50 ℃ 5 hours, cooled to room temperature, the filtrate was washed with water (30mL) diluted with diatomaceous earth filtration, the mixture was extracted with THF (50mL), the organic phase obtained was dried over anhydrous Na ₂ SO _4, then reduced Thickener, (50 mL) was diluted with water to give the residue, the mixture was extracted with DCM (50mL), the organic phase obtained was dried over anhydrous Na ₂ SO _4, then concentrated under reduced pressure to give the title compound as a brown solid (1.17g, 72.3% ).

MS (ESI, pos, ion) m/z: 128.1 [M+H] ⁺ .

Step 2) N- (2-Fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4- Formamide

The compound 4-amino-3-fluorophenol (1.0 g, 7.87 mmol) and 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4 - carboxylic acid (2.19g, 9.44mmol) suspended in CH ₂ Cl ₂ (20mL), followed by addition of EDCI (3.02g, 15.7mmol) to the reaction mixture and HOAT (0.21g, 1.57mmol), was heated to reflux and stirred After reacting for 20 hours, it was cooled to room temperature, water (10 mL) was added, and the obtained mixture was stirred at room temperature overnight, filtered, filtered, washed with water (5 mL), and then chromatographic column chromatography (CH ₂ Purification of ₂ / MeOH (v / v) = 70/1)

MS (ESI, pos, ion) m/z: 3421. [M+H] ⁺ .

Step 3) 4-(4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-3- Fluorophenoxy)pyridinium

To the compound N -(2-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-methyl DMF (2.5 mL) was added to a mixture of decylamine (300 mg, 0.879 mmol) and t- BuOK (118 mg, 1.05 mmol). After stirring at room temperature for 30 min, 4-chloropyridinecarbamide (165 mg, 1.05 mmol) was added. was heated to 120 deg.] C and the reaction was stirred for 5 hours and then cooled to room temperature, H ₂ O (50mL) and EtOAc (2mL), the resulting mixture was stirred overnight at room temperature, filtered off with suction, the filter cake was washed with water (5mL), dried in vacuo The title compound was obtained as a dark brown solid (370 mg, 91.2%).

MS (ESI, pos, ion) m / z: 462.2 [M + H] +, Rt = 3.012min.

Step 4) N- (4-((2-Aminopyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide

The compound 4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido)-3-fluoro phenoxy) pyridin-acyl amine (370mg, 0.746mmol) was dissolved in _{EtOAc (4.5mL), CH 3 CN} (4.5mL) and H ₂ O (2.5mL) mixed solvent, was cooled to 0 ℃, 30 minutes of stirring, After the addition of PhI(OAc) ₂ (288 mg, 0.895 mmol), EtOAc (EtOAc)EtOAc. The residue obtained is purified by silica gel column chromatography (CH ₂ Cl ₂ /MeOH (v/v)=250/9) and then purified by silica gel column chromatography (CH ₂ Cl ₂ / MeOH (v/v) = 50 /1) The title compound was obtained as a white solid (m.

MS (ESI, pos, ion) m/z: 434.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 10.90 (s, 1H), 8.46 (t, J = 8.7 Hz, 1H), 7.91 (d, J = 5.9 Hz, 1H), 7.54 (t, J = 7.6 Hz, 2H), 7.45 (t, J = 7.4 Hz, 1H), 7.36 (d, J = 7.3 Hz, 2H) , 6.86 (d, J = 9.0 Hz, 2H), 6.30 (dd, J = 5.9 Hz, 2.1 Hz, 1H), 5.96 (d, J = 2.0 Hz, 1H), 4.58 (s, 2H), 3.36 (s) , 3H), 2.79 (s, 3H).

Example 31 N -(4-((2-Amino-3-chloropyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimethyl-3-oxo-2-benzene Base-2,3-dihydro-1 H -pyrazole-4-carboxamide

Step 1) 3-Chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamide) )-3-fluorophenoxy)pyridinium

The compound N -(2-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-methyl The mixture of decylamine (300 mg, 0.879 mmol), t- BuOK (118 mg, 1.05 mmol) and DMF (3 mL) was stirred at room temperature for 30 min, then 3,4-dichloro-2-pyridinecarbamide (201 mg, 1.05) mmol), was heated to 120 deg.] C and stirred for 12 hours, followed by addition of EtOAc (1mL) and H ₂ O (20mL), the resulting mixture was stirred overnight at room temperature, suction filtration to give the title compound as a brown solid (379mg, 87.0%) .

MS (ESI, pos, ion) m / z: 496.0 [M + H] +.

Step 2) N- (4-((2-Amino-3-chloropyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimethyl-3-oxo-2-benzene Base-2,3-dihydro-1 H -pyrazole-4-carboxamide

The compound 3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1 H -pyrazole-4-carboxamido) 3-fluorophenoxy) pyridin-acyl amine (379mg, 0.764mmol) was suspended in _{EtOAc (4.5mL), CH 3 CN} (4.5mL) and H ₂ O (2.5mL) mixed solvent, was cooled to 0 deg.] C, after stirring for 30 minutes, was added _{PhI (OAc) 2 (295mg,} 0.917mmol), the reaction was stirred at 0 ℃ for 30 minutes, warmed to room temperature and stirred for 10 hours, filtered off with suction, the filter cake was washed with EtOAc (5mL), the the filtrate was concentrated under reduced pressure to give a residue _{(CH 2 Cl 2 / MeOH (} v / v) = 50/1) to give the title compound purified by silica gel column chromatography as a yellow solid (150mg, 47.0%).

MS (ESI, pos, ion) m/z: 468.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, CDCl ₃ ): δ (ppm) 10.97 (s, 1H), 8.53 (t, J = 9.0 Hz, 1H), 7.81 (d, J = 5.9 Hz, 1H), 7.56 (t, J = 7.6 Hz, 2H), 7.48 (t, J = 7.4 Hz, 1H), 7.39 (d, J = 7.4 Hz, 2H) , 6.95-6.90 (m, 1H), 6.90-6.86 (m, 1H), 6.17 (d, J = 5.9 Hz, 1H), 5.21 (s, 2H), 3.38 (s, 3H), 2.81 (s, 3H) ).

Biological test Biological analysis method

The LC/MS/MS system for analysis includes the Agilent 1200 Series vacuum degassing furnace, binary syringe pump, orifice autosampler, column incubator, and charged spray ionization (ESI) source for the Agilent G6430 three-stage quadrupole mass spectrometer . Quantitative analysis is performed in MRM mode. The parameters of MRM conversion are shown in Table A:

Analysis Agilent XDB-C18, 2.1 x 30 mm, 3.5 μM column was used and 5 μL of sample was injected. Analytical conditions: The mobile phase was 0.1% aqueous formic acid (A) and 0.1% methanolic formic acid (B). The flow rate was 0.4 mL/min. The mobile phase gradient is shown in Table B:

In addition, the Agilent 6330 Series LC/MS/MS spectrometer was equipped for analysis with a G1312A binary syringe pump, a G1367A autosampler and a G1314C UV detector; and an LC/MS/MS spectrometer with an ESI source. Apply a suitable cation model to each analyte using a standard solution Processing and MRM conversion for optimal analysis. Capcell MP-C18 columns were used during the analysis and were: 100 x 4.6 mm I.D., 5 [mu]M (Phenomenex, Torrance, California, USA). The mobile phase was 5 mM ammonium acetate, 0.1% aqueous methanol (A): 5 mM ammonium acetate, 0.1% methanol in acetonitrile (B) (70:30, v/v); flow rate was 0.6 mL/min; column temperature was kept at room temperature ; Inject 20 μL of sample.

Example A Stability in Human and Rat Liver Microsomes

Human or rat liver microsomes were incubated in polypropylene tubes and guided for replication. A typical incubation mixture consists of human or rat liver microsomes (0.5 mg protein/mL), target compound (5 μM) and a total volume of 200 μL of NADPH (1.0 mM) potassium phosphate buffer (PBS, 100 mM, pH 7.4). The compound was dissolved in DMSO and diluted with PBS to give a final DMSO solution concentration of 0.05%. The incubation was carried out in a water bath at 37 ° C in air, and after pre-incubation for 3 minutes, the protein was added to the mixture and the reaction was started. At different time points (0, 5, 10, 15, 30 and 60 min), the reaction was stopped by the addition of the same volume of ice-cold acetonitrile. Samples were stored at -80 °C until LC/MS/MS analysis.

The concentration of the compound in the human or rat liver microsome incubation mixture was determined by LC/MS/MS. The linear range of concentration ranges is determined by each test compound.

The parallel incubation assay used denatured microsomes as a negative control, incubation at 37 ° C, and the reactions were terminated at different time points (0, 15 and 60 minutes).

Dextromethorphan (70 μM) was used as a positive control and incubated at 37 ° C. The reaction was terminated at different time points (0, 5, 10, 15, 30 and 60 minutes). Positive and negative control samples are included in each assay to ensure the integrity of the microsomal incubation system. Furthermore, the stability data of the compounds of the present invention in human or rat liver microsomes can also be obtained from the following tests. Human or rat liver microsomes were incubated in polypropylene tubes and guided for replication. Typical incubation mixtures include human or rat liver microsomes (final concentration: 0.5 mg protein/mL), compound (final concentration: 1.5 μM) and a total volume of 30 μL of K-buffer solution (containing 1.0 mM EDTA, 100 mM, pH) 7.4). The compound was dissolved in DMSO and diluted with a K-buffer solution to give a final concentration of 0.2% DMSO. After pre-incubation for 10 minutes, 15 μL of NADPH (final concentration: 2 mM) was added for enzymatic reaction, and the entire experiment was carried out in an incubation tube at 37 °C. At various time points (0, 15, 30 and 60 minutes), the reaction was stopped by the addition of 135 μL of acetonitrile (containing IS). The protein was removed by centrifugation at 4000 rpm for 10 minutes. The supernatant was collected and analyzed by LC-MS/MS.

In the above test, ketanserin (1 μM) was selected as a positive control, incubated at 37 ° C, and the reaction was terminated at different time points (0, 15, 30 and 60 minutes). Positive control samples are included in each assay to ensure the integrity of the microsomal incubation system.

date analyzing

For each reaction, the concentration of the compound in human or rat liver microsome incubation (expressed as a percentage) is plotted as a percentage of the relative zero time point to extrapolate the intrinsic clearance of liver CL _int (ref.: Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Privacy of human hepatic clearance from in vivo animal experiments and in vitro metabolism studies with liver microsomes from animals and humans. Drug Metabolism and Disposition 2001, 29:1316- 1324.)

When the compound is incubated in human and rat liver microsomes, the compounds of the invention exhibit a good half-life (T _1/2 ).

Example B Pharmacokinetic Evaluation of Oral Quantification of Compounds of the Invention in Mice, Rats, Dogs and Monkeys

The present invention evaluates the pharmacokinetic study of the compounds of the invention in mice, rats, dogs or monkeys. The compounds of the invention are administered as an aqueous solution or as an aqueous solution of 2% HPMC + 1% Tween-80, 5% DMSO + 5% saline solution, 4% MC or capsule. For intravenous administration, animals are given a dose of 1 or 2 mg/kg. For oral doses (p.o.), rats and mice were 5 or 10 mg/kg, and dogs and monkeys were 10 mg/kg. Blood was taken at time points of 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 12 and 24 hours (0.3 mL) and at 3,000 or 4,000 rpm Centrifuge for 10 minutes. The plasma solution was collected and stored at -20 ° C or -70 ° C until the above LC/MS/MS analysis was performed.

When the compound is administered intravenously or orally, the compounds of the present invention exhibit good pharmacokinetic properties including desirable clearance (Cl), half-life (T _1/2 ) and good oral bioavailability.

The compounds of the present invention inhibit tyrosine kinase receptor activity, particularly inhibition of c-Met, VEGFR, Ron and Axl activities and efficacy as antitumor drugs are evaluated by the following animal xenograft model test. The results of the study indicate that the compound of the present invention can effectively inhibit c-Met, Phosphorylation of VEGF-R2, Ron and Axl, and dose-dependent inhibition of proliferation of xenografted tumors in nude mice.

Kinase assay

Kinase Assay accomplished by detecting incorporation of γ- ³³ P-ATP myelin alkali-protein (MBP). Preparation of 20 μg/mL MBP (Sigma #M-1891) Tris buffer (TBS; 50 mM Tris pH 8.0, 138 mM NaCl, 2.7 mM KCl), coated with high binding white 384-well plates (Greiner) ), 60 μL per well. Incubate for 24 hours at 4 °C. The plate was then washed 3 times with 100 μL of TBS. The kinase reaction was carried out in a total volume of 34 μL of kinase buffer (5 mM Hepes pH 7.6, 15 mM NaCl, 0.01% bovine serum albumin (Sigma #I-5506), 10 mM MgCl ₂ , 1 mM DTT, 0.02% Triton X-100). Compounds were dissolved in DMSO and added to each well with a final concentration of 1% DMSO. Each data was measured twice, and each compound was tested at least twice. For example, the final concentration of the enzyme is 10 nM or 20 nM. The reaction was started by adding unlabeled ATP (10 μM) and γ- ³³ P-labeled ATP (2 × 10 ⁶ cpm per well, 3000 Ci/mmole). Reflected at room temperature for 1 hour. The 384-well plates were washed with 7x PBS and then 50 μL of scintillation fluid per well was added. The results were measured using a Wallac Trilux counter. For those skilled in the art, this is only one of many detection methods, and other methods are also possible.

The above test method can give an inhibitory IC ₅₀ and/or an inhibition constant K _i . IC _{50 is} defined as the concentration of a compound that inhibits 50% of the enzyme activity under the conditions of the test. A curve containing 10 concentration points was made using a dilution factor of 1⁄2 log to estimate the IC ₅₀ value (for example, a typical curve was made by the following compound concentrations: 100 μM, 30 μM, 10 μM, 3 μM, 1 μM, 0.3 μM, 0.1 μM, 0.03 μM, 0.01 μM, 0 μM).

c-Met(h) kinase assay

Human c-Met was carried out in the presence of 8 mM MOPS at pH 7.0, 0.2 mM EDTA, 250 μM KKKSPGEYVNIEFG, 10 mM magnesium acetate and [γ- ³³ P-ATP] (specific activity about 500 cpm/pmol, concentration determined according to requirements) Incubate. The reaction was started after the addition of the MgATP mixture. After incubating for 40 minutes at room temperature, a 3% phosphoric acid solution was added thereto to terminate the reaction. 10 μL of the reaction solution was spotted on a P30 screening program and washed 3 times with 75 mM phosphoric acid in 5 minutes, and immediately placed in a methanol solution before drying and scintillation counting.

KDR(h) (VEGF-R2(h)) kinase assay

Human KDR is present in 8 mM MOPS at pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin 堿 protein, 10 mM magnesium acetate and [γ- ³³ P-ATP] (specific activity about 500 cpm/pmol, concentration determined according to need) Incubate under the conditions. The reaction was started after the addition of the MgATP mixture. After incubating for 40 minutes at room temperature, the reaction was terminated by adding a 3% phosphoric acid solution thereto. 10 μL of the reaction solution was spotted on a P30 screening program and washed 3 times with 75 mM phosphoric acid in 5 minutes, and immediately placed in a methanol solution before drying and scintillation counting.

Axl (h) kinase assay

Human Axl is present in 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin 堿 protein, 10 mM magnesium acetate and [γ- ³³ P-ATP] (specific activity about 500 cpm/pmol, concentration determined according to need) Incubate under the conditions. The reaction was started after the addition of the MgATP mixture. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of a 3% phosphoric acid solution. 10 μL of the reaction solution was spotted on a P30 screening program and washed 3 times with 75 mM phosphoric acid in 5 minutes, and immediately placed in a methanol solution before drying and scintillation counting.

The kinase assay in the present invention was performed by Millipore Corporation of the United Kingdom (Millipore UK Ltd, Dundee Technology Park, Dundee DD2 1SW, UK).

Kinase inhibitory activity of compounds of the invention may be tested by KINOME scan ^TM, and it is mainly based on fixed, the test ligand competitive binding ability of quantitatively measuring kinase activity of a sample with a bit of the guide point. The completion of this test requires the combination of the following three elements: DNA-labeled kinase, immobilized ligand, and sample to be tested. The ability of a test sample to compete with a immobilized ligand for binding to a kinase can be determined by determining the amount of PCR in the DNA tag.

For most of the assays, the kinase-tagged T7 phage strain was prepared from an E. coli host derived from the BL21 strain. E. coli was first cultured in logarithmic growth phase, then infected with T7 phage, and incubated at 32 ° C under continuous shaking until lysis, and the lysate was centrifuged and suction filtered to remove cell debris. The remaining kinase produced in HEK-293 cells was then labeled with DNA for detection of qPCR. The magnetic beads coated with streptavidin and the biotinylated small molecule ligand were reacted at room temperature for 30 minutes to form an affinity resin for the kinase assay. Good coordination excess biotin magnetic beads were blocked with blocking buffer ^{(SEABLOCK TM (Pierce), 1} % BSA, 0.05% Tween 20, 1 mM DTT) free ligand is removed by washing to reduce non-specific Combine. Kinase reactions are bound by, a good affinity for the ligand and sample to be tested beads 1x binding buffer ^{(20% SEABLOCK TM, 0.17x PBS} , 0.05% Tween -20,6mM DTT) is completed. All reactions were carried out in 96-well plates of polystyrene in a final volume of 0.135 mL. The wells were incubated for 1 hour at room temperature under continuous shaking. The affinity beads were washed with washing buffer (1x PBS, 0.05% Tween-20) and resuspended in elution buffer (1x). PBS, 0.05% Tween-20, 0.5 μM non-biotinylated affinity ligand), and incubated for 30 minutes at room temperature under continuous shaking. The kinase concentration in the eluate was determined by qPCR.

Kinase assay of the present invention is a DiscoveRx ^(TM) analysis company Scan service Kinome completed (42501 Albrae St.Fremont, CA 94538, USA), the test results of Examples of the present invention is shown in Table 3.

Kd-binding constants (Binding Constants) Cell phosphorylation test

Typically, the cells are pre-incubated with the test compound to achieve sufficient target binding. The level of autophosphorylation was measured by sandwich enzyme-ELISA (Sandwich-ELISA). A curve containing 8 concentration points was made using a dilution factor of 1⁄2 log, and IC ₅₀ values were estimated (2 determinations per concentration). The cell phosphorylation assay in the present invention can be carried out by ProQinase GmbH (ProQinase GmbH, Breisacher Straße 117 D-79106, Freiburg, Germany).

c-Met phosphorylation test

It is well known that the human gastric adenocarcinoma cell line MKN45 overexpresses c-Met. Overexpression of c-Met leads to constitutive, ligand-independent kinase autophosphorylation. With the addition of SU11274, the level of phosphorylated Met is significantly reduced, so that the inhibitory ability of the compound of the present invention can be determined. Phosphorylated Met signals can be quantified by sandwich enzyme-ELISA. A set of known Met inhibitors was set up to verify the reliability of the test method.

VEGF-R2 phosphorylation test

It is known that immortalized human umbilical vein endothelial cells (HUE) overexpress VEGF-R2. Stimulation of these cells with the physiological ligand VEGF-A results in significant receptor autophosphorylation. The cells are pre-incubated with the test compound to achieve sufficient target binding. Stimulation conditions were optimized to achieve dose-dependent inhibition of phosphorylated VEGF-R2 signaling, and phosphorylation signals were quantified by sandwich enzyme-ELISA. The VEGF-R2 inhibitor group was known to be tested to verify the reliability of the test method.

Axl phosphorylation test

Cellular Axl phosphorylation assays are typically performed using mouse embryonic fibroblasts (MEF). fine The cells express the full-length Axl protein by transfection. A highly Axl autophosphorylated transfected cell was then obtained by clonal selection. Then, with the addition of stellate spores, the level of phosphorylated Axl is significantly lowered, so that the inhibitory ability of the compound can be determined. Phosphorylated Axl levels were quantified by sandwich enzyme-ELISA.

Xenograft tumor model

The pharmacological effects of the compounds of the invention were evaluated by standard murine models of transplanted tumors. Human tumor cells (U87MG glioma cells, ATCC) were cultured, collected, and subcutaneously inoculated into 6-7 week old female nude mice (BALB/cA nu/nu, Shanghai SLAC Animal Laboratory). Solvent group and each dose group: n = 6-10)). When the tumor volume reached 100-250 mm ³ , the animals were randomly divided into a solvent control group (5% DMSO + 70% Captisol ^® (30%), 7% HCl (pH 1), 18% Captisol ^® (30%); or 7 % DMSO, 7% HCl (pH 1), 70% Captisol ^® (30%), 16% Captisol ^® (30%) and compound groups. Subsequent administration of the compound to the animals is carried out by gavage from anywhere in the 0 to 15 days after tumor cell inoculation, and usually once a day in the trial.

Tumor growth inhibition (TGI) analysis

The evolution of tumors is evaluated by the relationship between tumor volume and time. The long axis (L) and the short axis (W) of the subcutaneous tumor were measured twice a week by a caliper, and the volume of the tumor (TV) was calculated by the formula (L × W ² )/2). TGI was calculated from the median tumor volume of the solvent group and the median tumor volume of the drug group, expressed as a percentage of the median tumor volume of the solvent control group, and calculated by the following formula: The original statistical analysis was performed by repeated variance analysis (RMANOVA). Next, multiple comparisons were performed by the Scheffe psot hoc test method. Solvent alone (5% DMSO + 70% Captisol ^® (30%), 7% HCl (pH 1), 18% Captisol ^® (30%); or 7% DMSO, 7% HCl (pH 1), 70% Captisol ^® (30 %), 16% Captisol ^® (30%)) was a negative control.

Table 4 Research data of xenograft tumor model of the embodiment of the present invention

Finally, it should be noted that there are other ways in which the invention can be implemented. Accordingly, the embodiments of the present invention are intended to be illustrative, but not limited to the description of the present invention, and may be modified within the scope of the invention or equivalents added in the scope of the claims. All publications or patents cited herein are hereby incorporated by reference.

Claims (26)

a compound of formula (I): Or a stereoisomer, geometric isomer, tautomer, oxynitride, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof, wherein: Q is H, NR ^a R ^b , OR ^a , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a ;W is CR ⁷ or N; each X, Y and Z are independently H, D, C _1-6 alkyl, C _3-8 cycloalkyl, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl, C _3-7 heterocyclyl -C _1-4 alkylene, C _6-10 aryl, heteroaryl group of 5-10 atoms, C _6-10 aryl-C _1-4 alkylene or (5-10 atoms) Heteroaryl)-C _1-4 alkylene, wherein said C _1-6 alkyl, C _3-8 cycloalkyl, C _3-8 cycloalkyl-C _1-4 alkylene, C _{3 -7} heterocyclic group, C _3-7 heterocyclic group-C _1-4 alkylene group, C _6-10 aryl group, heteroaryl group of 5-10 atoms, C _6-10 aryl-C _{1- The 4} alkylene group and the (5-10 atom heteroaryl group)-C _1-4 alkylene group may be optionally 1, 2, 3, 4 or 5 independently selected from D, F, Cl, Br. , CN, C _2-6 alkenyl, C _2-6 alkynyl, OR ^a , NR ^a R ^b , R ^a OC _1-4 alkylene or R ^a R ^b NC _1-4 alkylene substituent Substituted; each R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ^{7 are} independently H, D, F, Cl, Br, CN, N ₃ , OR ^a , C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl or C _2-6 alkynyl; each R ^a , R ^b and R ^{c are} independently H, C _1-6 aliphatic, C _1-6 haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl -C _1-4 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-4 alkylene, C _6-10 aryl, heteroaryl group of 5-10 atoms , C _6-10 aryl-C _1-4 alkylene or (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group, when R ^a and R ^{b are} bonded to the same nitrogen atom And R ^a , R ^b , together with the nitrogen atom to which they are attached, may optionally form a substituted or unsubstituted heterocyclic ring of 3-8 atoms, wherein said C _1-6 aliphatic, C _{1 -6} haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _1-4 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-4 Alkyl group, C _6-10 aryl group, heteroaryl group of 5-10 atoms, C _6-10 aryl-C _1-4 alkylene group, (heteroaryl group of 5-10 atoms)-C _{The 1-4} alkylene group and the heterocyclic ring composed of 3-8 atoms may be optionally 1, 2, 3 or 4 independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _{1 -} Substituted by a ₆ haloalkyl group, a C _1-6 alkoxy group or a C _1-6 alkylamino group; and R ^d is H, C _1-6 alkyl, C _3-8 cycloalkyl-C _1-4 Alkylene, C _3-7 heterocyclyl, C _3-7 heterocyclyl-C _1-4 alkylene or C _6-10 aryl, when R ¹ , R ² , R ³ , R ⁵ (or R ⁴ ), when R ⁶ and R ^{7 are} both H, and R ⁴ (or R ⁵ ) is F, R ^{d is} not a C _3-7 heterocyclic group, wherein the C _1-6 alkyl group, C _3-8 Cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl, C _3-7 heterocyclyl-C _1-4 alkylene and C _6-10 aryl may optionally be 1,2 , 3 or 4 independently selected from D, F, Cl, Br, CN, OR ^a , NR ^a R ^b , C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, R ^a OC Substituted by a substituent of _1-4 alkylene or R ^a R ^b NC _1-4 alkylene. The compound according to claim 1, wherein Q is NR ^a R ^b , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a . The compound of claim 1, wherein each of X, Y and Z is independently H, D, C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl- C _1-2 alkylene group, C _3-6 heterocyclic group, C _3-6 heterocyclic group-C _1-2 alkylene group, phenyl group, heteroaryl group composed of 5-10 atoms, phenyl-C _1-2 alkylene or (heteroaryl group of 5-10 atoms)-C _1-2 alkylene group, wherein said C _1-4 alkyl group, C _3-6 cycloalkyl group, C _{3- 6} cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _1-2 alkylene, phenyl-C _1-2 alkylene, (5 -10 atomic heteroaryl)-C _1-2 alkylene, phenyl and heteroaryl group of 5-10 atoms may optionally be 1, 2, 3 or 4 independently selected from D, F, Cl, Br, CN, C _2-4 alkenyl, C _2-4 alkynyl, OR ^a , NR ^a R ^b , R ^a OC _1-2 alkylene or R ^a R ^b NC _1-2 alkylene Substituted by a substituent. The compound of claim 1, wherein each of R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ^{7 is} independently H, D, F or Cl. The compound of claim 1, wherein each of R ^a , R ^b and R ^{c is} independently H, C _1-4 alkyl, C _1-4 haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclic or C _3-6 heterocyclyl-C _1-2 alkyl, when R ^a and R ^b are the same nitrogen When atoms are attached, R ^a , R ^b , together with the nitrogen atom to which they are attached, may optionally form a substituted or unsubstituted heterocyclic ring of 3-8 atoms, wherein said C _1-4 alkyl group , C _1-4 haloalkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclyl, C _3-6 heterocyclyl-C _{1 The -2} alkylene group and the heterocyclic ring composed of 3-8 atoms may be optionally 1, 2, 3 or 4 independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1- Substituted by a _3- haloalkyl group, a C _1-3 alkoxy group or a C _1-3 alkylamino group. The compound of claim 1, wherein R ^d is H, D, C _1-4 alkyl, C _3-6 cycloalkyl-C _1-2 alkylene, C _3-6 heterocyclic ring Or a C _3-6 heterocyclyl-C _1-2 alkylene group, when R ¹ , R ² , R ³ , R ⁵ (or R ⁴ ), R ⁶ and R ^{7 are} both H, R ⁴ (or R ⁵ ) When F is, R ^{d is} not a C _3-6 heterocyclic group, wherein the C _1-4 alkyl group, C _3-6 cycloalkyl-C _1-2 alkylene group, C _3-6 hetero The cyclic group or C _3-6 heterocyclyl-C _1-2 alkylene group may be optionally 1, 2, 3 or 4 independently selected from D, F, CN, OR ^a , NR ^a R ^b , C ₁ Substituted by a substituent of _-3 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, R ^a OC _1-2 alkylene or R ^a R ^b NC _1-2 alkylene. The compound of claim 1, wherein Q is NH ₂ or -N(R ^c )C(=O)R ^d . The compound of claim 1, wherein each of X, Y and Z is independently H, D, CH ₃ , CH ₂ CH ₃ , phenyl or is 1, _{2, 3} , 4 or 5 independent A phenyl group substituted with a substituent selected from D, F or Cl. The compound of claim 1, wherein Q is: The compound of the above formula (1) has the structure represented by the formula (II): Wherein: Q is NR ^a R ^b , -N(R ^c )C(=O)R ^d or -N(R ^c )C(=O)OR ^a ; each X, Y and Z are independently H, D, C _1-6 alkyl, C _3-8 cycloalkyl, C _3-7 heterocyclic, C _6-10 aryl, heteroaryl of 5-10 atoms, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 alkylene, or (5-10 atomic heteroaryl) a C _1-4 alkylene group, wherein the C _1-6 alkyl group, C _3-8 cycloalkyl group, C _3-7 heterocyclic group, C _6-10 aryl group, 5-10 atoms Heteroaryl, C _3-8 cycloalkyl-C _1-4 alkylene, C _3-7 heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 alkylene The base and (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group may be optionally 1, 2, 3, 4 or 5 independently selected from D, F, Cl, Br, CN, Substituted by a substituent of C _2-6 alkenyl, C _2-6 alkynyl, OR ^a , NR ^a R ^b , R ^a OC _1-4 alkylene or R ^a R ^b NC _1-4 alkylene; R ^a , R ^b and R ^{c are} independently H, C _1-6 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclic, C _6-10 aryl, 5-10 atoms Heteroaryl, C _3-6 cycloalkyl-C _1-4 alkylene, C _3-6 heterocyclyl-C _1-4 alkylene, C _6-10 aryl-C _1-4 An alkylene group or a (heteroaryl group of 5-10 atoms)-C _1-4 alkylene group, wherein the C _1-6 alkyl group, a C _3-6 cycloalkyl group, a C _3-6 heterocyclic ring Base, C _6-10 aryl, heteroaryl group of 5-10 atoms, C _3-6 cycloalkyl-C _1-4 alkylene, C _3-6 heterocyclyl-C _1-4 alkylene a C _6-10 aryl-C _1-4 alkylene group and a (5-10 atom heteroaryl group)-C _1-4 alkylene group may optionally be 1, 2, 3 or 4 Substituted independently from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _1-6 alkoxy or C _1-6 alkylamino; and R ^d Is a C _1-6 alkyl group, wherein the C _1-6 alkyl group may be optionally 1, 2, 3 or 4 independently selected from D, F, Cl, OH, NH ₂ , C _1-6 alkane Substituted by an oxy group or a substituent of a C _1-6 alkylamino group. The compound of claim 10, wherein Q is NR ^a R ^b or -N(R ^c )C(=O)R ^d . The compound of claim 10, wherein each of X, Y and Z is independently H, D, C _1-4 alkyl or phenyl, wherein said C _1-4 alkyl and phenyl It may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from D, F or Cl. The compound of claim 10, wherein each of R ^a , R ^b and R ^{c is} independently H, C _1-4 alkyl, C _3-6 cycloalkyl, C _3-6 heterocyclyl a C _3-6 cycloalkyl-C _1-2 alkylene group or a C _3-6 heterocyclic group-C _1-2 alkylene group, wherein the C _1-4 alkyl group, C _3-6 cycloalkane a C _3-6 heterocyclyl group, a C _3-6 cycloalkyl-C _1-2 alkylene group and a C _3-6 heterocyclyl-C _1-2 alkylene group may optionally be 1,2, Substituting 3 or 4 substituents independently selected from D, F, Cl, CN, N ₃ , OH, NH ₂ , C _1-6 haloalkyl, C _1-6 alkoxy or C _1-6 alkylamino . Compound as defined in claim 1 in the range of item, wherein, R ^d is Me, Et, n -Pr, i -Pr, n -Bu, i -Bu , or t -Bu. The compound of claim 1, wherein Q is NH ₂ or -N(R ^c )C(=O)R ^d . The compound of claim 1, wherein each of X, Y and Z is independently H, D, Me, CH ₂ D, CHD ₂ , CD ₃ , ethyl, propyl, isopropyl, benzene A phenyl group substituted with 1, 2, 3, 4 or 5 substituents independently selected from D, F or Cl. The compound of claim 1, wherein Q is: The compound of claim 1, wherein the compound has one of the following structures: A pharmaceutical composition comprising a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or combination thereof . The pharmaceutical composition according to claim 19, which further comprises an additional therapeutic agent selected from the group consisting of a chemotherapeutic drug, an anti-proliferative agent, a drug for treating atherosclerosis, and a therapeutic agent. Pulmonary fibrosis drugs, or a combination thereof. The pharmaceutical composition according to claim 20, wherein the additional therapeutic agent is Adriamycin, Rapamycin, Temsirolimus, Everolimus, Ixabepilone, Gemcitabine (Gemcitabin), cyclophosphamide, dexamethasone, etoposide, fluorouracil, afatinib, alisertib, amuvatinib, axitinib , bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, danusertib, dovitinib, erlotinib (erlotinib), foretinib, ganetespib, gefitinib, ibrutinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, Motesanib, neratinib, niraparib, nilotinib, oprozomib, olaparib, pazopanib, pictilisib, ponatini b,quizartinib,regorafenib,rigosertib,rucaparib,ruxolitinib,seca Saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, Volasertib, an interferon, carboplatin, topotecan, taxol, vinblastine, vincristine, temozolomide, tosimo Tositumomab, trabedectin, belimumab, bevacizumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, ranibizumab, rituximab, tositumomab, trastuzumab or combinations thereof. A pharmaceutical composition according to any one of claims 1 to 18, or a pharmaceutical composition according to any one of claims 19 to 21, for use in the protection, treatment, treatment or alleviation Use of a drug for a patient's proliferative disease. The use of the compound or pharmaceutical composition according to claim 22, wherein the proliferative diseases are metastatic cancer, colon cancer, gastric adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver cancer, lung cancer, skin cancer, Thyroid cancer, brain tumor, neck cancer, prostate cancer, pancreatic cancer, CNS (central nervous system) cancer, malignant glioma, myeloproliferative disease, atherosclerosis or pulmonary fibrosis. A pharmaceutical composition according to any one of claims 1 to 18, or a pharmaceutical composition according to any one of claims 19 to 21, for use in the preparation of a biological specimen for inhibition Or the use of a medicament for modulating protein kinase activity, comprising the use of a compound according to any one of claims 1 to 18, or the use of any one of claims 19 to 21 The pharmaceutical composition is contacted with the biological specimen. The use of claim 24, wherein the protein kinase is a receptor tyrosine kinase. The use of claim 25, wherein the receptor tyrosine kinase is VEGFR, c-Met, Ron, Axl or a combination thereof.